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STUDIES ON THE MATURATION OF SECRETED QUORUM SENSING 
PEPTIDES THAT REGULATE S. AUREUS VIRULENCE 
Jeffrey Grant Johnson, Ph.D. 
The Rockefeller University 2015 
The accessory gene regulator (agr) locus in the commensal human pathogen, 
Staphylococcus aureus, is a two-promoter operon with allelic variability that encodes a 
quorum sensing circuit involved in regulating virulence in the bacterium. Secretion of 
unique autoinducing peptides (AIPs) and detection of their concentration via AgrC, a 
transmembrane receptor histidine kinase, coordinates local bacterial population density 
with global changes in gene expression. In order for S. aureus to produce AIP, three 
proteolytic transformations involving the proteins AgrB and SpsB are required. However, 
despite our current understanding of AIP peptide processing, the actual manner in which 
the AIP crosses the cellular membrane, and specifically the role of AgrB in this process, 
has not been examined. Neither is it clear whether SpsB cleaves all four variants of the 
AgrD precursor peptide. Initially, the aims of this thesis were to: 1) determine the role of 
AgrB in secreting the AgrD(1-32)-thiolactone and 2) confirm that SpsB is the protease 
responsible for the final cleavage step of AgrD in AIP biosynthesis. To achieve these 
goals, an in vivo secretion assay using intein chemistry to produce AIP in the absence of 
AgrB was developed to examine whether AgrB facilitates AIP secretion.  Also, SpsB 
biochemical assays were used to provide a thorough investigation of the final cleavage 
step in AIP biosynthesis for AgrD-I and AgrD-II. The findings of this work indicate that 
AgrB does not facilitate secretion, and SpsB can only cleave AgrD-I correctly but not 
AgrD-II. Taken together, these observations suggest that AgrB and SpsB are two proteins 
 
associated with AIP biosynthesis, but there are likely other proteins that need to be 
identified. The final aim of this work was to investigate the effect of AIP macrocycle size 
on AgrC activation. Since staphylococcal virulence can be inhibited through antagonism 
of its quorum sensing system, there has been tremendous interest in understanding the 
structure-activity relationships underlying the AIP-AgrC interaction. The defining 
structural feature of the AIP is a 16-membered, thiolactone-containing macrocycle. 
However, the importance of ring size on agr activation or inhibition has not been 
explored. This deficiency is addressed through the synthesis and functional analysis of 
AIP analogs featuring enlarged and reduced macrocycles. This study is the first to 
interrogate AIP function using both established cell-based reporter gene assays and newly 
developed in vitro AgrC-I binding and autophosphorylation activity assays.  Based on our 
data, we present a model for robust agr activation involving a cooperative, 3-points-of-
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Chapter 1. Introduction  
1.1 Regulation of Virulence in Staphylococcus aureus 
1.1.1  Emergence of Antibiotic-Resistant Strains of S. aureus 
Staphylococcus aureus is part of the commensal microbial flora of ~30% of the adult 
population. In spite of its normal, beneficial nature, S. aureus is an opportunistic 
pathogen and a major health threat worldwide when it is capable of invading mucous 
membranes or soft tissue.[1] Once invasion occurs, the bacterium is a remarkable, 
dynamic pathogen that is known to cause both acute and chronic illnesses such as 
bacteremia, sepsis, endocarditis and toxic shock syndrome.[2, 3] Although the immune 
system and treatment with antibiotics can clear these infections, there are several risk 
factors that include a weakened immune system, surgery, and/or implanted medical 
devices that can lead to fatal infections.[4] Noticeably, these risk factors often persist in a 
hospital environment, and virulent S. aureus strains can thrive in hospitals, where 
vulnerable patients being treated for an unrelated problem may become infected with a 
commensal strain or with a strain spread in the hospital.[5] Such infections have only 
become more lethal with the emergence of antibiotic resistant strains of S. aureus (e.g. 
MRSA and VRSA). In 2005, there were over 278,000 MRSA-related hospitalizations, 
and estimates place MRSA-related deaths of at least 18,000 per year in the United States, 
which is nearly as many deaths as AIDS, tuberculosis and viral hepatitis combined.[6, 7]  
 
Researchers have been trying to understand the emergence of antibiotic resistant 
S. aureus strains starting with penicillin resistance in the 1940s.[8, 9] As these new resistant 
strains emerged, new antibiotics were used to combat infections, resulting in several 
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waves of antibiotic resistant strains of S. aureus.[3] Methicillin, the first semisynthetic 
penicillin (Figure 1), was introduced in October 1960 and within 6 months the first 
methicillin-resistant S. aureus (MRSA) strains had been isolated.[6, 10] Between 1998 and 
2007, hospital-acquired MRSA (HA-MRSA) infections increased from 3.2 hospital 
discharges to 4.8 discharges per 1000.[11] While this increase was statistically significant, 
even more significant was the increase in community-acquired MRSA (CA-MRSA) 
infections. During the same time period, CA-MRSA infections increased from 0.4 
hospital discharges to 3.3 discharges per 1000—an 8-fold increase. Alarmingly by 2007, 
CA-MRSA infections accounted for 82% of all MRSA infections in children under the 
age of fifteen.[11] The threat of MRSA infections has, thus, left the hospital.[12, 13] 
 
During this 4-decade evolution of MRSA infections, S. aureus was also under 
another selective pressure from vancomycin—one of the antibiotics of last resort for 
Gram-positive bacteria (Figure 1). By the late 1990s, the first vancomycin intermediate-
resistant S. aureus (VISA) strains were isolated in Japan, and the first vancomycin-
resistant S. aureus (VRSA) strain was isolated in the United States in 2002.[3, 14-17] 
Uncompromisingly fueled by its need for survival, this tiny organism continues to expand 
its arsenal and defense to dominate in a chemical war between host and pathogen. To 
combat the pervasive, pathogenic potential of this bacterium, research efforts to further 
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Figure 1.  Chemical Structures of Several Antibiotics Used to Treat S. aureus 
Infections 
A)  Penicillin G or benzylpenicillin is one of the more common penicillin antibiotics.  B)  
Methicillin is a derivative of pencillin, but it is a penicillinase-resistant β-lactam 
antibiotic.  C)  Vancomycin belongs to the glycopeptide class of antibiotics.  All three of 
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1.1.2  A Quorum Sensing Circuit Coordinates Virulence in S. aureus 
In bacteria, extracellular small-molecules play a major role in cell-cell communication, 
which involves the production, release, and community-wide detection of such small 
molecules. Quorum sensing (QS) is one form of cell-cell communication that allows a 
bacterial strain to monitor its own population and to adjust gene expression according to 
bacterial population changes.[20, 21] In a QS circuit, a signaling molecule—an 
autoinducer—is constitutively secreted in proportion to bacterial population density. 
Once a threshold autoinducer concentration is achieved, the target receptor is activated 
resulting in a specific, coordinated response through targeted gene transcription and 
expression. Thus, activation of energetically demanding processes is limited to instances 
in which there are enough bacteria present to elicit the desired effect. Synchronized 
behaviors regulated by QS circuits include bioluminescence, sporulation, conjugation, 
pigment production, biofilm formation and production of virulence factors.[20, 22, 23] There 
are two general types of QS systems in bacteria: LuxIR circuits in Gram-negative 
bacteria and oligopeptide two-component circuits in Gram-positive bacteria. In the LuxIR 
circuit, the LuxI-type enzyme catalyzes the formation of a specific acyl-homoserine 
lactone (AHL) autoinducer that freely diffuses in and out of a cell. The LuxR-type 
proteins bind a specific AHL autoinducer once it reaches a threshold concentration.[24] In 
Gram-positive bacteria, the autoinducers are short peptides called autoinducing peptides 
(AIPs) that are typically detected by a classical histidine kinase two-component signaling 
(TCS) system.[21, 23] 
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In the Gram-positive bacterium, S. aureus, the accessory gene regulator (agr) 
locus encodes a quorum sensing circuit that includes a canonical TCS system.[25] In 
general, TCS systems are ubiquitous in bacteria, allowing them to sense and react to a 
variety of stimuli, including osmolarity, pH, oxygen, chemoattractants, and 
autoinducers.[26] Each TCS is typically composed of a receptor histidine protein kinase 
(HPK) that senses the signal and a response regulator (RR) transcription factor that 
modulates gene expression. The HPK receptor typically forms a dimer, and each receptor 
protomer consists of a sensory domain and an histidine kinase (HK) domain, which is 
further divided into two subdomains:  1) an α-helical coiled-coil region containing the 
dimerization interface and histidine phosphorylation site (DHp) and 2) the catalytic 
kinase domain (CA).[27-29] Stimulus detection by the HPK sensory domain triggers 
activation of the HK domain, resulting in trans-autophosphorylation of the contralateral 
histidine and then phosphoryl-group transfer to a conserved aspartate in the TCS-
associated RR. 
 
As part of the agr locus encoded QS system, there is also an AIP autoinducer that 
helps coordinate virulence factor production.[25, 30, 31] S. aureus has a diverse arsenal of 
virulence factors by which it evades the host immune system and then becomes very 
toxic in the correct host environment. The two main classes of virulence factors are 
associated with different phases of population growth in S. aureus (Figure 2).[2] During 
the lag and exponential phases, virulent S. aureus cells produce cell wall-associated 
factors that facilitate tissue attachment and evasion of the host immune system, allowing 
the bacteria to accumulate and possibly form a biofilm.[21] For example, microbial surface 
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components recognizing adhesive matrix molecules (MSCRAMMS) adhere to the 
extracellular matrix to give the bacteria an attachment point in the host. Protein A binds 
IgG antibodies to form a protective coat and evade the host immune system.[1, 2]  
 
Once the S. aureus bacterial population size achieves the autoinducer threshold 
concentration, the cell wall-associated factors are down-regulated in late exponential 
phase and stationary phase, allowing for detachment from the original colonization site 
and possible establishment of an invasive infection.[32] At the same time, the bacterium 
secretes enzymes and toxins, termed exoproteins, to degrade host tissue and to promote 
spread of the infection.  The degradative enzymes include proteases and hemolysins, 
which lyse red blood cells by creating pores in the cell membranes or by hydrolyzing 
membrane lipids.  Enterotoxins are the causative agents of S. aureus food poisoning and 
contribute to toxic shock syndrome and other diseases by stimulating T-cells to produce 
proinflammatory cytokines in excessive amounts.[1, 2, 32] Such coordination of virulence 
factors is conserved not only in Staphylococci[33] but also within the phylum firmicutes[34] 
including pathogenic bacteria such as Enterococcus faecalis,[35] Listeria 
monocytogenes,[36] Clostridium perfringens,[37] and Clostridium botulinum[38] all showing 
identifiable AIP-like signals. 
  




Figure 2.  The Effect of S. aureus Population Growth on Virulence Factor 
Expression 
Adapted from references 2 and 32. Cell surface-associated virulence factors are highly 
expressed during exponential growth in order to promote attachment to the host 
extracellular matrix and evade the host immune system. In stationary phase, the cell 
surface-associated virulence factors are down-regulated and expression of secreted 
exoproteins is induced to promote invasion of the host and impart toxicity.[1, 2, 32] 
Staphylococci monitor their increase in population density using the quorum sensing 
circuit encoded by agr, which regulates the transition between exponential and stationary 


















































	   8 
While the agr locus is considered a global regulator of S. aureus virulence, it is 
only one of several genetic loci that produce a complex signaling network that 
coordinately regulate the staphylococcal virulon (Figure 3).[39-42] The staphylococcal 
accessory regulator (sar) and its relatives are important regulators of virulence that 
mediate many of their effects by influencing agr transcription: SarA, SarU and SarR up-
regulate agr transcription. SarA and SarU are also repressed by SarR and SarT, which 
thereby indirectly down-regulate agr transcription. Some Sar family proteins regulate 
virulence factors independently of agr. In a variety of infection models, loss of function 
mutations in either agr or sar exhibit reduced virulence, and the virulence of double agr- 
sar- mutants is, in some models, further reduced.[43-47] The mgrA locus also appears to 
regulate sar transcription and thereby agr transcription.[48]  It also up-regulates some 
efflux pumps and exoproteins in S. aureus among many other genes involved in 
virulence. Other important loci include S. aureus exoprotein expression (sae),[49] which 
may act downstream of agr to maintain hemolysin and coagulase expression;[50] 
staphylococcal respiratory response (srr), which is required for optimal growth in 
anaerobic conditions and inhibits agr output;[51] and repressor of toxins (rot), which 
counteracts many effects of agr but also induces expression of some exoproteins.[52-54] 
Because of this complex genetic network of virulence loci in S. aureus, it is still not 
precisely understood what role agr plays in initiating and establishing an infection. 
 
The agr locus of S. aureus contains two divergent promoters, P2 and P3, of which 
the P2 transcript encodes a 4-gene operon, agrBDCA, whose gene products are four 
proteins involved in the biosynthesis  (AgrB and D) and detection (AgrC and A) of the 
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AIP—the autoinducer of the agr QS system (Figure 4A).[21, 25, 55] For AIP biosynthesis, 
AgrD undergoes two proteolytic cleavage events:  1) AgrB cleaves off the C-terminus of 
AgrD and catalyzes the AIP thiolactone cyclization via an enzyme-mediated trans-
thioesterification reaction,[56, 57] and 2) a signal peptidase cleaves AgrD near its newly-
formed, cyclized C-terminus[58] to release the mature AIP into the surrounding, cellular 
environment, where it increases in concentration as bacterial growth continues. The four 
allelic AIPs expressed by S. aureus are 7-9 amino acid residues in length (Figure 4B). 
Structurally, they have 2-4 amino acid residues connected to a thiolactone macrocycle, 
which contains 5 amino acid residues and a thiolactone linkage formed by condensation 
of the sulfhydryl group of a conserved Cys residue and the a-carboxyl group.[45] Similar to 
other staphylococci, these AIPs also have at least two hydrophobic residues at their C-
terminus.[59] AIP binding of AgrC, a membrane-bound receptor histidine kinase, results in 
the activation of a TCS system comprised of AgrA and AgrC. Upon AIP binding, AgrC 
dimers undergo autophosphorylation and then phosphoryl-group transfer to AgrA, the 
TCS response regulator.[21, 55] Phosphorylated AgrA binds and activates the P2 and P3 
promoters completing a strong, positive feedback loop.[47] The P3 transcript encodes 
RNAIII, which encodes the δ-hemolysin toxin and is a regulatory RNA and effector 
molecule of S. aureus virulence factors.[25, 60] 
 
  




Figure 3.  A Network Schematic of Some of the Genetic Loci That Control Virulence 
in S. aureus 
The regulation and expression of virulence genes such as α-hemolysin (hla), δ-hemolysin 
(hld), serine proteases (splA-F), exotoxins (hlgA-C and pmtA-D), and Protein A (spa) is 
modulated by a complex, interactive network of many regulatory loci, including the agr 
locus, in S. aureus. Repressive interactions are represented in red. Activating interactions 
are represented in green. The sar locus is the staphylococcal accessory regulator, 
including SarA, SarU and SarR, which up-regulate agr transcription. MgrA is a 
transcription regulator with homology to SarA and MarR proteins. Other important TCS 
systems include:  arlR and -S, S. aureus exoprotein expression (sae) and staphylococcal 
respiratory response (srr). Genes of interest: tst = toxic shock toxin; rot = repressor of 
toxin; tdcB = threonine dehydratase; and aur = aureolysin.  norA, norB and tetK are 
efflux pumps. sigB encodes an alternative sigma factor in S. aureus.  
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While the agr locus is conserved among the staphylococci, it has undergone an 
interesting evolutionary divergence, giving rise to variant specificity groups, of which 
there are four groups in S. aureus and at least two groups in several other staphylococcal 
species. The sequence variability of each agr specific group appears within the genes of 
agrB, agrD, and the transmembrane sensor domain of agrC, giving rise to the variability 
of the AIP and its receptor.[21, 33, 61] (It is important to note that a S. aureus bacterium can 
only express one of the four specificity groups.[61]) Meanwhile, agrA is identical across all 
four agr groups of S. aureus. Each group produces a distinct AIP with a different amino 
acid sequence and with differing ligand-receptor specificities with its AgrC receptor. 
These different ligand-receptor interactions are responsible for agr group identification 
and activation when cognate AIP and AgrC interact.[62] Interestingly, a heterologous 
pairing of AIP and AgrC inhibits the agr feedback loop while still allowing bacterial 
growth to continue.[61] The only exception to this intergroup interference is the cross- 
activation observed between groups I and IV, which is likely due to these two AIPs 
differing in sequence by a single amino acid.[63] Intergroup quorum sensing interference 
may be unique to S. aureus, since such a phenomenon has not been observed among the 
agr groups of S. epidermidis.[33]  The in vivo relevance and therapeutic implications of 
this intriguing phenomenon are the subject of ongoing study in several laboratories. This 
cross-group antagonism has also proven a valuable tool for studying AIP structure-
activity relationships (SAR) and makes agr an especially attractive model system for the 
study of quorum sensing in Gram-positive bacteria. 
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Figure 4.  The agr Quorum Sensing Circuit 
A) Schematic depicting the general agr QS circuit in S. aureus (black arrows). The P2 
operon (blue) contains four genes to synthesize and detect AIP. The AgrD precursor 
peptide is processed into the mature AIP. (Schematic of sequence and structure of the 
four possible AIPs is shown in B.) Production of AIP requires an integral membrane 
protease, AgrB. Secretion of the AIP involves the AgrD precursor crossing the bacterial 
membrane and a second cleavage step that liberates AIP into the extracellular 
environment. AIP (dark blue) binds to homodimeric AgrC, a receptor histidine kinase 
(HK), which induces its autokinase activity. Activated AgrC relays the phosphoryl group 
to the response regulator, AgrA, which then activates transcription of both P2 and P3 
(purple) operons in the agr locus. This results in a positive feedback on the circuit and an 
up-regulation of the P3 transcript, RNAIII, which controls the expression of agr-related 
virulence genes. A heterologous AIP (orange and red) suppresses agr expression and 
RNAIII production by inhibiting AgrC autokinase activity.[21, 55] 
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1.2 Molecular Components of the agr Locus 
The agr system is one of the most extensively studied QS systems with the work of 
several laboratories providing a relatively detailed picture of the molecular mechanisms 
in this biological system. Our understanding of this system is nevertheless a work in 
progress, and the following sections detail what is known in the field and what questions 
remain to be answered. 
**Note:  one convention employed herein will be to designate group specificity when 
referring to agr-encoded proteins by adding the group number in roman numerals 
following the protein or AIP (e.g. AIP-I, AgrB-II, AgrC-III and AgrD-IV).  If no 
specificity group is designated, it can be assumed that a general statement is being made 
about the referenced agr molecule—protein or AIP. 
 
1.2.1 AIP Biosynthesis 
The AIP sequence is embedded within the AgrD polypeptide (Figure 5A).[25, 64]  In S. 
aureus, AgrD is a polypeptide chain of either 46 or 47 amino acids depending on the 
specificity group. (AgrD-II is the only one consisting of 47 amino acids.) Structurally, 
AgrD can be divided into three general domains:  1) the N-terminal 24 residues form an 
amphipathic helix that is capable of targeting the AgrD polypeptide to the cell 
membrane;[64] 2) the middle section of AgrD contains the amino acid sequence for the 
AIP molecule;[31, 64] and 3) the C-terminus of AgrD is highly acidic and contains key 
residues for recognition of and removal by AgrB.[57] These three general domains of 
AgrD are conserved among all staphylococcal species.[21, 40] 
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Figure 5.  AgrD Sequence Alignment and Structural Characteristics 
A) S. aureus AgrD sequences aligned with the AIP sequences colored navy blue and 
conserved residues shaded light blue. Domain characterization and cleavage sites are 
indicated, and the residues leading into the AIP N-terminal cleavage site are numbered. 
B) Schematic representation of a typical bacterial signal peptide, which usually contains a 
positively charged N-terminus (N), a central hydrophobic region (H), and a polar, C-
terminal region (C).[65] Helix-breaking proline or glycine residues are often found in the 
middle of the H-region and between the H- and C-regions at the -6 position relative to the 
cleavage site. The signal peptidase (SPase) recognition sequence consists of small 
aliphatic residues at positions -1 and -3, relative to the cleavage site. The most common 
residue at these positions is Ala, although other common residues are listed. Compared to 
this schematic, the N-terminus of AgrD has some C-region characteristics.  
 
Membrane Association Domain  
(MAD) 




	  	  	  	   	   	   	  
Residue #          10               20        30        40 
AgrD-I MNTLFNLFFDFITGILKNIGNIAA   YSTCDFIM  DEVEVPKELTQLHE 
     6  5  4  3  2  1  
AgrD-II MNTLVNMFFDFIIKLAKAIGIVG   GVNACSSLF  DEPKVPAELTNLYDK 
     5  4  3  2  1 
AgrD-III MKKLLNKVIELLVDFFNSIGYRAAY   INCDFLL  DEAENPKELTQLHE 
     7  6  5  4  3  2  1 
AgrD-IV MNTLLNIFFDFITGVLKNIGNVAS   YSTCYFIM  DEVEIPKELTQLHE 
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The N-terminal helix can vary significantly in sequence with only 5 of 32 residues 
conserved among the AgrD polypeptides of S. aureus. Despite this variability, the 
amphipathic properties are thought to be maintained. Removal of the first 12 residues of 
AgrD-I is also tolerated with some AIP-I being produced, but deletion of the first 14 
residues prevents AIP-I biosynthesis.[64] If these removed amino acids are replaced with 
an artificial amphipathic helix, AIP-I production can be rescued, suggesting the function 
of this section is membrane targeting, but not necessarily to mediate any specific 
interactions with AgrB.[64] More recently, the AgrD N-terminal leader was discovered to 
exist in the amyloid fibrils of S. aureus biofilms.[66, 67] Such behavior resembles the small 
peptide toxins expressed by S. aureus known as phenol-soluble modulins (PSMs).[68] Like 
PSMs, the N-terminus of AgrD forms and seeds amyloid fibrils outside the cell and 
displays cytolytic and proinflammatory properties, indicating that the N-terminus of 
AgrD might be another virulence factor directly expressed by agr.[66, 67] How a S. aureus 
bacterium might secrete and/or regulate this amphipathic leader peptide is not understood 
at all.  
 
In other work, the N-terminus of AgrD-I was replaced with a transmembrane 
helix to limit the orientation of AgrD-I to the cytoplasmic side of the membrane, but this 
altered AgrD-I did not lead to AIP production, indicating that the N-terminal leader must 
be amphipathic to allow AgrB processing.[64] Additionally, the processing of AgrD results 
in a secreted peptide. However, the N-terminus does not resemble a canonical signal 
peptide typically used to target polypeptides to the secretion machinery embedded in the 
cell membrane (Figure 5B);[65] and using signal peptide predictive software indicates that 
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the N-terminus of AgrD does not include classical, recognizable elements of signal 
peptides.[69] Thus, the N-terminal, amphipathic helix of AgrD targets the molecule to the 
cell membrane, where it associates with AgrB for further processing into AIP. That is 
also why, herein, the N-terminus of AgrD is referred to as the membrane association 
domain (MAD).  
 
The small AIP-encoding domain of AgrD also shows considerable divergence 
within S. aureus. For now, it is important to note that among the four S. aureus AIPs 
there is a conserved cysteine residue at the -5 position relative to the AgrB cleavage site 
(Figure 5A). This cysteine forms the thiolactone ring structure of AIP. Also, AIP-I and -
IV vary by one amino acid. 
 
The C-terminal tail is the most conserved portion of AgrD in S. aureus, especially 
the first nine residues.[33] The C-terminal portion begins with the residues aspartate and 
glutamate as the first two amino acids followed by two other absolutely conserved 
proline and glutamate residues at the sixth and eighth positions, respectively, relative to 
the AgrB cleavage site.  The conserved proline residue at the +6 position has been used to 
predict the C-terminus of AIP autoinducers within several other Gram-positive bacteria 
that still require some experimental validation.[21] There are also two conserved leucine 
residues in the C-terminus of AgrD. Some elegant genetic work using alanine point 
mutants has shown that the first conserved glutamate (E34) and leucine (L41) residues 
are essential for AIP production and AgrB cleavage of AgrD.[57] It has also been reported 
that only a small portion of the C-terminus can be removed and still maintain AIP 
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production. Deleting the four most C-terminal amino acid residues is tolerated, which 
further confirms the importance of the E34 and L41 residues, since they are more than 
four amino acid residues from the C-terminus.[57] Finally, the C-terminus is highly 
negatively charged with at least four acidic residues within a 14-residue span. In order to 
biologically synthesize and secrete AIP, AgrB must remove this densely charged region 
of AgrD. While there is no clear secretion mechanism for AIP, secretion of this small 
peptide would clearly benefit from removal of this acidic patch. Therefore, the C-
terminus of AgrD can be referred to as the secretion inhibitor domain (SID), which AgrB 
removes. 
 
AgrB is a 22-kDa integral membrane protein and cysteinyl endopeptidase that 
removes the SID of AgrD and mediates the formation of the AIP thiolactone 
macrocycle.[56, 57, 70] In many respects, AgrB is a unique feature of the staphylococcal agr 
system since it lacks significant sequence similarity with other quorum-sensing proteins 
and does not share homology with other cysteine proteases or other autoinducer 
processing proteins in Gram-positive bacteria.[25, 56] When comparing the different AgrB 
sequences among S. aureus agr types there is a significant amount of variation between 
strains. Overall hydrophobic sections that make up transmembrane sections are 
conserved, though the sequences of these regions are diverse—a common feature of 
integral-membrane protein homologs. Interestingly, the N-terminal portion of AgrB is 
highly conserved among staphylococcal species, with the first 34 residues being 
absolutely conserved among the four S. aureus agr groups. This region is required for 
AgrB function. [70] However, its role in AIP production is currently unknown.  
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The group specificity of AgrB in the processing of AgrD is not as stringent as that 
of AIP-AgrC interactions. While in most cases AgrB will only process its cognate AgrD, 
there are exceptions. AgrB-III can process AgrD-I to form AIP-I, and AgrB-I can process 
AgrD-III to form AIP-III.[61] AgrB-I and -IV may also be capable of processing both 
AgrD-I and -IV, as the sequences of these two groups are very similar, but this possibility 
has yet to be tested. In trying to understand the basis for AgrB-AgrD specificity, Zhang et 
al. constructed a panel of AgrB-I/II chimeras by swapping homologous segments of the 
two proteins, then determined their ability to synthesize active AIPs from AgrD-I or 
AgrD-II.[71] The authors narrowed down the determinants of specificity in AgrB-I to 
amino acids 43 to 67 and to residues 126 and 141 in AgrB-II. These regions correspond 
to either the second and fourth transmembrane regions according to one AgrB topology 
map,[56] or a cytoplasmic loop and an extracellular loop in another AgrB topology map.[72] 
While the lack of expression and localization data for the mutant proteins is a caveat of 
this study, it is nonetheless interesting that the specificity determinants for AgrB-I and 
AgrB-II appear to be in different regions of the primary sequence. Further study will need 
to focus on how these patches impart specificity and how they recognize AgrD. 
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Figure 6.  Topology Models of AgrB 
AgrB topological studies using a A) PhoA-fusion protein strategy[56] or B) SCAM.[72] The 
catalytic residues C84 and H77 are indicated with either a blue circle or purple triangle, 
respectively, in their approximate location. The italicized numbers identify the residue 
number at the beginning or end of a proposed transmembrane domain, which are 
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Attempts to structurally characterize AgrB have proceeded slowly. Two studies a 
decade apart have produced topology maps of AgrB, which have several major 
disagreements.[56, 72] The first study used alkaline phosphatase (PhoA) fusions of AgrB in 
E. coli to try to map the topology of AgrB in the inner membrane (Figure 6A). This 
method generated a topology map with six transmembrane regions, in which both the N- 
and C-termini are predicted to be inside the cell and a 27-residue loop located outside the 
cell. Topological studies indicate that the catalytic residues (H77 and C84) are located on 
the cytoplasmic face of the membrane.[56] The second study used the substituted cysteine 
accessibility method (SCAM) to investigate AgrB topology (Figure 6B).  SCAM resulted 
in a topology map with four transmembrane regions, in which both the N- and C-termini 
are predicted to be outside the cell and a re-entrant loop on the cytoplasmic face positions 
the catalytic residues near the membrane.[72] Clearly, a crystal structure will be the only 
way to resolve these topological discrepancies. 
 
Initially, progress towards elucidating the mechanism of AIP biosynthesis 
preceded slowly from the original report in 1995 that indicated AgrB is involved in the 
process.[31] Recent research, however, has helped elucidate the cleavage mechanism of 
AgrB. The first evidence for an AgrB-mediated removal of the AgrD SID came from 
Western blot analysis of crude cell lysates containing epitope-tagged AgrD, in which 
only AgrD intermediates corresponding to the MAD and AIP sequences were observed; 
and there was no intermediate detected corresponding to the AIP and SID sequences.[70] 
Mutagenesis experiments also revealed that residues H77 and C84 are required for 
production of an active AIP;[70] and later Thoendel et al. used Western blot analysis to 
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detect an AgrB-AgrD-I intermediate in membrane fractions of an E. coli strain that 
expresses AgrB-I and His6-tagged C28A AgrD-I.[57] They were also able to prevent 
formation of this acyl-enzyme intermediate by using a C84S AgrB single-point 
mutation.[57] The C84S AgrB-I and C28A AgrD-I point mutants indicate that AIP 
biosynthesis requires a thioester intermediate to then undergo a thioester exchange step to 
form the AgrD(1-32)-thiolactone. From all of this work, a detailed AgrB-mediated 
cleavage mechanism can be proposed as follows (Figure 7):  The SID of AgrD is 
removed when the sulfhydryl group of C84 in AgrB attacks the amide carbonyl of the 
32nd amino acid in AgrD to form an acyl-enzyme thioester intermediate. (H77 of AgrB 
acts as a general base to deprotonate C84.) The thiolactone macrocycle of AIP is formed 
when the conserved sulfhydryl group of C28 in AgrD attacks the acyl-enzyme thioester 
intermediate in an intramolecular trans-thioesterification reaction.[56, 57] The product of 
AgrB cleavage is a 32-residue polypeptide with a C-terminal thiolactone macrocycle, 
which includes the last five C-terminal amino acid residues (28-32). 
 
  





Figure 7.  Proposed AgrB Cleavage Mechanism of AgrD to Form the AgrD(1-32)-
thiolactone Precursor  
Proposed mechanism of AgrB cleavage of AgrD.  C-terminal cleavage of AgrD (dark 
blue) is mediated by residues H77 and C84 of AgrB to yield an acyl-enzyme 
intermediate,[56, 57] which is released via intramolecular trans-thioesterification with the 
sulfhydryl group of the conserved C28 residue of AgrD.  The product of AgrB cleavage 
is a 32-residue polypeptide with a C-terminal thiolactone macrocycle, which includes the 
last five C-terminal amino acid residues (28-32).  This AIP precursor will often be 
referred to as the AgrD(1-32)-thiolactone.  The cytoplasmic proximal region of AgrB is 
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The next step in AIP biosynthesis following formation of the AgrD(1-32)-
thiolactone requires transport of the intermediate across the membrane in preparation for 
release into the external environment. There is no clear mechanism for AIP secretion. In 
the literature, it is assumed that AgrB is somehow involved in transporting the 
intermediate it forms across the membrane.[56, 57, 70-72] Only recently, has some work tried 
to investigate the role of AgrB in AIP secretion. After screening many AgrB mutants 
obtained from random mutagenesis, three point mutations were found to affect AIP 
production although none of the three inhibited AgrB peptidase activity. K129, K130 and 
K131 of AgrB form a lysine patch, and when mutated to glutamate, they inhibit secretion 
of an active AIP but not AgrB peptidase activity.66 These residues are predicted to be in 
an extracellular loop or near the extracellular membrane face in the topology maps.[56, 72] 
This same study attempted to determine whether AgrB forms oligomers. Oligomerization 
of AgrB might indicate that AgrB forms a pore to help transport the AgrD(1-32)-
thiolactone across the membrane.  Expressing a T7-AgrB fusion protein and a His6-
tagged AgrB together in E. coli, the authors argue, based on co-immunoprecipitation 
data, for the existence of a complex between the two proteins.[72] However, this study did 
not shed light on whether this complex was a dimer or some higher oligomer, nor did it 
address the functional relevance of this complex for secretion. Consequently, the 
secretion mechanism for the AIP precursor remains poorly understood. 
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Figure 8.  Type I Signal Peptidases 
A) A sequence alignment of several type I SPases compares spsB and spsA to the 
classical Gram-negative (LepB, E. coli) and Gram-positive (SipS, B. subtilis) SPases and 
reveals that SpsB does have the catalytic serine/lysine dyad in the conserved regions of 
known SPases while SpsA does not.[73] B) The active site of SpsB (apoenzyme, pdb file 
1KN9) is depicted in a stick model with oxygen (red), nitrogen (blue), sulfur (yellow) and 
carbon (blue-gray).[74] S90 is the nucleophile and K145 acts as a general base in the 
hydrolysis of peptide bonds. C) This model for signal peptide insertion into the 
cytoplasmic membrane and cleavage by type I SPase is adapted from van Roosmalen et 
al.[65] First, the signal peptide interacts with the membrane, inserting into the membrane 
and unlooping to pull part of the mature protein through the membrane. During or shortly 
after translocation by the protein transport machinery (not shown), the signal peptide is 
cleaved by type I SPase and, thereby, the mature protein is released from the membrane. 










    A    B    C 
LepB  QIPSGSMMPTLLIGDF  YIKRAVGLPGDKVT  MGDNRDNSADSR 
SipS  VVDGDSMYPTLHNRER  YVKRIIGLPGDTVE  MGDNRRNSMDSR 
SpsB  TIKGESMDPTLKDGER  YVKRVIGVPGDKVE  LGDNREVSKDSR 
SpsA  VIPNNDMSPTLNKGDR  YTSRIIAKPGQSMA  LNDHDNNQHDSR 
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AIP production requires three chemical transformations:  two proteolytic cleavage 
steps and thiolactone formation. AgrB accomplishes one cleavage step and forms the AIP 
thiolactone macrocycle. While it is unlikely AgrB performs all three chemical 
transformations to produce AIP, there are no other candidate proteins encoded in agr.[25] 
For over a decade, there was speculation that other proteins in addition to AgrB may be 
involved in AIP production.[56, 70, 75] In 2007, a new player in AIP processing was 
discovered—SpsB—the type I signal peptidase (SPase) in S. aureus.[58] Type I SPases 
utilize a Ser-Lys catalytic dyad (Figure 8A & B),[65, 74, 76-78] and they are membrane bound 
proteases responsible for removing N-terminal signal peptides as proteins are being 
secreted through the Sec or Tat secretion pathways (Figure 8C).[65, 76] In Gram-positive 
bacteria, SPases have an N-terminal transmembrane segment that anchors the catalytic 
domain to the outside of the membrane.[65, 74, 76] In S. aureus, SpsB is essential for cell 
growth and viability.[73] Proximal to the spsB gene is another open reading frame, spsA, 
and only 15 nucleotides separate the two genes. Alignment of these two genes with LepB 
(E. coli SPase) and SipS (B. subtilis SPase) indicates that SpsA is a catalytically inactive 
SPase, where the conserved Ser-Lys catalytic dyad is replaced by Asp and Ser, 
respectively.[73] Therefore, SpsB is thought to be the only active type I SPase in S. aureus, 
although many other Gram-positive bacteria may have multiple SPases.[65] 
 
It has been reported that SpsB carries out the second cleavage event of AgrD-I, 
removing the N-terminal region.[58] In support of this assertion, signal-peptidase inhibitors 
were capable of preventing AIP production and agr activation in both agr-I and agr-II 
strains, albeit at millimolar concentrations. Also, a synthetic peptide substrate derived 
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from AgrD-I, NIAAYST tagged with fluorescein was added to various lysate fractions; 
and the correct cleavage products were identified by comparing their agarose gel 
retention times to synthetic standards. Through a series of fractionation and inhibition 
experiments, the proteolytic activity was attributed to SpsB.[58] It remains untested 
whether SpsB is involved in AIP production for all four specificity groups of S. aureus 
and other staphylococcal strains, so further investigation is necessary to verify the 
universal requirement of SPase in AIP biosynthesis. 
 
Using all the experimental findings outlined above, a model for AIP biosynthesis 
has been proposed (Figure 9). First, AgrD associates with the cytoplasmic membrane via 
its MAD. At the membrane, AgrB catalyzes cysteine-dependent nucleophilic attack on 
AgrD, removing the SID through a two-step process:  1) the formation of a covalent 
intermediate in which AgrD and AgrB are linked through a thioester bond and 2) the 
conserved sulfhydryl group of C28 in AgrD exchanges with the acyl-enzyme thioester 
intermediate through a trans-thioesterification reaction to create the thiolactone 
macrocycle and to form the AgrD(1-32)-thiolactone—the AIP precursor. Finally, the 
precursor is transported across the membrane through an unknown mechanism, where a 
membrane protease such as SpsB removes the MAD sequence to release AIP into the 
extracellular environment. While some of the steps such as AgrD targeting to the 
membrane, AgrB-mediated cleavage and SpsB-mediated cleavage have been 
demonstrated, experimental evidence supporting the other steps is lacking. 
  






Figure 9.  Proposed AIP Biosynthetic Pathway Model 
A proposed AIP biosynthetic pathway model adapted from Theondel et al.:[72] Step 1, the 
MAD of AgrD helps target AgrD to the cytoplasmic membrane. Step 2, AgrB removes 
the SID of AgrD. Step 3, the acyl-enzyme thioester intermediate undergoes a trans-
thioesterification reaction with the conserved Cys residue of AgrD, liberating the peptide 
from AgrB and forming a thiolactone macrocycle at the C-terminus of the peptide. Step 4, 
the AgrD(1-32)-thiolactone is transported to the outer face of the membrane. Step 5, a 
membrane protease such as SpsB removes the MAD of AgrD, releasing AIP from the 
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+, ++, +++ = weak to strong activity.  The dash (—) indicates no activity detected.  nt = not tested.  Dapa = 
diaminopropanoic acid. trAIP = truncated AIP.  AA = amino acids.  The small D indicates a D-amino acid.  
Endocyclic amino acid residues are in boldface. 
^The activity for these AIPs and AIP derivatives were determined using a cell-based reporter gene assay 
with GFP instead of β-lactamase. 
“Both cell-based reporter gene assays (GFP and β-lactamase) were used to determine the activity for these 
AIPs and AIP derivatives. 
Table 1. SAR of Previously Synthesized AIPs and AIP Derivatives 






AgrC Activation AgrC inhibition 
I II III IV I II III IV 
AIP-I YSTCDFIM +++ — — + — +++ +++ — 
AIP-II GVNACSSLF — +++ — — +++ — +++ +++ 
AIP-III INCDFLL — — +++ — +++ +++ — ++ 
AIP-IV YSTCYFIM ++ — — +++ — +++ +++ — 
AIP I-II YSTCSSLF — — — — +++ ++ +++ +++ 
AIP II-I GVNACDFIM — — — — ++ +++ ++ + 
AIP-II Lactone GVNASSSLF — — nt nt +++ — nt nt 
AIP-I Lactam YST(Dpr)-FIM + nt nt nt nt nt nt nt 
AIP-II Lactam GVNA(Dapa)-SSLF — + nt nt +++ — nt nt 
tr-AIP-I” Ac-CDFIM + — — — +++ +++ +++ +++ 
tr-AIP-II CSSLF — — — — ++ ++ +++ ++ 
tr-AIP-III^ Ac-CDFLL nt nt nt nt +++ +++ — +++ 
tr-AIP-IV CYFIM — — — — ++ +++ +++ + 
tr-AIP-I/IV 2A CAFIM — — — — +++ +++ +++ +++ 
Y1A AIP-I  ASTCDFIM ++ nt nt nt — nt nt nt 
S2A AIP-I YATCDFIM +++ nt nt nt — nt nt nt 
T3A AIP-I YSACDFIM ++ nt nt nt — nt nt nt 
D5A AIP-I/IV YSTCAFIM — — — — +++ +++ +++ +++ 
F6A AIP-I YSTCDAIM + nt nt nt — nt nt nt 
I7A AIP-I YSTCDFAM + nt nt nt — nt nt nt 
M8A AIP-I YSTCDFIA + nt nt nt — nt nt nt 
M8I AIP-I YSTCDFII +++ — — ++ — +++ +++ — 
G1A AIP-II AVNACSSLF — +++ nt nt +++ — nt nt 
V2A AIP-II GANACSSLF — ++ nt nt +++ — nt nt 
N3A AIP-II GVAACSSLF — — — — +++ ++ +++ +++ 
S6A AIP-II GVNACASLF — +++ nt nt +++ — nt nt 
S7A AIP-II GVNACSALF — +++ nt nt +++ — nt nt 
L8A AIP-II GVNACSSAF — — nt nt — — nt nt 
F9A AIP-II GVNACSSLA — — nt nt — — nt nt 
D5N AIP-I/IV YSTCNFIM +++ — ++ — — +++ — +++ 
D5F AIP-I/IV YSTCFFIM +++ — — +++ — +++ +++ — 
I1A AIP-III^ ANCDFLL nt nt nt nt +++ +++ ++ +++ 
N2A AIP-III^ IACDFLL nt nt nt nt +++ +++ — +++ 
D4A AIP-III^ INCAFLL nt nt nt nt +++ +++ +++ +++ 
F5A AIP-III^ INCDALL nt nt nt nt — — — + 
L6A AIP-III^ INCDFAL nt nt nt nt — — — — 
L7A AIP-III^ INCDFLA nt nt nt nt — — — — 
D-I1 AIP-III^ DINCDFLL nt nt nt nt +++ +++ +++ +++ 
D-N2 AIP-III^ IDNCDFLL nt nt nt nt +++ +++ +++ +++ 
D-C3 AIP-III^ INDCDFLL nt nt nt nt — — — — 
D-D4 AIP-III^ INCDDFLL nt nt nt nt ++ +++ — +++ 
D-F5 AIP-III^ INCDDFLL nt nt nt nt — — — + 
D-L6 AIP-III^ INCDFDLL nt nt nt nt — — — — 
D-L7 AIP-III^ INCDFLDL nt nt nt nt +++ +++ — +++ 
AIP-III 8AA” YINCDFLL nt nt — nt +++ +++ +++ +++ 
AIP-III 9AA AYINCDFLL nt nt — nt nt nt ++ nt 
b-AIP-I biotin-YSTCDFIM ++ — — — — +++ +++ — 
Ac-AIP-I Ac-YSTCDFIM +++ — — — — +++ +++ — 
fl-AIP-I fluorescein-YSTCDFIM ++ — — — — +++ +++ — 
AIP-II acid GVNACSSLF-OH — — — nt — — — nt 
AIP-II thioester GVNACSSLF-SR — — — nt — — — nt 
AIP-I peptomers 10-20 library — — — — ++ ++ ++ ++ 
AIP-I norleucyl YSTCDFI(Nle) — nt nt nt — nt nt nt 
AIP-I methionyl 
sulfoxide 
YSTCDFIM* — nt nt nt — nt nt nt 
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1.2.2 AIP Structure and Activity 
A large effort has been made toward determining the structure–activity relationships 
(SAR) of the four AIPs by employing synthetic methods and a rapid, quantitative 
agrP3::blaZ reporter assay[31, 45, 59, 62, 63, 79-83] or a similar reporter gene assay using gfp 
instead of blaZ.[84, 85] Efficient chemical synthesis of AIPs combines solid-phase peptide 
synthesis (SPPS) and solution phase chemistry.[45, 63, 80, 83, 84] In the most efficient protocol 
using BOC chemistry, the linear peptide is first synthesized by SPPS on an α-thioester-
generating resin, then cleaved from the solid support, and the final AIP product is 
obtained by spontaneous trans-thioesterification of the unprotected peptide α-thioester in 
neutral aqueous solution.[63] Synthetic AIPs are extremely potent agonists and antagonists 
of cognate and non-cognate AgrC receptors, respectively, with EC50 and IC50 values in 
the low to sub-nanomolar range.[45, 62, 63, 80, 83, 84] The recognition determinants for agonism 
are much more stringent than those for antagonism, consistent with the requirement for 
group-specific AIP–AgrC interactions for activation but not inhibition (Table 1).[45, 62, 63, 82, 
86] For example, the exocyclic “tail” residues are dispensable for inhibition but not 
activation.[45, 62, 84] Indeed, some truncated AIPs consisting of only the pentapeptide 
macrocycles inhibit all four S. aureus AgrC receptors, including their cognate AgrC.[83] 
Furthermore, replacing the thiolactone linkage of the AIP with a lactam or lactone causes 
a dramatic reduction in agonistic potency but has virtually no effect on antagonism.[45, 80] 
Linear versions of the AIPs are completely inactive, indicating that a macrocyclic 
structure is one requirement for inhibition as well as for activation.[45] The presence of 
two bulky hydrophobic residues at the C-terminus, a strongly conserved feature of the 
staphylococcal AIPs (Figure 10), also seems to be critical for binding and activity since 
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alanine substitutions at either of these positions in AIP-I, -II and -III have all resulted in a 
dramatic reduction in agonist and antagonist potency.[45, 59, 80, 84] Recent NMR studies 
produced structures of the four native AIPs that revealed a tri-residue “hydrophobic 
knob” essential for binding and therefore bioactivity (Figure 11).[86] Thus, the macrocycle 
and hydrophobic binding motif are important for bioactivity, and the thioester and tail 
residues are additionally required for AgrC receptor activation but not necessarily for 
binding or inhibition. 
 
While all four S. aureus AIPs follow the general paradigm described above, 
determinants of specific AIP–AgrC interactions vary considerably among the different 
groups. Alanine scanning mutagenesis revealed that the key residues for receptor 
activation lie in different positions in the sequences of different AIPs. [45, 80, 84] For 
example, D5 of AIP-I and D4 of AIP-III are endocyclic, and N3 of AIP-II is in the tail. 
Each residue is a critical determinant for specific activation of its cognate AgrC receptor. 
Replacing these critical residues’ side chain functionalities with the methyl group of 
alanine leads to the D5A AIP-I, D4A AIP-III and N3A AIP-II mutants that results in loss 
of specificity but not activity, as the AIP analogs maintain antagonism of non-cognate 
AgrC receptors and are converted to antagonists of their cognate receptors (Table 1). 
Conversely, substitution of an amide for the acid in D5N AIP-I unexpectedly converts the 
peptide to an AgrC-III agonist while maintaining cognate AgrC-I activation, and D5F 
AIP-I is also an agonist of AgrC-I. [63] Finally, nonnative appendages, such as biotin, can 
be conjugated to the N-terminus of AIP-I without significantly affecting its activity, but 
the addition of one amino acid to the N-terminus of AIP-III leads to a loss of agonism. [63]  
















         
 
Figure 10.  Sequence Alignment Indicates a Hydrophobic, C-terminal Motif in 
Known and Predicted Staphylococcal AIPs   
Polar residues are shaded blue and non-polar residues are shaded yellow, highlighting the 
conserved C-terminal hydrophobic motif outlined in black. The conserved cysteine is 
shaded in gray, and note that the S. intermedius AIP contains a serine instead of a 
cysteine, which forms a lactone instead of a thiolactone. This figure is adapted from 
Wright et al. [59] 
 
S. aureus, group I   Y S T C D F I M 
S. aureus, group IV   Y S T C Y F I M 
S. aureus, group III    I N C D F L L 
S. aureus, group II  G V N A C S S L F 
S. capitis, group I  G A N P C Q L Y Y 
S. capitis, group II  G A N P C A L Y Y 
S. epidermidis, group I   D S V C A S Y F 
S. epidermidis, group II  K Y N P C S N Y L 
S. epidermidis, group III  K Y N P C A S Y L 
S. warnerii   Y S P C T N F F 
S. caprae, group I  G Y S T C S Y Y F 
S. caprae, group II  G Y R T C N T Y F 
S. lugdunensis, group I    D I C N A Y F 
S. lugdunensis, group II    D M C N G Y F 
S. carnosus  K Y N P C V G Y F 
S. simulans, group I  K Y N P C L G F L 
S. simulans, group II  K Y Y P C F G Y F 
S. intermedius  R I P T S T G F F 
S. auricularis, group I  K A K T C T V L Y 
S. auricularis, group II  K T K T C T V L Y 
S. arlettae  G V N P C G G W F 
S. gallinarum V G A R P C G G F F 
S. xylosus  G A K P C G G F F 
S. conhii cohnii  G G K V C S A Y F 
S. cohnii urealyticum  S V K P C T G F A 
	  













Figure 11.  AIP Binding Hydrophobic Knob Motif 
A space-filling model of AIP-III displaying hydrophobic residues in yellow and 
hydrophilic in green.  This figure is adapted from Tal-Gan et al. [86] The model is oriented 
with the AIP macrocycle extending out of the plane of the paper and the AIP tail is 
hidden behind. The red triangle indicates the side chains of AIP-III involved in this 
proposed “hydrophobic knob” binding motif, which is necessary for AgrC binding. The 
light blue dot indicates another important interaction within AIP-III for activation—the 
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Competitive antagonism best explains the mechanism of intergroup agr 
interference of the AgrC receptor.[79] The less stringent AIP sequence requirements for 
antagonism suggest that an AIP binding event is sufficient for blocking activation of 
AgrC by a cognate AIP and that AgrC activation requires an additional, specific agonistic 
interaction. Wash-out and order of addition experiments indicated that both agonists and 
antagonists bind AgrC in a reversible manner,[79] consistent with competitive antagonism 
and contradictory to an earlier model involving receptor acylation by the thioester-
containing AIP. [45] Inverse agonism has also been observed in constitutively active AgrC 
mutants, which does further support competitive binding of AgrC and raises the 
possibility that some non-cognate AIPs induce and/or stabilize an inactive receptor 
conformation.[87] Recently, AgrC-I was incorporated into nanometer-scale lipid bilayer 
discs (nanodiscs) for in vitro biochemical assays, and among other findings, AIP-II was 
not only confirmed as an inverse agonist of AgrC-I but also shown to stabilize AgrC-I in 
an inactive conformation.[88] Thus, the mechanism of intergroup agr interference of AgrC 
occurs in a competitive fashion where AIP can act as a simple, neutral antagonist or help 
to stabilize an inactive conformation of AgrC as an inverse agonist. [31, 79, 83, 87, 88] 
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1.2.3 Detecting the AIP Through a Two Component Signaling System 
AgrC is an HPK that belongs to the small, unique HPK10 subfamily of QS receptors in 
Gram-positive bacteria (Figure 12A and B).[89] These receptors have a polytopic 
transmembrane sensor domain, a distinct sequence pattern, F[RK]HDYXN, around the 
histidine phosphoryl-acceptor residue (known as the H box), and catalytically important 
N-box and G-box residues. They lack a D-box motif, typically involved in nucleotide 
binding. Besides these differences, AgrC does not contain a coiled-coil HAMP (histidine 
kinase, adenylyl cyclase, MCP, and phosphatase) domain but instead has a putative 
coiled-coil in the DHp subdomain (Figure 12A),[55, 88] which likely mediates 
homodimerization. In order to determine whether AgrC exists as a pre-formed or ligand-
induced dimer, co-immunoprecipitation of differentially tagged versions of AgrC in the 
absence and presence of AIP was performed. This analysis indicated that AgrC exists as a 
preformed dimer in the absence of AIP.[90]  
 
The sensor domain of HPK10 family members is predicted to be polytopic.[89, 91] To 
obtain more accurate topographical description of the HPK10 sensory domain, [55, 92] 
bioinformatic analysis of sixteen HPK10 sequences using TOPCONS, which merges the 
topology predictions of five different predictive programs into a single consensus 
topology,[93] generated a consensus topology for an HPK10 sensory domain with four 
highly conserved TM domains within the C-terminal two-thirds of the sensory domain 
sequence that have the same orientation in all sixteen HPK10 receptors.[55] It also indicated 
that the N-terminus of the sensor domain is not well conserved and that the position and 
number of TM domains is variable among the 16 different HPK10 receptors, of which 
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AgrC was included. The AgrC sensor domain consists of the first ~205 amino acids out 
of 430.[94] Two different experimental studies have tried to determine the topology of the 
AgrC sensor domain. The first study used hydropathy analysis of AgrC along with AgrC-
phoA fusion proteins, which indicated AgrC possesses six transmembrane (TM) helices 
and the N- and C-termini of the AgrC sensor domain on the cytosolic side of the 
membrane.[94] A more recent study, however, reported a topology for AgrC with seven 
TM helices. Wang et al.[95] used AgrC-GFP fusion proteins and the substituted cysteine 
accessibility method (SCAM) to determine AgrC’s topology with a periplasmic N-
terminus and a cytosolic C-terminus.[95] (Similar topological inconsistencies were 
observed in structural studies of another HPK10 family member, PlnB.[96, 97]) While the 
topology of the AgrC sensor domain is unresolved, experimental results and 
bioinformatics suggest there is some variability in its N-terminal portion.[55] What effect 
such variability has in the sensor domain is not fully understood, although some efforts 
have attempted to understand where AIP might bind and interact with AgrC.  
 
In order to find the specificity determinants in AgrC, sensor domain chimeras 
were constructed by dividing the AgrC sensor domain into proximal and distal segments 
(Figure 12C).[59] Using the six TM helices predicted by Lina et al.,[94] residues 86-93 of 
AgrC-I are located within the third transmembrane domain and are identical in AgrC-I, -
III and –IV. They were, therefore chosen as the site for splicing AgrC chimeras together 
(red line in Figure 12C). The resulting constructs were transduced into a β-lactamase 
reporter strain in order to analyze their activities.[63] In general, the functionality of each 
chimera was proportional to the degree of sequence conservation between the two 
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contributing receptors. AgrC-I and IV sensor domains share 87% sequence identity, and 
both AgrC-I::IV (N-terminal portion of AgrC-I fused to C-terminal portion of AgrC-IV 
sensor domain) and AgrC-IV::I were functional. Chimeras involving AgrC-III (~54% 
sequence identity with AgrC-I and IV) were functional but had unpredictable activities. 
Chimeras involving the most divergent receptor, AgrC-II, were not functional. Attempts 
to detect AgrC and the chimeras by western blot were unsuccessful in this study; thus, it 
was unclear whether the lack of function was due to poor expression or the inability to 
respond to the AIP agonist. The activities of the six functional chimeras, AgrC-I::IV, -
IV::I, -I::III, -III::I, -III::IV, and -IV::III, were tested (Table 2).[59] 
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Figure 12.  Histidine Protein Kinase Family 10 Alignment and AgrC Domain and 
Sensor Structure 
A) Alignment of three conserved motifs among six HPK10 family members and two 
distantly related HPKs of Gram-negative bacteria.[89] Residues that are identical among 
all HPKs shown are shaded yellow and other conserved motifs are shaded turquoise. The 
H-box histidine is the site of phosphorylation, and the N-box and G-box asparagine and 
glycine residues are important for ATP binding. B) The domain structure of AgrC, 
including the positions of the residues shaded yellow in (A). The hash marks indicate a 
predicted coiled-coil. The transmembrane topology of AgrC-I is shown,[94] along with 
three residues important for recognition of AIP-I.[82] C) Topology of AgrC-I. The red line 
in the third transmembrane region represents the splicing junction for chimeras used in 
the study by Wright et al.[59] The shaded residues indicate the amino acid residues that 
differ with AgrC-IV. Five key residues for group I/IV specificity are highlighted 
(residues important for AIP-I recognition are shaded blue).[82] This figure is adapted from 
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AgrC (S. aureus)  230 INNEMRKFRHDYVNILTTL  330 SRSIGIILDNAIEAS  382 FQESFSTKGEGRGLGLSTLKEIA 
AgrC (S. epidermidis) 227 INNEMRKFRHDYVNILTTL  327 SRIIGIIVDNAIEAS  379 FEQGFSTKGDNRGLGLSTLKELT 
ComD (S. pneumoniae) 239 LYNEIRGFRHDYAGMLVSM  339 VRIMSVLLNNAVEGS  391 FALGFSTKGRNRGVGLNNVKELL 
SppK (L. sakei)  248 QYTELRRFKHDYQNILLSL  348 IRIIGILLDNAIEQA  399 SELGYSTKGAGRGTGLANVQDLI 
PinB (L. plantarum) 245 QYLELRKFKHDYKNLIASL  342 VRIIGNLLDNAIEQA  393 FETGYSTKGSNRGLGLTNVRDLV 
CbnK (C. piscicola) 230 NQQKLRKFKHDYENLLLSL  330 VRVVGITLDNAIEGA  382 MIQGTSSKENHKGLGLSNIQEIK 
 
 
EnzZ (E. coli)  234 RTLLMAGVSHDLRTPLTRI  334 PLSIKRAVANMVVNA  391 VRGDSARTISGTGLGLAIVQRIV 
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The chimeras of the group I and IV receptors were activated by both AIP-I and -
IV and inhibited by AIP-II and truncated AIP-II (trAIP-II), in line with the trends 
observed with the two native receptors (Table 2). However, AgrC IV::I was activated 
much more strongly by AIP-I than AIP-IV; whereas, the opposite was true for AgrC-I::IV 
(Table 2). As previously suggested by Lina et al.,[94] this result indicated that the major 
determinant of AIP recognition is in the distal, C-terminal region of the sensor, at least 
within agr group-I and -IV. In order to find the individual amino acids responsible for 
ligand specificity in AgrC-I and -IV, Geisinger et al. explored the distal, C-terminal 
region of the AgrC sensor domain.[82] Of the 27 amino acid differences between the 
AgrC-I and -IV sensor domains, only seven are located in the C-terminal region of 
interest; and five of those seven are located in or near an extracellular loop close to the 
splicing junction site, placing them nearly in the center of AgrC (Figure 12C). These five 
residues of interest in AgrC-IV were systematically replaced with the corresponding 
amino acids in AgrC-I, and reciprocal mutations were made in AgrC-I. The activities of 
the resulting constructs showed that the main specificity determinants between AgrC-I 
and -IV are indeed the five divergent residues in the second extracellular loop, which are 
residues 100, 101, 104, 107 and 116 (Figure 12C). Systematic mutation of these residues 
and testing them with synthetic AIPs revealed an interesting trend that indicated some 
specificity determinants of AgrC-I and -IV for their cognate AIPs. Position five of AIP-I 
(Asp) and positions 104, 107, and 116 in AgrC-I (Thr, Ser, Ser) are all polar amino acids, 
while the corresponding positions in AIP-IV (Tyr) and AgrC-IV (Val, Val, Ile) are all 
nonpolar. Thus, Geisinger et al. hypothesized that polar versus nonpolar interactions 
drive specificity in this case.[82] 
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Table 2.  Activities of AIPs and AIP Derivatives against AgrC Sensor Domain 
Chimeras 
 
 Activation EC50 (nM), (95% CI) 
AIP 











— + ++ 
AIP-II — — — — + 3100 
+ 
640 















D5A AIP-I — — — — ++ ++ 




— — ++ ++ 
trAIP-II — — — — ++ 160 
++ 
50 
Linear AIP-I nt nt nt nt + 3100 
+ 
6700 
Linear AIP-II — nt nt nt — + 
 
 Inhibition IC50 (nM), (95% CI) 
AIP 
Derivative AgrC-I::IV AgrC-IV::I AgrC-III::I AgrC-III::IV AgrC-I::III AgrC-IV::III 
AIP-I nt nt nt + nt nt 
AIP-II + + + + nt nt 
AIP-III — + + + nt nt 
AIP-IV nt nt + nt nt nt 
D5N AIP-I + nt + + nt nt 
trAIP-II + + + + nt nt 
 
Chimera notation:  AgrC-X::Y, referring to the agr group identities of the N-terminal (X) 
and C-terminal (Y) portions of the sensor domain.  Precise EC50 and IC50 values and 95% 
confidence intervals are given if known. Number of plus (+) symbols indicates the 
approximate activity. + = EC50 or IC50 value >200 nM. ++ = EC50 or IC50 value <200 nM.  
nt = not tested.  The dash (—) indicates no detectable activity.  
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The sensor domain chimeras in which the proximal region was derived from 
AgrC-III followed the trend of the AgrC-I/IV chimeras, but were much less sensitive to 
activation by the AIPs. For example, AgrC-III::I was activated by AIP-I at concentrations 
two orders of magnitude higher than that required to activate AgrC-IV::I and was not 
cross-activated by AIP-IV (Table 2). Similarly, AgrC-III::IV was activated by AIP-IV 
but not AIP-I or III. More surprising were the results with the AgrC-I::III and -IV::III 
chimeras.  Just as the chimeras described above, they were preferentially responsive to 
AIP-III; however, both of these chimeras were also strongly activated by many other 
AIPs (Table 2). These included several potent inhibitors of AgrC-III, such as AIP-I, -II 
and -IV,[45, 61] and inhibitors of all four agr groups, such as D5A AIP-I and trAIP-II.[62, 63] 
Even linear AIP-I and -II, which are generally inert against AgrC,[45, 61] were found to 
weakly activate one or both of these chimeras. Moreover, no AIP or AIP derivative tested 
was an inhibitor of either receptor. While the requirements for activation are typically 
stricter than those for inhibition, AgrC-I::III and -IV::III are activated by any ligand that 
can bind. In other words, a distortion within these chimeras bypasses the need for any 
specific contacts, meaning that they are no longer regulated by group-specific 
determinants presumed to be responsible for activation of native AgrC receptors. Instead, 
all that is required for activation is the ability to bind. 
 
It is generally accepted that AIP binding results in trans-autophosphorylation of 
an AgrC dimer, where an AgrC protomer within the dimer phosphorylates the opposite 
protomer.[90] Once trans-autophosphorylation occurs, the phosphoryl-group is transferred 
from AgrC to a conserved aspartate residue in AgrA.[98] Recently, there was direct 
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evidence of phosphoryl-group transfer from AgrC-I to AgrA. Wang et al. were able to 
purify and incorporate AgrC into nanometer-scale lipid bilayer discs (nanodiscs) for the 
first biochemical assays of AgrC.[88] Among many of their findings, one interaction they 
reported was radio-labeled phosphorelay from AgrC-I in nanodiscs and AgrA, when 
AgrC-I nanodiscs were incubated with AIP-I and [γ-32P]ATP and then AgrA was added. 
Their results also indicated that AIP binds AgrC in a 2:2 stoichiometry, and they reported 
a binding constant of 122 nM for AIP-I. More importantly, they elucidated how the AgrC 
sensor domain transduces the extracellular AIP signal to trigger intracellular kinase 
activation (Figure 13).[88] The TMH-DHp linker of AgrC has strong helical propensity, so 
it was hypothesized that AgrC uses helical twisting to autophosphorylate itself. To test 
this model, a cysteine crosslinking strategy was used to interrogate whether this linker 
region undergoes conformational changes in the presence of AIP and then trap those 
conformations by forming a nonnative disulfide linkage. The TMH-DHp region of AgrC-
I was shown to rotate in a counter-clockwise fashion in the presence of AIP-I (agonist) 
and in a clockwise fashion in the presence of AIP-II (inverse agonist).[88] Thus, 
conformational changes in AgrC lead to autophosphorylation, which enables AgrC to 
pass the AIP signal further onto AgrA. 
 
  




Figure 13.  AgrC Signal Transduction Model 
This model is adapted from Wang et al.[88] When the sensor domain of AgrC interacts 
with AIP, it induces rotational motion within the linker helix of the DHp subdomain, 
which connects the sensor domain and the histidine kinase domain. When the AIP is the 
cognate agonist of AgrC (AIP-I in the model), the linker helix rotates counter-clockwise 
leading to trans-autophosphorylation of AgrC and an active histidine kinase. In the event 
that an antagonist or inverse agonist (AIP-II in the model) binds AgrC-I, the linker helix 
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AgrA is the response regulator (RR) of the agr TCS system and contains 238 
amino acids split into two domains, according to predictions based on homology 
modeling (Figure 14A).[99] It is a transcriptional regulator belonging to the LytTR family 
of regulators.[100] The putative phosphorylation site aspartate is in the N-terminal CheY-
like receiver domain, which presumably modulates DNA binding by the C-terminal 
LytTR domain. The majority of RRs bind DNA via helix-turn-helix or winged helix 
motifs, but RRs of the LytTR family contain a novel fold.[99, 100] A crystal structure of 
residues 137-238 of AgrA in complex with a 15-base pair DNA duplex showed that it 
contains a novel 10-stranded β-fold (Figure 14B and C).[100] Residues H169 and R233 
make base-specific contacts with DNA, and subsequent mutagenesis confirmed they are 
essential for DNA binding (Figure 14C). Addition of acetyl phosphate promotes homo-
dimerization of AgrA, suggesting that the phosphorylated dimer is the active species; and 
electrophoretic mobility shift assay (EMSA) experiments with the agr P2 promoter 
indicate AgrA binds as a dimer with high affinity (Kd = 0.16 nM), 24-fold higher 
compared to un-phosphorylated AgrA (Kd = 3.8 nM).[98] A frameshift mutation in agrA 
resulting in a C-terminal amino acid sequence of KKNIIR instead of KKI causes a delay 
in RNAIII production and lack of δ-hemolysin activity in S. aureus strain RN4220.[101] 
Possibly, the AgrA C-terminus may be important for homo-dimerization, stability and/or 
other protein-protein interactions. However, the crystal structure does not provide further 
clarity or support for such a role of the C-terminal end in AgrA activity.[100, 101] DNaseI 
footprinting assays of the P2-P3 promoter region demonstrated two regions of protection, 
both overlapping the AgrA binding site direct repeats previously identified based on 
consensus LytTR binding sequences. AgrA binds to P2 with higher affinity than the P3 
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promoter (Kd 0.16 nM vs 1.7 nM).[98] This difference may explain why the P2 promoter is 
turned on before the P3 promoter when agr is activated. Finally, the conformational 
changes associated with phosphorylation and how they regulate the LytTR domain as 
well as AgrA’s recognition of and interaction with AgrC are yet to be characterized. 
 
1.2.4 RNAIII—the Effector Molecule of agr 
The primary effector molecule of the agr response, RNAIII, acts as both a messenger and 
antisense RNA to carry out multiple functions.[60] RNAIII is a 514-nucleotide regulatory 
RNA transcribed from the P3 promoter, which is near the P2 promoter but divergent in its 
transcribed directionality.[25] The RNAIII secondary structure contains 14 hairpins (Figure 
15), including three C-rich hairpins, which is unusual for an AT-rich organism such as S. 
aureus.[102] Near the 5’-end is a region responsible for inducing α-hemolysin toxin 
translation (hla) as well as a region containing the hld gene. Closer to the 3’-end are the 
hairpins (numbers 12-14) involved in negative regulation of translation. The high content 
of hairpin structures enables RNAIII to have an unusually long half-life of 45 minutes in 
culture.[103, 104] Nucleotides 85-165 of RNAIII encode the exotoxin δ-hemolysin (hld 
gene), which is a 26 amino acid amphipathic peptide capable of forming pores within cell 
membranes (Figure 15).[25, 105] A region downstream of the δ-hemolysin gene encoded in 
the RNAIII transcript regulates its expression; however, the mechanism of regulation is 
poorly understood.[102, 106] Initially, it was believed that δ-toxin was mediating much of the 
regulatory effects of agr activation. Further analysis revealed it was the mRNA itself that 
was responsible.[60] 
  




Figure 14.  AgrA Domain Structure and LytTR Domain Crystal Structure 
A) AgrA domain structure. The N-terminal CheY-like receiver domain is phosphorylated 
by AgrC, which causes a conformational change in the C-terminal DNA binding LytTR 
domain. The approximate position of the phosphorylation site aspartate based on 
sequence alignment is shown (Asp-59 in S. aureus). B) The crystal structure of the AgrA 
LytTR domain in complex with DNA (pdb code 3BS1),[100] demonstrating that AgrA has 
a novel ten-stranded β-fold arranged into three antiparallel β-sheets. Three key residues 
that interact with DNA are indicated. The β-strands are colored blue, and helices are 
colored red.  
crystal structure in (B) 
A) 
B) 
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RNAIII regulates gene expression at the translational level by base pairing with 
the mRNA of numerous virulence genes as well as the Rot transcriptional regulator. 
RNAIII promotes translation by relieving RNAI hairpins and making a ribosome binding 
site (RBS) available as it does with α-hemolysin toxin.[48] Conversely, RNAIII inhibits 
protein translation by antisense pairing with mRNA 5’ untranslated regions, often 
overlapping the RBS, or forming double-stranded mRNA structures unrecognizable by 
the translation initiation complex.[53, 103, 107-109] Formation of double-stranded RNAs has the 
dual effect of creating a substrate for RNase III which will cleave the targeted mRNA to 
remove the RBS and decrease the half-life of the mRNA.[47, 49] Inhibition of Rot 
translation also leads to large changes in gene regulation, resulting in upregulation of 
secreted virulence factors and downregulation of surface proteins.[52] Through these 
mechanisms RNAIII positively or negatively regulates the expression of numerous 
virulence factors at multiple levels (Table 3). 
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Figure 15.  RNAIII  Structure 
Secondary structure of S. aureus RNAIII—the 514 nucleotide RNA that is the agr 
effector molecule.95 RNAIII hairpins are designated with circled numbers while circled 
letters signify long-range interactions that establish general domains. The RNA sequence 
for hld—the δ-hemolysin toxin encoded in RNAIII— is indicated by the boxed start and 
stop codons within the structure. Nucleotides that basepair with and activate hla 
translation are colored green. Nucleotides demonstrated to inhibit translation of genes are 
red.  This figure is an adaptation from Benito et al.[102] 
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Table 3.  Genes regulated by agr 
 
Genes upregulated by agr 
Gene Product Function Note Reference 
Secreted Enzymes 
splA-F Spl proteases Serine proteases C [110] 
sspA V8 Protease Serine protease C [111, 112] 
aur Aureolysin Metalloprotease C [111, 112] 
sspB Ssp Protease Cysteine protease C [111] 
scpA Staphopain Cysteine protease C [111] 
lip Lipase Fatty acid breakdown C  
geh Glycerol ester hydrolase Fatty acid breakdown C  
sak Staphylokinase Plasminogen activator C [30] 
ureA-G Urease Urea neutralization C  
plc PI-Phospholipase-C Phosphatidyl-inositol hydrolase C [113] 
fme Fatty acid modifying enzyme Bactericidial fatty acid neutralization C [114] 
Toxins 
hla Alpha-toxin Cytolysin, pore forming A [30, 60, 107] 
hlb Beta-hemolysin Cytolysin, sphingomyelinase C [30] 
hld Delta-toxin Cytolysin, pore forming B [30, 115] 
hlgBC Gamma-hemolysin Cytolysin, two-component pore forming C [116] 
lukD/E Leukocidin Cytolysin, two-component pore forming C [116] 
lukS/F Panton-Valentine leukocidin Cytolysin, two-component pore forming C [116] 
lukG/H Leukocidin Cytolysin, two-component pore forming C  
tst Toxic Shock Syndrome Toxin-1 Superantigen C [30] 
seb Enterotoxin B Superantigen C [117, 118] 
sec Enterotoxin C Superantigen C [119] 
sed Enterotoxin D Superantigen C [120] 
etaAB Exfoliative toxins Desmoglein cleavage (Scalded-skin syndrome) C [121, 122] 
Other 
PSMα1-4 Alpha PSMs Cytolysin, PMN chemotaxis, inflammatory B [123] 
PSMβ1-2 Beta PSMs Inflammatory B [123] 
arcR Transcriptional regulator Arginine catabolism regulation C  
rsaE RsaE sRNA Gene regulation C [124] 
cap5 Polysaccharide capsule type 5 Antiphagocytic C [125] 
cap8 Polysaccharide capsule type 8 Antiphagocytic C [126] 
pmtA-D Components for PSM transport ABC transporter B  
Genes downregulated by agr 
Gene Product Function Note Reference 
Surface Proteins 
fnbAB Fibronectin Binding Proteins A/B Fibrinogen and fibronectin adhesion A [127] 
spa Protein A Antibody Fc-region binding A [30, 60, 103] 
coa Coagulase Plasminogen to plasmin conversion A [109, 128] 
SA1000 Surface Protein Fibrinogen and fibronectin adhesion A [108] 
Other 
ssl5,8 Staphylococcal superantigen-like 
proteins 5 and 8 
Ssl5 inhibits PMN adherence C [129] 
rot Repressor of toxins transcription 
factor 
Gene regulation A [53, 108] 
Note: 
A.  Post-transcriptional regulation by RNAIII. 
B.  Direct regulation by the AgrA transcriptional regulator 
C.  agr regulation has been demonstrated by microarray[52, 123, 130, 131] or proteomic[132] studies. 
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1.3 Specific Aims 
Outlined below are the specific aims of the thesis project, which in part were originally 
submitted in November 2010. Progress toward each of these aims is reported herein. 
AIM 1.  Identifying the components necessary for secreting S. aureus AIPs 
AgrD is a membrane-associated polypeptide that undergoes two proteolytic cleavage 
steps to release a mature AIP. While it has been shown that AgrB performs the first 
cleavage step to remove the SID of AgrD and form the thiolactone ring of the AIP, the 
role of AgrB during the secretion process is unknown. We will use intein protein 
chemistry in agr null S. aureus cells to express several AIP precursors and replace the 
known function of AgrB to investigate the role of AgrB in secreting AIP.   
AIM 2.  Secreting the AIP precursor across the S. aureus plasma membrane 
As the precursor to AIP, AgrD has a unique, module-like design, which seems poised to 
enable AIP secretion through a series of processing events that alter its interaction with 
the bacterial membrane. Physicochemical, biophysical and mutational studies of AIP and 
AgrD will help test a hypothesized secretion mechanism. 
AIM 3.  Elucidating the final cleavage step to release the AIP 
The final step in the AIP biosynthetic pathway is cleavage of the MAD of AgrD releasing 
AIP into the extracellular environment. SpsB, a type-I signal peptidase, is believed to 
catalyze this cleavage event, although it has only been shown to cleave an AgrD-I 
derived peptide. Further biochemical analysis will try to confirm the role of SpsB in AIP 
biosynthesis among the four S. aureus agr specificity groups. 
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AIM 4.  The effect of enlarging the AIP thiolactone macrocycle on AgrC 
No SAR study of AIP has investigated the effect of AIP macrocycle size on agr 
activation or inhibition. AIP-I will be used as a scaffold to investigate the effect of 
increasing or decreasing the size of the AIP thiolactone macrocycle on agr activation. 
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Chapter 2. The Final Steps in AIP Biosynthesis:  Secreting the AgrD(1-32)-
Thiolactone 
2.1 Introduction 
Progress towards elucidating the mechanism of AIP biosynthesis has preceded slowly 
since the initial 1995 report that AgrB is involved in AIP processing.[31] AIP production 
requires three chemical transformations of AgrD:  two proteolytic cleavage steps and 
thiolactone formation. Research has shown that AgrB is responsible for the first cleavage 
step in AIP biosynthesis,[56, 57, 70-72] which removes the SID of AgrD and forms the 
thiolactone macrocycle of the AgrD(1-32)-thiolactone (Figures 6 and 7). AgrB 
accomplishes this step as a cysteinyl endopeptidase forming an acyl-enzyme thioester 
intermediate between AgrB and AgrD, which undergoes trans-thioesterification with the 
conserved sulfhydryl group of Cys-28 in AgrD to form the new thiolactone macrocycle 
of the AgrD(1-32)-thiolactone (Figure 7).[57, 70, 72] These steps prepare the AIP sequence of 
AgrD for externalization and its final chemical transformation.  
 
The secretion mechanism of the partially processed AgrD protein is not 
understood.  One reason AIP secretion is poorly understood involves a general 
uncertainty about which secretion system the cell uses.  While AgrD does not have a 
classical signal peptide as seen in proteins meant for the Sec, Tat or Com secretion 
systems, it does have one element of a Sec-type signal peptide: a type I signal peptidase 
cleavage site (Figure 5C), which would suggest SpsB is the second enzyme involved in S. 
aureus AIP biosynthesis.[58, 73, 133] Still, AgrD does not share other common, structural 
elements of a protein secreted through the Sec pathway (Figure 5).[65, 133] Lacking any 
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clear evidence for a secretion pathway, it has been proposed that AgrB not only processes 
AgrD but also facilitates AgrD’s partitioning into the membrane.[56-58, 72] However, AgrB 
is a small membrane protein (23 kDa) and has no known homology with any type of 
bacterial transporter.[56] Furthermore, there is no clear published evidence that AgrB 
forms higher order oligomers in order to form some type of pore—only dimers have been 
observed in vitro.[72] Most recently, Thoendel et al.[72] reported several mutants of AgrB 
that could cleave AgrD but did not lead to AIP production. These mutations were in the 
lysine patch of AgrB (K129, K130 and K131), and when any of these three residues were 
mutated to glutamate, AIP secretion was not observed.  However, their data cannot 
conclusively determine whether these AgrB mutants inhibit AIP secretion or instead 
promote hydrolysis of the acyl-enzyme thioester intermediate, which would not produce 
mature AIP and explain the observed AgrB cleavage of AgrD. Clearly, there is the need 
for an investigation of the role, if any, of AgrB in AIP secretion. 
 
Herein, we describe our efforts to better understand the secretion step of AIP 
biosynthesis. While we suspect that AgrB is not involved in secretion, there is no 
definitive evidence for or against AgrB facilitating transport of the AgrD(1-32)-
thiolactone across the cellular membrane. We, therefore, engineered strains of S. aureus 
cells that are agr— and express an AgrD(1-32)-intein fusion protein.  These cells can 
express the AgrD(1-32)-I-thiolactone using an intein-mediated thioester intermediate, 
which is independent of AgrB-I. The production of AIP by this new S. aureus strain was 
characterized using a modified version of the rapid, quantitative agrP3::blaZ reporter 
assay previously used to investigate the SAR between AIP and AgrC.[31, 45, 59, 62, 63, 79-83] We 
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also re-introduce AgrB into this new S. aureus background to examine the effect AgrB 
may have on AIP secretion and production.  
 
2.2 The role of AgrB in AIP Secretion 
2.2.1 Engineering the AgrD(1-32)-intein Fusion Protein for Expression in S. aureus 
Cells 
Investigating the role of AgrB in AIP secretion is challenging due to the requirement of 
the enzyme in the first step of AIP biosynthesis. Thus, simply deleting AgrB would 
eliminate AgrD(1-32)-thiolactone production, precluding any studies on secretion of this 
molecule. In principle, producing AgrD(1-32)-I-thiolactone in an AgrB-independent 
fashion would make it possible to test whether AgrB is necessary for AIP secretion. To 
our knowledge, no other staphylococcal protein catalyzes the formation of such a cyclic 
peptide, so there is not another biosynthetic pathway to exploit and replace the enzymatic 
role of AgrB. Instead, we chose to replace the catalytic activity of AgrB using intein 
protein chemistry. Inteins are protein autoprocessing domains that catalyze protein-
splicing events.[134, 135] Their reaction mechanism is well characterized and involves a 
thioester intermediate (Figure 16). In fact, Camarero et al. used an intein to mediate the 
cyclization of an SH3 protein domain in E. coli cells that was biologically active and 
adopted the native SH3 fold.[136] Initially, we tried using the same Mxe GyrA intein used 
by Camarero et al. to produce the AgrD(1-32)-I-thiolactone in S. aureus cells with a C-
terminal thiolactone macrocycle. However, AIP production was not detected using a 
multistage MALDI-MS method developed to detect AIP molecules from cell culture 
medium without a liquid chromatography step.[137] Furthermore, intein-mediated cleavage 
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was undetectable in cell lysates using SDS-PAGE and Western blot analysis (data not 
shown). We suspected the slow splicing rate of the Mxe GyrA intein (~24 hrs) might be 
the problem, and as such turned our attention to a newly discovered group of inteins with 
ultrafast splicing kinetics.[138] These ultrafast protein splicing inteins belong to a 
subfamily of split inteins, where the intein exists as two separate protein domains that 
splice in trans instead of in cis.  The split intein splicing event follows a similar 
mechanism for protein splicing (Figure 16), except that the first step is a binding 
interaction between the N- and C-inteins. Shah et al. characterized a modified set of split 
inteins that were fused together to provide a biochemical tool for generating protein α-
thioester derivatives for such things as expressed protein ligation (EPL).[138] These new 
artificially fused split inteins have splicing rates within a few minutes as opposed to 
several hours for the Mxe GyrA intein. 
  




Figure 16.  Intein-mediated Protein Splicing 
The chemical mechanism of protein splicing using an intein is schematized.  Cys-1 of the 
intein domain mediates an N to S acyl shift in the C-terminal residue of the N-extein. A 
flanking Cys residue at the C-terminal end of the intein then attacks the branched 
intermediate to transfer the N-extein domain near the C-extein domain via trans-
thioesterification. Then, an Asn residue at the -1 positon in relation to the C-terminal Cys 
mediates succinimide formation, removing the intein and leaving the N-extein linked to 
the C-extein via a thioester bond. Finally, the thioester linkage connecting the N- and C-
exteins undergoes an S to N acyl shift to form a stable amide bond within the new 
protein. This figure is adapted from Vila-Perello et al.[134] 
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We decided to use the fused Npu split intein (inteinNpu) described by Shah et al. 
[138] along with a fused Ssp split intein (inteinSsp). The latter was added because it had 
previously been used to carry out EPL in cells.[139] In the EPL mechanism, an intein 
generates a recombinant protein α-thioester if the Cys residue at the C-terminal end of the 
intein is mutated to Ala, which traps the branched thioester intermediate formed after the 
first N to S acyl shift in the intein reaction mechanism (Figure 16, step 1). An exogenous 
thiol can then be added to release a protein α-thioester derivative. In the fused split intein 
constructs, the C-terminal end of the intein was mutated from CFN to AFN, and there is 
also a C-terminal His6-tag for purification and/or analysis purposes. For our purposes, the 
sulfhydryl group of Cys-28 in AgrD is expected to attack the branched thioester 
intermediate formed between the fused split intein and the N-terminus of AgrD, forming 
the AgrD(1-32)-I-thiolactone (Figure 17A). We engineered plasmids from a shuttle 
vector system that contain either the gene for AgrD(1-32)-inteinNpu or AgrD(1-32)-
inteinSsp under a cadmium-inducible promoter. [140] These plasmids were incorporated into 
agr-I—/spa— S. aureus cells (RN10306) for expression. We also engineered strains of S. 
aureus that only expressed the inteinNpu or inteinSsp proteins, respectively (Figure 17B). 
Finally, we engineered strains of S. aureus that express catalytically inactive inteins by 
mutating the catalytic Cys to Ala, which is the 33rd residue in both of the AgrD(1-32)-
intein constructs (Figure 17B). These strains, therefore, express either C33A AgrD(1-32)-
inteinNpu or C33A AgrD(1-32)-inteinSsp fusion proteins. (See Chapter 6 for a list of all 
plasmids and S. aureus strains used and engineered.) 
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Figure 17. Generation of the AgrD(1-32)-I-thiolactone in vivo using a Fused Split 
Intein System 
A) The intein-mediated in vivo cyclization mechanism to form the AgrD(1-32)-I-
thiolactone.  Like the intein splicing mechanism, the cyclization mechanism requires an 
N to S acyl shift within the full-length protein, which is mediated by the Cys-1 of the 
fused split intein domain. Divergent from intein splicing, however, the thioester 
intermediate undergoes trans-thioesterification with the sulfhydryl group of the conserved 
Cys in AIP, Cys-28 of the AgrD(1-32)-I domain. B) Schematics for the full-length 
inteinSsp-containing constructs.  Note the naming convention for C33A AgrD(1-32)-I-
inteinSsp, which indicates the point mutation in the construct is for the catalytic Cys 
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2.2.2 Expression and Characterization of the AgrD(1-32)-I-inteinNpu and AgrD(1-
32)-inteinSsp Expressing S. aureus Cells 
To follow the intein-mediated cyclization reaction, we analyzed whole cell lysates of 
cells expressing AgrD(1-32)-I-inteinNpu and AgrD(1-32)-I-inteinSsp over a 6-hour induced 
growth timespan with SDS-PAGE and Western blot.  Using the AgrD(1-32)-I-inteinSsp 
whole cell lysates as an example (Figure 18), the Western blot analysis detected the C-
terminal His6-tag of the inteinSsp construct.  Within two hours of cadmium induction, 
Western blot analysis detects the full-length AgrD(1-32)-I-inteinSsp construct (Figure 18, 
lane 2).  By four and six hours of induced growth, expression of the full-length construct 
continues and the appearance of only the inteinSsp domain occurs (Figure 18, lanes 3 and 
4), suggesting that a portion of the full-length AgrD(1-32)-I-inteinSsp protein is lost 
presumably through the cyclization of the D1-32 domain. The uninduced AgrD(1-32)-I-
inteinSsp cells do not contain either of these proteins (Figure 18, lane 1).  Furthermore, the 
inactive split intein S. aureus strain (C33A AgrD(1-32)-I-inteinSsp) only expresses a full-
length construct (Figure 18, land 5), which is expected; and the cells expressing only 
inteinSsp are provided as a marker for the protein that accumulates over time in the 
Western blot analysis (Figure 18, lane 7).  The cells expressing AgrD(1-32)-I-inteinNpu or 
the inteinNpu construct behaved similarly to the AgrD(1-32)-I-inteinSsp constructs (data not 
shown). From this analysis, the AgrD(1-32)-I-intein expressing cells could produce the 
AgrD(1-32)-I-thiolactone in the absence of AgrB. 
 
 
          







lane 1 2 3 4 5 6 7 
[Cd2+] (μM) 0 10 10 10 10 0 10 
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Figure 18.  Western Blot Analysis of the AgrD(1-32)-inteinSsp Expressing Cells 
Western blot analysis of whole cell lysates from AgrD(1-32)-inteinSsp over a 6-hr. Cd2+-
induced expression is shown (middle, lanes 1-4). Whole cell lysates from Cd2+-induced 
C33A AgrD(1-32)-inteinSsp and inteinSsp expressing cells are also included (lanes 5 and 7, 
respectively). Since it has a low molecular weight and has no epitope tag, detection of the 
AgrD(1-32)-thiolactone is prohibited. Following SDS-PAGE, the proteins were 
transferred to a nitrocellulose membrane and probed with an Anti-His antibody. The 
membrane was imaged with a LI-COR Odyssey Infrared Imager. As a loading control, 
SDS-PAGE analysis of the cell cultures is also provided (bottom). The 12% Bis-Tris gel 
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 While a tagless AgrD(1-32) domain in AgrD(1-32)-intein constructs might 
produce the most biologically relevant molecule, it also makes detection of the AgrD(1-
32)-thiolactone difficult because of its low molecular weight and lack of epitope tag. 
Thus, the Western blot analysis of AgrD(1-32)-inteinSsp (Figure 18) does not provide any 
evidence for the AgrD(1-32) domain or its presumed thiolactone macrocycle, which is 
essential for AIP activity. It can only suggest that intein-mediated cleavage has occurred. 
After trying several different techniques, we used HPLC-MS to detect AIP-I from sterile-
filtered cell culture supernatants of AgrD(1-32)-inteinNpu and AgrD(1-32)-inteinSsp (Figure 
19). This HPLC-MS analysis provides direct evidence that the cells expressing either 
AgrD(1-32)-intein constructs can produce mature AIP-I in the absence of AgrB. 
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Figure 19.  HPLC-MS Detection of AIP-I from AgrD(1-32)-intein Expressing Cells 
A) HPLC-MS analysis of cell culture supernatants from uninduced (top left) and induced 
(top middle) cells expressing AgrD(1-32)-inteinNpu and the wild-type (WT) group I cells 
(RN6734, top right). The MS chromatograms were taken from similar retention times 
during the HPLC gradient. The AgrD(1-32)-inteinNpu cells secrete a small molecule with a 
very similar molecular weight (961.37) as AIP-I in wild-type S. aureus cells (961.32). B) 
HPLC-MS analysis of cell culture supernatants from uninduced (bottom left) and induced 
(bottom middle) cells expressing AgrD(1-32)-inteinSsp and wild-type (WT) group I cells 
(RN6734, top right).  MS chromatograms were prepared as in A, and similarly, AgrD(1-
32)-inteinSsp cells secrete a small molecule with a similar molecular weight (961.39) as 
AIP-I in RN6734 cells (961.32).  
A) 
B) 
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2.2.3 Cell Culture Supernatants from Cells Expressing AgrD(1-32)-intein 
Constructs Stimulate the TCS of agr-I 
Having detected AIP-I from cells expressing the AgrD(1-32)-intein constructs, we 
wanted to further investigate their cell culture supernatants in a biological context. From 
our HPLC-MS analysis (Figure 19), we knew that the concentration of AIP-I was likely 
low (low nanomolar) in the culture supernatants, because of the low intensity of the 
signal. With a low concentration of AIP in the culture, any biochemical tool used to 
analyze the cell culture supernatants would require some AIP signal amplification.  
Therefore, we turned to the workhorse tool of AIP detection:  the β-lactamase reporter 
assay, which reports on signal transduction through the entire agr TCS and has been used 
extensively for assessing AIP activity.[45, 62, 63, 80, 83, 87] It also amplifies the AIP signal by 
inducing expression of β-lactamase that can be monitored using a colorimetric readout 
like hydrolysis of nitrocefin, a β-lactam, which changes colors upon cleavage (See 
Appendix). Using this assay, we monitored and reported the change in OD490 normalized 
to cell density (OD650) as a way to measure β-lactamase activity (Figure 20A). We 
observed elevated levels of β-lactamase activity in cell culture supernatants of the 
induced AgrD(1-32)-inteinNpu cells and AgrD(1-32)-inteinSsp cells relative to uninduced 
AgrD(1-32)-intein cell culture supernatants (Figure 20A). Since expression of the 
AgrD(1-32)-inteinNpu and AgrD(1-32)-inteinSsp proteins requires cadmium-induction, we 
also monitored the growth of the β-lactamase reporter gene assay cells to make sure the 
cadmium did not inhibit their growth (Figure 20B). A wild-type agr-I cell (RN6734) 
culture supernatant is included to show that the assay cells respond to a known source of 
AIP-I agonist. 
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Figure 20. Biological Activity of the AgrD(1-32)-intein Cell Culture Supernatants 
A) β-lactamase activity assay of cell culture supernatants from cells expressing either 
AgrD(1-32)-inteinNpu or AgrD(1-32)-inteinSsp is plotted. Filtered cell culture supernatants 
were incubated with an exponential phase culture of group I S. aureus reporter strain 
(RN9222). Samples were removed after 60 minutes and assayed for β-lactamase activity 
by the nitrocefin method. After normalizing OD490 readings with cell density, ΔOD490 was 
calculated by subtracting an intial OD490 reading from the endpoint OD490 reading. The 
plot is relative to the CY-GP media normalized to zero. Errors; SD, n = 3. Important p-
values are indicated with a bracket and the numerical p-value above. B) Monitored 
growth of Group I S. aureus reporter strain (RN9222) in the presence of cell culture 
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 In addition to stimulating AgrC-I and thereby β-lactamase activity, we also sought 
to inhibit AgrC-I activation. Previous work identified D5A AIP-I as a self-inhibitor of 
AgrC-I, making it a global antagonist of agr.[63, 80] We engineered another set of AgrD(1-
32)-intein constructs with a point mutation in the AgrD(1-32) domain, changing the AIP 
sequence from the wild-type to the D5A AIP-I sequence (Asp-29 in the AgrD(1-32) 
domain).  We again incorporated these constructs into S. aureus cells and confirmed their 
expression with Western blot analysis (data not shown).  We then tested the D29A 
AgrD(1-32)-intein cell culture supernatants with the β-lactamase reporter assay (Figure 
21). The D29A point mutation in the AgrD(1-32) domain abolishes β-lactamase activity 
in the reporter assay. We also tested the cell strains that express the catalytically inactive 
intein constructs, C33A AgrD(1-32)-inteinNpu and C33A AgrD(1-32)-inteinSsp.  These 
constructs also do not stimulate AgrC-I, as measured by β-lactamase activity. Finally, we 
tested the pure AgrD(1-32)-I-thiolactone (150 nM) in the growth medium to determine if 
it could activate the reporter gene assay cells. (AgrD(1-32)-I-thiolactone was 
recombinantly expressed in E. coli and purified by Boyuan Wang, a graduate student in 
the lab, who provided a small amount for this experiment.) Importantly, there was little 
measureable β-lactamase activity induced by the AgrD(1-32)-I-thiolactone when 
incubated with cells for the 60-min assay.  Combining all of these observations, the cells 










Figure 21. Cell Culture Supernatants from the D29A AgrD(1-32)-intein Expressing 
Cells Inhibit AIP-induced β-lactamase Activity 
β-lactamase activity assay of cell culture supernatants from cells expressing the D29A 
AgrD(1-32)-intein constructs is plotted. Filtered cell culture supernatants from the 
indicated strain were incubated with an exponential phase culture of group I S. aureus 
reporter strain (RN9222). Samples were removed after 60 minutes and assayed for β-
lactamase activity by the nitrocefin method. Normalized ΔOD490 was calculated the same 
as in Figure 20A. The plot is relative to the CY-GP media normalized to zero. Errors; SD, 
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2.2.4 AIP-induced β-lactamase Activity is Not the Result of Cell Lysis 
While in vivo AIP-I production in the absence of AgrB is remarkable, there is no 
evidence that the AIP being produced was actually secreted. It is possible that cell lysis 
during induced growth could release the AgrD(1-32)-I-thiolactone, AgrD(1-32)-inteinNpu 
or AgrD(1-32)-inteinSsp proteins into the growth medium, where SpsB could process the 
AIP precursor at the outer membrane leaflet. Thus, AIP activation could result from a 
non-secretion pathway. To investigate whether AIP activation of AgrC results from 
cellular lysis, we designed a real-time assay to lyse cells and then test those cell culture 
lysates with the β-lactamase reporter assay. The assay involved lysing cells in the culture 
media via a bead-beating method. Briefly, at a certain timepoint (~5 hrs. after induction), 
half the cell culture was added to sterilized beads and vortexed for 10 mins. Upon bead 
removal, the resulting cell lysate in the growth medium was added back to the cell culture 
for a 30-min. incubation at 37°C to allow the possible processing of the AIP precursor by 
the remaining whole cells. Using this cell lysis assay, we could lyse ~40% of the cells 
expressing either AgrD(1-32)-inteinNpu or AgrD(1-32)-inteinSsp in the cell cultures (Table 
4), which was determined via the classical dilution method for calculating colony-
forming units (CFUs).  
 
 Next, we tested the partially lysed cell culture supernatants of the cells expressing 
the AgrD(1-32)-inteinNpu or AgrD(1-32)-inteinSsp proteins with the β-lactamase reporter 
assay. Again, using AgrD(1-32)-inteinSsp as an example, we observed that the addition of 
cell culture lysate does not increase β-lactamase activity above the activity observed from 
induced AgrD(1-32)-inteinSsp cell culture supernatant (Figure 22).  The cell culture 
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supernatants from the various strains that express the AgrD(1-32)-inteinNpu proteins 
behaved similarly to the AgrD(1-32)-inteinSsp in the lysis experiments (data not shown). 
We also analyzed the cell culture supernatants via Western blot and observed that the 
partially lysed cell culture supernatants contain measureable amounts of the AgrD(1-32)-
inteinSsp protein (Figure 22, below bars 5 and 6 of the plot). As expected, none of the 
unlysed cell culture supernatants have measureable amounts of their AgrD(1-32)-intein 
proteins, meaning that cell lysis within these cell cultures is well below ~40%. To further 
show that whole cells could not process the lysed culture supernatants to produce mature 
AIP, we included in our analysis a second lysed cell culture supernatant of the AgrD(1-
32)-inteinSsp cells. As previously described, cells expressing AgrD(1-32)-inteinSsp were 
lysed by the bead-beating method but the lysed culture portion was added to and 
incubated with a cell culture of the uninduced inactive intein cells expressing C33A 
AgrD(1-32)-inteinSsp, which should have produced no mature AIP up to the point of 
adding the lysed AgrD(1-32)-inteinSsp cell culture supernatant.  Thus, any increased signal 
in the β-lactamase assay would result from processing of the AgrD-I-thiolactone 
contained in the added AgrD(1-32)-inteinSsp cell culture lysate supernatant (Figure 22). 
We observed no increase in β-lactamase activity from this hybrid cell culture supernatant, 
further confirming that cell lysis is not responsible for the observed mature AIP-I. The 
same experiment was also included in our analysis of the cells expressing AgrD(1-32)-
inteinNpu and produced similar results.  










Table 4. Colony Forming Unit (CFU) Data for Cell Lysis of Cell Cultures 
from  AgrD(1-32)-inteinNpu or   AgrD(1-32)-inteinSsp Cells 
Controlled Cell Lysis After 3 Hours of Induced Growth 
Cell Strain Induced Culture Bead Lysis Culture % of Induced Lysed 
AgrD(1-32)-
inteinNpu 1.58 x 10
9 cfu/ml 9.4 x 108 cfu/ml 59 % 
AgrD(1-32)-
inteinSsp 2.24 x 10
9 cfu/ml 1.26 x 109 cfu/ml 56 % 
Controlled Cell Lysis After 5.5 Hours of Induced Growth 
Cell Strain Induced Culture Bead Lysis Culture % of Induced Lysed 
AgrD(1-32)-
inteinNpu 3.64 x 10
9 cfu/ml 2.20 x 109 cfu/ml 60 % 
AgrD(1-32)-
inteinSsp 3.76 x 10
9 cfu/ml 2.44 x 109 cfu/ml 65 % 
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Figure 22. Cell Lysis of AgrD(1-32)-inteinSsp Cells Does Not Generate AIP-I Activity 
β-lactamase activity assay of cell culture supernatants from AgrD(1-32)-inteinSsp 
expressing cells is plotted (top). Filtered cell culture supernatants from the indicated 
strain were incubated with an exponential phase culture of group I S. aureus reporter 
strain (RN9222). Samples were removed after 60 minutes and assayed for β-lactamase 
activity by the nitrocefin method. Normalized ΔOD490 was calculated as in Figure 20A. 
The plot is relative to the CY-GP media normalized to zero. Errors; SD, n = 3. Important 
p-values are indicated with a bracket and the numerical p-value. Western blot analysis of 
the AgrD-fused split intein cell culture supernatants is also provided (middle). Following 
SDS-PAGE, the proteins were transferred to a nitrocellulose membrane and probed with 
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2.2.5 AgrB-I Does Not Facilitate an Increase in AIP-I Activity 
By eliminating cell lysis as a possible cause for AIP-induced β-lactamase activity within 
the cells expressing AgrD(1-32)-intein constructs, we could turn our attention toward the 
role AgrB might play in secretion of the AgrD(1-32)-thiolactone. We engineered a new 
set of S. aureus strains that expressed either a AgrD(1-32)-inteinNpu or AgrD(1-32)-
inteinSsp construct and a variant of AgrB in agr—/spa— S. aureus cells. One variant of 
AgrB expressed was an alanine mutation at the Cys-84 residue—the catalytic residue of 
AgrB. This C84A mutation would not be able to catalyze formation of the AgrD(1-32)-
thiolactone, but if AgrB facilitates secretion, this mutant should be able to carry out that 
process. Two variants of AgrB expressed were double mutants: C84A, K129E AgrB and 
C84A, K131E AgrB, which were used to investigate whether the lysine patch is critical to 
AgrB-mediated secretion as proposed by Thoendel et al.[72] The wild-type AgrB was also 
included in this set of experiments, which made a total of eight new strains expressing 
either the AgrD(1-32)-inteinNpu or AgrD(1-32)-inteinSsp with one of the four variants of 
AgrB. For characterization purposes, all four variants of AgrB contained a C-terminal 
FLAG epitope tag, and Western blot analysis of each strain confirmed expression of an 
AgrB variant in the whole cell lysate along with AgrD(1-32)-inteinNpu or AgrD(1-32)-
inteinSsp proteins (Figure 23). For unknown reasons, we were unable to engineer strains 
that expressed the C84A, K130E AgrB mutant. 
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Figure 23. AgrB Mutants Co-Expressed with AgrD(1-32)-inteinNpu or AgrD(1-32)-
inteinSsp 
Western blot analysis of whole cell lysates from cells expressing various AgrB mutants 
with either AgrD(1-32)-inteinNpu or AgrD(1-32)-inteinSsp over a 6-hr. induced growth 
period is shown. AgrB mutants with a C-terminal FLAG tag are shown in the middle 
panel. The cells expressing WT AgrB proteins were run on a separate SDS-PAGE gel. 
Following SDS-PAGE, the proteins were transferred to a nitrocellulose membrane and 
probed with an anti-FLAG antibody. The membrane was imaged with a LI-COR Odyssey 
Infrared Imager. The same whole cell lysates were also checked to see whether they 
expressed AgrD(1-32)-inteinNpu (bottom left panel) or AgrD(1-32)-inteinSsp (bottom right 
panel), respectively. Following SDS-PAGE, the proteins were transferred to a 
nitrocellulose membrane and probed with an Anti-His antibody. The membrane was 
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Using the β-lactamase reporter gene assay, we tested all of the strains expressing 
AgrB with either AgrD(1-32)-inteinNpu or AgrD(1-32)-inteinSsp to assay AIP-I activity and 
determine what effect the different variants of AgrB have on AIP-I secretion (Figures 24 
and 25). When compared to the cells expressing only AgrD(1-32)-inteinNpu (Figure 24) or 
AgrD(1-32)-inteinSsp (Figure 25), which produce AIP-I in the absence of AgrB, none of 
the cell culture supernatants from cells expressing an AgrB variant and an AgrD(1-32)-
intein construct produced an increase of AIP-induced β-lactamase activity. Most of the 
AgrB expressing cells induced the same amount of β-lactamase activity as the non-AgrB 
expressing cells.  Only in the instance of the cells expressing the C84A AgrB with an 
AgrD(1-32)-intein construct had a slight decrease in activity compared to the cells only 
expressing the AgrD(1-32)-intein proteins. Still, the C84A single point mutant did not 
induce an increase in β-lactamase activity. The C84A AgrB mutants with a lysine point 
mutation induced similar amounts of β-lactamase activity as the AgrD(1-32)-intein, as 
did the WT AgrB mutants. In all, there are six cell culture supernatants that indicate 
AgrB does not statistically increase AIP secretion—two of which are WT AgrB. In the 
other two cell culture supernatants from the cells expressing a C84A AgrB mutant, there 
was a slight decrease in β-lactamase activity observed. 
 
  
	   73 
 
 
Figure 24. AgrB Does Not Increase AIP-I Activity in the AgrD(1-32)-inteinNpu-
expressing Cell Culture Supernatants 
β-lactamase activity assay of cell culture supernatants from cells expressing AgrD(1-32)-
inteinNpu protein in the absence or presence of an indicated AgrB variant is plotted. 
Filtered cell culture supernatants from the indicated strain were incubated with an 
exponential phase culture of group I S. aureus reporter strain (RN9222). Samples were 
removed after 60 minutes and assayed for β-lactamase activity by the nitrocefin method. 
Normalized ΔOD490 was calculated the same as in Figure 20A. The plot is relative to the 
CY-GP media normalized to zero. Errors; SD, n = 6. Important p-values are indicated 
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Figure 25. AgrB Does Not Increase AIP-I Activity in the AgrD(1-32)-inteinSsp-
expressing Cell Culture Supernatants 
β-lactamase activity assay of cell culture supernatants from cells expressing AgrD(1-32)-
inteinSsp protein in the absence or presence of an indicated AgrB variant is plotted. 
Filtered cell culture supernatants from the indicated strain were incubated with an 
exponential phase culture of group I S. aureus reporter strain (RN9222). Samples were 
removed after 60 minutes and assayed for β-lactamase activity by the nitrocefin method. 
Normalized ΔOD490 was calculated the same as in Figure 20A. The plot is relative to the 
CY-GP media normalized to zero. Errors; SD, n = 6. Important p-values are indicated 
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2.3 Characterization of AgrD Physicochemical Properties 
2.3.1 The SID Sequence of AgrD Can Inhibit AIP Secretion 
Previous research has shown which residues in the C-terminus of AgrD are essential for 
AgrB recognition and cleavage,[57] but there has been no other study to characterize the 
SID (secretion inhibitor domain) of AgrD. Since several S. aureus cell strains described 
in Section 2.2.3 can produce AIP-I in the absence of AgrB-I, we designed a similar cell 
experiment to examine the effect that the SID sequence might have on AIP secretion and 
production. S. aureus cells were engineered to express a chimera of the MAD (membrane 
association domain) and SID sequence in the AgrD(1-32) domain of the AgrD(1-32)-
intein constructs. We expected this chimera to inhibit secretion by interfering with the 
ability of AgrD(1-32) to associate with membrane.  In the chimera, the 15-residue SID 
sequence of AgrD-II (Figures 5A and 23A, underlined sequence) is inserted into the 
MAD sequence of the AgrD(1-32) domain. We chose the 15-residue SID sequence of 
AgrD-II because its 15th amino acid residue (Lys) aligns well with Lys-17 of the D(1-32) 
domain (Figure 26A). Thoendel et al. also proposed that the SID sequence forms a α-
helix,[57] so it could potentially maintain the proposed α-helix of the MAD in AgrD.[64] 
We then tested the cell culture supernatants of the chimera AgrD(1-32)-inteinSsp using the 
β-lactamase reporter gene assay (Figure 26B). As expected, the SID sequence inserted 
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Figure 26. SID Sequence Insertion in the AgrD(1-32) Domain Stops AIP-I Activity 
A) Sequence alignment of the AgrD(1-32)-I domain and the chimera AgrD(1-32)-I 
domain. The AgrD-II SID sequence is underlined.  B) β-lactamase activity assay of the 
chimera AgrD(1-32)-inteinSsp expressing cells is plotted. Filtered cell culture supernatants 
from the indicated strain were incubated with an exponential phase culture of group I S. 
aureus reporter strain (RN9222). Samples were removed after 60 minutes and assayed for 
β-lactamase activity by the nitrocefin method. Normalized ΔOD490 was calculated the 
same as in Figure 20A. The plot is relative to the CY-GP media normalized to zero. 
Errors; SD, n = 3. Important p-values are indicated with a bracket and the numerical p-
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2.3.2 Distribution-Coefficients for Several AIPs and AgrD(1-32)-thiolactone 
Peptides 
To our knowledge, there is no published solubility data for AIP or the 1-32 AgrD 
Thiolactone. Previous research using SDS-PAGE and Western blot analysis has shown 
that the MAD anchors AgrD in the membrane and enables processing of AgrD into 
AIP.[64] To supplement these observations, we wanted to investigate the solubility 
properties of AIP and the AIP precursor. Therefore, we synthesized AIP-I, AIP-II, N-
terminal acetylated AIP-I, N-terminal acetylated AIP-II, AgrD(1-32)-I-thiolactone, and 
AgrD(1-32)-II-thiolactone using a Boc-SPPS strategy developed by Lyon et al. for the 
synthesis of thiolactone-containing peptides.[63, 141] Briefly, the linear peptide α-thioester 
was generated by SPPS employing a Boc-Nα protection logic and using a 3-
mercaptopropionamide-based linker system. Following cleavage from the support with 
anhydrous HF, the crude unprotected peptide was cyclized in an acetonitrile:water 
mixture at neutral pH via an intramolecular trans-thioesterification reaction. All of the 
peptides were then purified by RP-HPLC and characterized by ESI-MS (See Chapter 6 
for characterization data). 
 
We then calculated distribution-coefficients at pH 5.9 (LogD5.9) for all 6 of these 
peptides and one control compound, chloramphenicol, via the shake flask method with 
HPLC detection to determine the abundance of each peptide in either the aqueous buffer 
fraction (pH 5.9) or 1-octanol fraction (Table 5).[142] The β-lactamase reporter assay is 
buffered at pH 5.9, so these LogD values describe how these molecules might behave 
during the assay. Based on our calculated values, the AIP molecules are not lipophilic. In 
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the instance of AIP-II, acetylation affects solubility, while it does not affect the solubility 
of AIP-I. This trend is likely a result of the charged Asp residue of AIP-I, whereas, AIP-
II only has a charge at its N-terminus, which is removed by the acetyl group. Finally, the 
trend towards insolubility continues with the AgrD(1-32)-I-thiolactone and AgrD(1-32)-
II-thiolactone. As expected, they are less soluble than any of the other AIP peptides and 
have LogD/LogP values that suggest they are slightly lipophilic, when compared to 




































aMass observed is ([M + H+]) 
bLiterature values of LogD7.4 obtained from Kerns et al. [142] 
cWe characterized chloramphenicol using the same protocol as the peptides, and 
obtained an LogD5.9 of 1.1 ± 0.1.  
 
  
Table 5. Calculated LogD5.9 Values for AIPs and AgrD(1-32)-thiolactones 
Molecule Expected Mass Observed Mass LogD5.9 
AIP-I 960.4 961.4a -0.69 ± 0.05 
Ac-AIP-I 1002.4 1003.4a -0.61 ± 0.04 
AgrD(1-32)-I-
thiolactone 3631.2 3630.8
a 0.41 ± 0.01 
AIP-II 878.4 879.4a -1.33 ± 0.04 
Ac-AIP-II 920.4 921.4a -0.3 ± 0.2 
AgrD(1-32)-II-
thiolactone 3417.1 3417.1
a 0.6 ± 0.4 
Molecule   Literature LogDb 
Chloramphenicolc   1.14 
Acetaminophen   0.51 
L-Dopa   -2.57 









' LogDpH = Log 
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2.4 Conclusions 
In this work, we investigated the role of AgrB-mediated secretion of AgrD(1-32)-
thiolactone. Our data extend the current understanding of how AgrB is involved in AIP 
secretion. To investigate secretion of AgrD(1-32)-thiolactone, we reported the design and 
characterization of an AIP secretion assay, which is sensitive to low levels of AIP-I in 
cell culture supernatants. An important characterization of the secretion assay was to 
show that cell lysis of the engineered cells expressing AgrD(1-32)-intein constructs is not 
the source of AIP. A real-time cell lysis assay showed that cell lysis does not result in 
increased AIP-induced β-lactamase activity. We conclude that our AIP secretion assay 
can produce AIP in the absence of AgrB. To our knowledge, this assay provides the first 
instance of AIP production in the absence of AgrB. We, therefore, went on to examine 
the role that AgrB has in AIP secretion.  Using this secretion assay, we showed that AIP-I 
is secreted in an AgrB-independent manner and that AgrB, when present, does not 
increase AIP-I levels in cell culture supernatants. Therefore, we find that the primary role 
of AgrB in AIP biosynthesis is limited to preparing AgrD for secretion by cleaving the 
SID and forming the thiolactone macrocycle of AIP-I. While this new AIP secretion cell-
based assay can assess the role of AgrB in secretion, it cannot reveal whether another 
unknown protein is involved in AIP secretion. Consequently, further endeavors must 
focus on how the AgrD(1-32)-thiolactone crosses the membrane. 
  
	   81 
Chapter 3. The Final Steps in AIP Biosynthesis: Cleaving the AgrD(1-32)-
Thiolactone 
3.1 Introduction 
Following our findings in Chapter 2, we chose to investigate the final step in AIP 
biosynthesis—cleavage of the AgrD(1-32)-thiolactone.   Upon crossing the membrane, 
the AgrD(1-32)-thiolactone requires removal of the AgrD MAD (membrane association 
domain) in order to produce the mature AIP. This second cleavage event presumably 
occurs on the extracellular side of the membrane in order to liberate the mature AIP into 
the extracellular milieu (Figure 9).  Initially, AgrB was proposed to catalyze the second 
cleavage event, because the P2 promoter of agr does not encode a second processing 
protein.[25, 56] Thus, AgrB could hypothetically be the only other protein necessary for AIP 
biosynthesis besides AgrD. However, the N-terminus of AgrD does not include the 
known AgrB cleavage site, which is C-terminal to the AIP sequence in AgrD (Figure 5A) 
which supports the idea that another protease is responsible for MAD cleavage to finish 
AIP biosynthesis. Indeed, the type I signal peptidase of S. aureus—SpsB—can correctly 
cleave a small peptide derivative of AgrD-I.[58] This observation not only proposes a new 
player in AIP biosynthesis, but also indicates that the agr locus of S. aureus may not 
encode all of the necessary proteins for AIP production. 
 
The MAD cleavage event is poorly understood in comparison to the SID cleavage 
event mediated by AgrB, where there are conserved residues, enabling AgrB recognition 
and cleavage. [56-58, 72] In the only characterization of SpsB with relation to AIP 
biosynthesis, Kavanugh et al. showed that SpsB correctly cleaves a fluorescein-labeled 
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AgrD-I derived peptide.[58] While their findings certainly implicate SpsB, their assay 
showing biological relevance was done with whole cells, meaning that other peptidases 
were catalytically active; and they did observe nonspecific cleavage of their AgrD-I 
derived peptide during these assays. To determine whether SpsB correctly cleaved their 
peptide, they carried out in vitro assays with purified SpsB and a fluorescein-labeled 
peptide with the sequence fl-NIAAYST (AIP-I residues underlined). The agarose gel 
assay they developed only detected fluorescence, so they could only follow cleavage 
products that contained a fluorophore. Using this assay, they observed a cleavage product 
that they assign to fluorescein labeled NIAA based on migration, but they did not fully 
characterize the cleavage using RP-HPLC and/or mass spectrometry. [58] They also did 
not show SpsB cleavage of peptides derived from all four specificity groups of AgrD 
polypeptides. It should also be noted that an SpsB knockout is lethal,[73] so it has been 
difficult to characterize the involvement of SpsB in AIP biosynthesis using genetic tools. 
 
A thorough investigation into the potential role of SpsB in the final step of AIP 
biosynthesis across the four groups is needed. Removal of the MAD produces a tail on 
the AIP that is biologically important—especially in the instance of AIP-II and AIP-III, 
where research has shown that incorrect tail length produces AIP molecules with self-
inhibitory activity.[62, 63, 83] For example, the tail of AIP-III, which is the shortest among 
the four AIPs, could include a Tyr residue at the N-terminus (based on the sequence of 
AgrD-III) just like AIP-I and AIP-IV (Figures 4B and 5A). However, AIP-III with this 
additional Tyr residue is a self-inhibitor of its cognate AgrC-III receptor.[63] Thus, SpsB 
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must cleave each AIP correctly; otherwise, it could have deleterious effects on S. aureus 
virulence regulation. 
 
Herein, we describe our efforts to better understand the role of SpsB cleavage in 
AIP biosynthesis. We present an investigation of the SpsB catalysis of AgrD derived 
peptides in biochemical and cellular assays.  We surveyed several non-fluorescein 
labeled, AgrD derived peptides using in vitro SpsB cleavage assays. Using cellular 
assays, we then examined SpsB cleavage in the context of a membrane. We then decided 
to incorporate SpsB into proteoliposomes to further examine its activity in the context of 
a membrane. Finally, we thoroughly examine SpsB cleavage of AgrD-II—the first 
investigation to examine whether SpsB can cleave another specificity group AgrD 
polypeptide besides AgrD-I.  
 
3.2 Biochemical Investigation of the Δ1-21 SpsB Deletion Mutant 
 
3.2.1 Expression and Purification of the Δ1-21 SpsB Deletion Mutant 
Previous research suggests that a truncated version of SpsB lacking the N-terminal 
membrane anchor is active in biochemical assays.[58, 143] Indeed, Kavaunagh et al. have 
shown that the purified Δ1-20 SpsB deletion mutant cleaves a fluorescein labeled AgrD-I 
derived peptide, albeit not to completion even after 60-hr incubations.[58] Still, this finding 
was a great starting point for further biochemical analysis of SpsB with other AgrD 
derived peptides.   
  




Figure 27. Characterization of the His6-tagged 22-191SpsB deletion mutant protein 
A) Size-exclusion chromatogram of tr-SpsB in a Tris-HCl (pH 7.5) and 200 nM NaCl 
buffer. The purified tr-SpsB is well behaved and elutes as a monomer. B) SDS-PAGE 
analysis of the purified tr-SpsB deletion mutant. Gel is stained by coomassie. The 
relevant molecular weight markers are represented. C) Molecular weight of tr-SpsB as 
determined by ESI-MS analysis. The MW is calculated using Bruker software with an 
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After several unsuccessful attempts to purify recombinant SpsB, we designed an 
N-terminal His6-tagged Δ1-21 SpsB deletion mutant (tr-SpsB) that also contained a TEV 
protease cleavage sequence between the His6-tag and SpsB. (The TEV site is necessary, 
because in our hands, tr-SpsB could auto-cleave a thrombin cleavage sequence, resulting 
in purification problems.) tr-SpsB was expressed in E. coli and purified from the pellet 
under denaturing conditions. Upon refolding via dialysis, tr-SpsB was further purified 
using size-exclusion chromatography (Figure 27A and B). Finally, the identity of the 
purified tr-SpsB was confirmed using mass spectrometry (Figure 27C). Since tr-SpsB 
required refolding, we confirmed its activity using a peptide with a consensus SpsB 
cleavage sequence (control peptide, Table 6) generously provided by Dr. Miquel Vila-
Perello, a senior researcher at Princeton University. tr-SpsB cleavage of the control 
peptide went to completion within 10 hours under both conditions described by Rao et 
al.[143] and Kavanaugh et al.[58] (Figure 28, Tables 6 and 7), which primarily differ by what 
aids SpsB solubility: 0.5% Triton X-100 or 25% glycerol, respectively.[58, 143] tr-SpsB 
cleavage was monitored via RP-HPLC and cleavage products were determined using 
mass spectrometry. This assay enabled quantification of the starting materials and 
cleavage products, which was one of the shortcomings of the fluorescent agarose gel shift 
peptidase assay.[58] 	  
 
3.2.2 tr-SpsB Cleavage of AgrD Derived Peptides in vitro 
 With a new assay to monitor tr-SpsB activity, we synthesized several peptide 
amides using a standard Fmoc protocol.[144] Briefly, linear peptide α-amides were 
generated by solid phase peptide synthesis (SPPS) employing a Fmoc-Nα protection 
	   86 
logic and using a rink amide solid support. Following cleavage from the support with a 
standard TFA cocktail, the crude unprotected peptides were then purified by RP-HPLC 
and characterized by ESI-MS (See Table 6 and Chapter 6 for characterization data). 
 
After modifying the previously published assay conditions to include a low salt 
concentration and 20% glycerol instead of 25%,[58, 143] we re-produced the cleavage of a 
fluorescein-labeled peptide similar to the one previously tested, except that our peptide 
had fluorescein directly coupled to the N-terminus (fl-AH peptide, Figure 29, Tables 6 
and 7). Using the glycerol conditions, the cleavage did not go to completion after almost 
48 hours, which was previously observed.[58] In our hands, the cleavage went to ~40% 
completion (Table 7), which the previous assay could not determine. In contrast, the 
Triton conditions significantly affected SpsB with cleavage of the fl-AH peptide only 
going to ~7% completion (Table 7). Surprisingly, SpsB could not process the non-
fluorescein labeled peptide, where the fluorescein group was replaced with an acetyl 









Figure 28. SpsB Cleavage of a Control Peptide 
RP-HPLC analysis of the control peptide substrate in the presence or absence of tr-SpsB. 
After 12 hours, the control peptide (250 μM) is completely consumed and the appearance 
of the cleavage products is detected. Both reactions were carried out in the Triton assay 
conditions (See Chapter 6). After 12 hours, both reactions were acidified and injected for 
HPLC analysis (gradient of 0-73% B, over 30 mins.). Fractions from each peak were 



























Ac-GPTARAVTSGA-NH2 Ac-GPTARA-OH + H-VTSGA-NH2 
mass = 1027.5 mass = 613.6 mass = 432.2 
tr-SpsB 
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Within the AgrD polypeptide sequence (Figure 5A), there is a conserved IG motif 
in the MAD that is located at around -6 position relative to the N-terminal cleavage site 
of AIP. Gly and Pro residues are presumed helix-breaking residues within signal peptides 
recognized by type I signal peptidases.[65] We noticed within the fl-AH and AH peptides 
that the conserved IG motif in AgrD was excluded (Figure 5A).  We synthesized two 
peptides that included this sequence motif (Table 6, IG-AIP-I and IG-AIP-III), and they 
were tested with the SpsB activity assay.  Again, we observed no cleavage of the AgrD-I 
derived peptide or the AgrD-III derived peptide (Table 7). Suspecting possible inhibition 
of SpsB by some of these peptides, we devised a competition assay where the control 
peptide was incubated with tr-SpsB and either the AH or IG-AIP-III peptide. tr-SpsB 
cleaved the control peptide, but it did not cleave either of the AgrD-I derived peptides 
(Figure 30A and B, respectively).  We also found that there was no concentration 
dependence for either IG-AIP-I or AH peptide, which were tested at concentrations up to 
1 mM or 400 μM, respectively (data not shown). In our hands, tr-SpsB could not cleave 
AgrD derived peptides unless they had fluorescein. 
 
  




Table 6.  Peptides used in SpsB in vitro assays  
Peptide Sequence Expected Mass Observed Mass [M+H]+ HPLC Rt (min.) 
Control Ac-GPTARAVTSGA-NH2 1027.5 1028.5 11.36 
fl-AH fl-NIAAYST-NH2 1095.4 1096.4 17.96 
AH Ac-NIAAYST-NH2 779.4 780.4 17.48 
IG-AIP-I Ac-KNIGNIAAYST-NH2 1191.6 1192.6 15.30 




Table 7.  RP-HPLC Analysis of in vitro SpsB Activity Assays 
Peptide Sequence Cleavage (Triton Rxn)^ 
Cleavage 
(Glycerol Rxn)^ Notes 
Control Ac-GPTARA/VTSGA-NH2 Yes, 100% Yes, 100% within 12 hrs 
fl-AH fl-NIAA/YST-NH2 Yes, 6.6% Yes, 41.4% up to 48 hrs. 
AH Ac-NIAA/YST-NH2 None None  
IG-AIP-I Ac-KNIGNIAA/YST-NH2 None None rxn. went 48 hrs. 
IG-AIP-III Ac-NSIGYRAAY/IN-NH2 None None  
 










Figure 29. SpsB Cleavage of the fl-AH Peptide 
RP-HPLC analysis of two reaction timepoints of the fl-AH peptide in the presence of tr-
SpsB. Even after 46.5 hours, the fl-AH peptide is not consumed. Only one cleavage 
product was detected. Both reactions were carried out in the glycerol assay conditions 
(See Chapter 6). After the indicated time, both reactions were acidified and injected for 
HPLC analysis (gradient of 0-73% B, over 30 mins.). Fractions from each peak were 
























fl-NIAAYSt-NH2 fl-NIAA-OH + H-YST-NH2 
mass = 1095.4 mass = 745.7 mass = 368.2 
tr-SpsB 




Figure 30. tr-SpsB Assays of the Control Peptide with AH or IG-AIP-I Peptides 
A) RP-HPLC chromatogram is shown of the competition tr-SpsB assay with the control 
and AH peptides after 12 hours. Both peptides are at 100 μM, and the assay was carried 
out in the 20% glycerol conditions. B) RP-HPLC chromatogram is shown of the 
competition tr-SpsB assay with the control and IG-AIP-I peptides after 12 hours. Both 
peptides are at 150 μM, and the assay was carried out in the 20% glycerol conditions. 
Theoretical reaction schemes are provided to the right of the RP-HPLC chromatogram for 
each competition assays. After the indicated time, both reactions were acidified and 
injected for RP-HPLC analysis (gradient of 0-73% B, over 30 mins.). Fractions from each 
peak were analyzed using ESI-MS, and the masses are reported as [M + H]+. Peaks are 
slightly shifted from Rt reported in Table 6, because the assays were analyzed on a 
different HPLC than the one used for the purified peptides.  



















Ac-GPTARA-OH   +   H-VTSGA-NH2 
mass = 1027.5 mass = 613.6 mass = 432.2 
Ac-NIAA-OH     +     H-YST-NH2 
mass = 779.4 mass = 429.5 mass = 368.2 
tr-SpsB 



















Ac-GPTARA-OH   +   H-VTSGA-NH2 
mass = 1027.5 mass = 613.6 mass = 432.2 
Ac-KNIGNIAA-OH   +   H-YST-NH2 
mass = 1191.4 mass = 842.5 mass = 368.2 
tr-SpsB 
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3.2.3 Whole Cell Assays with the IG-AIP Peptides 
 Kavanaugh et al.[58] used whole cells to initially observe cleavage of their 
fluorescein-labeled peptide. Given this, we tried digesting the IG-AIP-I and IG-AIP-III 
(each assay at a concentration of 150 μM) peptides with whole S. aureus cells (RN6734), 
which had been washed with and re-suspended in a buffered saline solution (Tris-HCl, 
pH 8, and 200 mM NaCl) for the assay. After an 18-hr incubation and cell removal, the 
filtered supernatant was analyzed via RP-HPLC and cleavage products were 
characterized using ESI-MS.  Using this whole cell assay, we observed cleavage of both 
peptides (Table 8). For the IG-AIP-I peptide, there was several cleavage products 
detected, of which one had a mass consistent with correct cleavage of the peptide. For the 
IG-AIP-III peptide, no cleavage product detected corresponded to the expected cleavage 
site. While the cells used in the assay were group I wild-type, SpsB is conserved among 
all the agr specificity groups,[73] so a lack of IG-AIP-III cleavage sheds doubt on the role 
of SpsB in AIP-III biosynthesis. Instead of increasing the evidence that SpsB is the only 
protease able to cleave the MAD of AgrD, these biochemical assays suggest that either 
SpsB is not the universal protease for AIP biosynthesis or it requires another component 
not present in the in vitro HPLC assay.  
 
  




Expected SpsB cleavage is indicated with /. Acetylation of the N-terminus is indicated with Ac. 











Likely Fragment Notes 
IG-AIP-I Ac-KNIGNIAA/YST-NH2 1192.6 Ac-KNIGNIAAYST-NH2 no cleavage 
  842.5 Ac-KNIGNIAA-OH correct cleavage 
  738.4 H-NIAAYST-NH2 
non-specific 
cleavage1 
  473.3 Ac-KNIG-OH non-specific cleavage1 
  369.2 H-YST-NH2 correct cleavage 
IG-AIP-III Ac-NSIGYRAAY/IN-NH2 1282.6 Ac-NSIGYRAAYIN-NH2 no cleavage 
  893.4 Ac-NSIGYRAA-OH 
non-specific 
cleavage1 
  822.4 Ac-NSIGYRA-OH non-specific cleavage1 
  550.3 H-AAYIN-NH2 
non-specific 
cleavage1 
  479.3 H-AYIN-NH2 
non-specific 
cleavage1 
  408.2 H-YIN-NH2 
non-specific 
cleavage1 
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3.3 SpsB Requires a Membrane to Cleave AgrD-I (work on this section was 
accomplished in collaboration with Boyuan Wang and Xinhui [Connie] Wang) 
3.3.1 Expression and Purification of the Proteins Required for AIP Biosynthesis  
In the tr-SpsB biochemical assay, SpsB was solubilized and not incorporated into its 
native membrane environment. In the cell-based assay, SpsB was endogenously 
expressed, so it would have been incorporated into the membrane, where it could 
presumably cleave the IG-AIP-I substrate peptide correctly. We decided to incorporate 
SpsB and other AIP-related proteins into proteoliposomes (vesicles), which were 
reconstituted via the detergent-removal method (Figure 31).[145] Briefly, proteins and 
lipids dissolved in detergent are mixed together, and the detergent is removed using Bio-
Beads. To accomplish this biochemical analysis, this new approach required purification 
of the full-length SpsB, so we designed and expressed an N-terminal His5-tagged, fl-SpsB 
protein, which was solubilized from the membrane fraction of E. coli cell lysates with n-
Dodecyl β-D-maltoside (DDM) and then purified (Figure 32A). Several constructs of 
AgrD were recombinantly expressed and purified as well as AgrB-I and AgrB-II (Figure 
32B and C), which were also solubilized in detergents (See Chapter 6 for detailed 
expression and purification protocol). (Note, we were unable to obtain AgrB-III and 
AgrD-III with much success, so group I and II components were employed.) To detect 
and analyze the cleavage products of the vesicle assays, we employed several analytical 
approaches, including SDS-PAGE, RP-HPLC and MS, or the β-lactamase reporter assay 
(Figure 31). 
 
   









Figure 31. Liposome Assay Schematic for AgrD Cleavage  
The general strategy for incorporating the proteins involved in AIP biosynthesis into 
proteoliposomes is illustrated. The general strategy is outlined by Rigaud et al.[145] Once 
the vesicles are prepared, they can be analyzed using SDS-PAGE, HPLC and MS, or the 
























Analysis via  
HPLC and MS, or  
β-lactamase assay 
Analysis via  
SDS-PAGE 





Figure 32. Purified Protein Components for AIP Biosynthesis 
SDS-PAGE analysis of proteins used in proteoliposome reconstitution. A) fl-SpsB was 
analyzed using a 12% Bis-Tris SDS-PAGE gel, which was stained by coomassie. B) 
AgrB-II is shown as an example. It was analyzed using a 15% Tris-HCl gel, which was 
stained by coomassie. C) The AgrD proteins were analyzed using a 16.5% Tris-tricine 
gel, which was stained by coomassie. The relevant molecular weight markers are 
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3.3.2 Cleavage Products Produced from Proteoliposomes Containing AgrB, AgrD, 
and fl-SpsB 
Having purified AgrD, AgrB and fl-SpsB, we decided to reconstitute them into 
proteolipsomes (vesicles), presumably incorporating all the essential proteins of the AIP 
biosynthetic pathway in a lipid bilayer. After incubating vesicles containing various 
combinations of AgrD with fl-SpsB and AgrB for 12 hours, we analyzed the vesicles via 
SDS-PAGE (Figure 33). We prepared vesicles that contained fl-SpsB and AgrD-I or 
AgrD-II. In the SDS-PAGE analysis of these vesicle assays, we observed fl-SpsB 
cleavage of AgrD-I and AgrD-II, but AgrD was not fully consumed in either reaction 
(Figure 33, lanes 2 and 6, respectively). We also reconstituted the group specific AgrB 
and AgrD proteins into vesicles to try and observe AgrB cleavage of AgrD. In the SDS-
PAGE analysis of the AgrB and AgrD-containing vesicles, we also observed cleavage 
(Figure 33, lanes 3 and 7, group I and group II, respectively). However, SDS-PAGE 
analysis cannot indicate whether this cleavage product contains the thiolactone 
macrocycle. Finally, in the vesicles where the full AIP biosynthetic pathway was 
reconstituted into vesicles, SDS-PAGE analysis suggests that AgrD was cleaved twice 
(Figure 33, lanes 4 and 8, group I and group II, respectively). By comparing lane 2 with 
lane 4 and lane 6 with lane 8, the SpsB cleavage product is visible (albeit weakly) in the 
AgrD cleavage products (white arrows within image), although it is difficult to 
distinguish them in the Tris-tricine gel, where small peptides easily diffuse. While these 
initial attempts to reconstitute fl-SpsB cleavage of AgrD within a membrane were 
encouraging, SDS-PAGE analysis could not detect the small AIP molecule and cannot be 
used to determine, whether the correct cleavage products are produced. 
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 Group I Group II 
Lane 1 2 3 4 5 6 7 8 
fl-SpsB  +  +  +  + 
AgrB   + +   + + 
AgrD + + + + + + + + 
          
 
Figure 33. SDS-PAGE Analysis of AIP Biosynthesis Proteoliposomes 
SDS-PAGE analysis of various AIP producing proteins in vesicles is shown. The 
liposomes were analyzed using a 16.5% Tris-tricine gel, which was stained by coomassie. 
The various vesicle components are indicated above each gel lane. The relevant 
molecular weight markers are also indicated. fl-SpsB is indicated. The region where 
AgrD and/or its cleavage products appear is also indicated. AgrB-II is a well-behaved 
protein in the SDS-PAGE analysis. However, AgrB-I appears as a smear in the gel. 
White arrows are provided to indicate where the fl-SpsB cleavage products appear in the 
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To determine what AgrD cleavage products were produced in the vesicle assays, 
we analyzed the AgrD-containing vesicles with fl-SpsB and/or AgrB via RP-HPLC and 
mass spectrometry (Table 9). For solubility purposes, we reconstituted vesicles 
containing either N-terminal FLAG and His6-tagged AgrD-I or AgrD-II (FLAG-AgrD-I 
and FLAG-AgrD-II, respectively). We also had wild-type AgrD-I available for vesicle 
incorporation. In order to perform this analysis, vesicle lipid removal was accomplished 
with solid phase extraction (SPE) columns and lyophilized elutions thereof were then 
dissolved and injected into the RP-HPLC.  Fractions from the RP-HPLC analysis were 
then analyzed via ESI-MS.  
 
In the AIP-I biosynthesis vesicles containing either FLAG-AgrD-I or AgrD-I, 
MS-detected cleavage products confirmed AgrB cleavage and removal of the SID of 
AgrD-I (Table 9, Rxn. 2 and 4). We also detected the AgrD(1-32)-I-thiolactone, when 
wild-type AgrD-I was incorporated into vesicles (Table 9, Rxn. 2). These vesicles also 
contained AgrD fragments of the hydrolyzed thiolactone molecule (Table 9, Rxn. 2 and 
4). Hydrolysis of the thiolactone is not unexpected at a pH of 8, which is the optimal pH 
for SpsB activity.[143] In addition to containing fragments suggesting correct AgrB 
processing of AgrD-I, all of the reactions where fl-SpsB was reconstituted into vesicles 
containing AgrD-I (Table 9, Rxn. 1-4) produced fragments suggesting correct fl-SpsB 
cleavage. All of the vesicles containing fl-SpsB also contained fragments indicating 
cleavage between the Ser-26 and Thr-27 residues of AgrD-I (Table 9, Rxn. 1 and 3). This 
non-specific cleavage of AgrD-I would produce a truncated tail in AIP-I (Table 9, Rxn. 
1-4). Finally, we did not detect the mature excised AIP-I in any of the vesicles. Taken 
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together, these data suggest that fl-SpsB can correctly cleave AgrD-I when reconstituted 
into a membrane, but it may also result in non-specific cleavage. 
 
 Having detected SpsB cleavage of AgrD-I, it was now possible to investigate 
SpsB cleavage of AgrD-II. In the AIP-II biosynthesis vesicles, we again confirmed 
correct AgrB-II cleavage and removal of the AgrD-II SID (Table 9, Rxn. 6). However, 
these vesicles produced no fragments that corresponded to correct SpsB cleavage of 
AgrD-II, although there were several fragments suggesting non-specific cleavage (Table 
9, Rxn. 5 and 6). The vesicles containing fl-SpsB and FLAG-AgrD-II also only produced 
fragments with this non-specific cleavage (Table 9, Rxn. 5). Furthermore, the non-
specific cleavage observed would produce AIP-II without the tail sequence, which is a 
known AgrC-II antagonist.[62, 83] As with the AIP-I biosynthesis vesicles, mature AIP-II 
was not detected, but more importantly, we suspected that SpsB was not the protease 
responsible for cleaving the MAD of AgrD-II. 
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AgrD-I +  
fl-SpsB 
5297 AgrD-I unreacted 
2938 H-MNTLFNLFFDFITGILKNIGNIAAYS-OH incorrect cleavage 
2688 H-MNTLFNLFFDFITGILKNIGNIAA-OH correct SpsB cleavage 
2627 H-YSTCDFIMDEVEVPKELTQLHE-OH correct SpsB cleavage 










3631 H-MNTLFNLFFDFITGILKNIGNIAAYSTCDFIM^ AgrD-I Thiolactone 
2938 H-MNTLFNLFFDFITGILKNIGNIAAYS-OH incorrect cleavage 
2688 H-MNTLFNLFFDFITGILKNIGNIAA-OH correct SpsB cleavage 
2376.5 H-TCDFIMDEVEVPKELTQLHE-OH incorrect SpsB cleavage 





7360 FLAG-AgrD-I unreacted 
5001 FLAG-MNTLFNLFFDFITGILKNIGNIAAYS-OH incorrect cleavage 
4751 FLAG-MNTLFNLFFDFITGILKNIGNIAA-OH correct SpsB cleavage 
2376 H-TCDFIMDEVEVPKELTQLHE-OH incorrect cleavage 










5001 FLAG-MNTLFNLFFDFITGILKNIGNIAAYS-OH incorrect cleavage 
4751 FLAG-MNTLFNLFFDFITGILKNIGNIAA-OH correct SpsB cleavage 
2376 H-TCDFIMDEVEVPKELTQLHE-OH incorrect cleavage 





7212 FLAG-AgrD-II unreacted 
4961 H-MNTLVNMFFDFIIKLAKAIGIVGGVNA-OH incorrect cleavage 
2269 H-CSSLFDEPKVPAELTNLYDK-OH incorrect cleavage 




+ AgrB-II + 
fl-SpsB 
7212 FLAG-AgrD-II unreacted 
5498 FLAG-MNTLVNMFFDFIIKLAKAIGIVGGVNACSSLF-OH correct AgrB cleavage 
4961 H-MNTLVNMFFDFIIKLAKAIGIVGGVNA-OH incorrect cleavage 
4180 FLAG-MNTLVNMFFDFIIKLAKA-OH incorrect cleavage 
2269 H-CSSLFDEPKVPAELTNLYDK-OH incorrect cleavage 
1732 H-DEPKVPAELTNLYDK-OH correct AgrB cleavage 
^C-terminus is cyclized to form thiolactone macrocycle 
 
   Substrate             Epitope Tag            AgrD Sequence   
     AgrD-I  MNTLFNLFFDFITGILKNIGNIAAYSTCDFIMDEVEVPKELTQLHE 
       FLAG-AgrD-I MDYKDDDDKHHHHHHGG MNTLFNLFFDFITGILKNIGNIAAYSTCDFIMDEVEVPKELTQLHE 
      FLAG-AgrD-II MDYKDDDDKHHHHHHGG MNTLVNMFFDFIIKLAKAIGIVGGVNACSSLFDEPKVPAELTNLYDK 
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3.4 Detection of AIP from the Proteoliposomes Containing fl-SpsB and AgrD(1-32)-I 
Thiolactone 
In an attempt to detect the AIP-I activity from the vesicle-reconstituted AIP-I 
biosynthesis, we developed a coupled vesicle and β-lactamase assay (See Appendix). 
After overnight incubation, AIP-I or AIP-II biosynthesis vesicles were buffered to pH 5.9 
and then incubated with their respective group β-lactamase reporter assay strain. AIP-
induced β-lactamase activity was then determined using the nitrocefin method. Initial 
attempts to detect AIP-I activity from vesicles containing AgrD, AgrB and fl-SpsB led to 
inconclusive results, possibly reflecting the very small amounts of mature AIP generated 
using this fully reconstituted system. In an effort to simplify our vesicle assay system to 
detect AIP activity, we prepared vesicles with fl-SpsB and pre-formed AgrD(1-32)-I-
thiolactone, which was synthesized either using recombinant methods employing intein 
fusions or using Boc-SPPS as discussed previously in Sections 2.2.3 and 2.3.2, 
respectively. We then tested the buffered vesicles with the β-lactamase assay to detect 
activity associated with AIP-I. Excitingly, we detected AIP-I activity using this coupled 
vesicle and β-lactamase assay (Figure 34). As a control, AIP-I was also incorporated into 
vesicles to ensure the reporter gene assay cells responded to a known agonist. 
Importantly, we were also able to detect the generation of AIP-I from the fl-SpsB and 
AgrD(1-32)-I-thiolactone vesicle system using RP-HPLC-MS (Figure 35).   




Figure 34. fl-SpsB Cleaves the AgrD(1-32)-I-thiolactone to Generate AIP-I Activity 
β-lactamase activity assay of the fl-SpsB and AgrD(1-32)-I-thiolactone vesicles is 
plotted. The indicated vesicles were incubated with an exponential phase culture of group 
I S. aureus reporter strain (RN9222). Samples were removed after 60 minutes and 
assayed for β-lactamase activity by the nitrocefin method. Normalized ΔOD490 was 
calculated the same as in Figure 20A. The plot is relative to empty vesicles normalized to 
zero. Errors; SD, n = 3. The important p-value is designated with a bracket and the 
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  <	  0.0001 
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Figure 35. AIP-I Production from SpsB and AgrD(1-32)-I-thiolactone 
Proteoliposomes Confirmed Via RP-HPLC-MS Analysis  
RP-HPLC-MS analysis of SpsB cleavage of AgrD(1-32)-I-thiolactone is shown. After 
lipid removal with SPE columns, the 70% elution was analyzed with RP-HPLC-MS at 
the Princeton University Molecular Biology MS Facility. Peaks at 352.26 and 1021.62 
Daltons correspond to the detergents FC-12 and DDM (dimerized), respectively. The 
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3.5 fl-SpsB Does Not Cleave AgrD-II (work on this section was accomplished in 
collaboration with Xinhui [Connie] Wang) 
3.5.1 fl-SpsB Does Not Cleave AgrD(1-32)-II-thiolactone 
While we had successfully detected AIP-I production, all of our previous efforts 
suggested that SpsB does not cleave AgrD-II. Using the same approach to detect AIP-I 
production, we decided to try and reconstitute fl-SpsB and AgrD(1-32)-thiolactone into 
vesicles. We had previously synthesized the group II thiolactone using the general 
strategy of Lyon et al.[63] for distribution-coefficient measurements (See Section 2.3.2 for 
description and Chapter 6 for characterization data). 
 
 Since fl-SpsB cleavage of AgrD-II only produced non-specific cleavage, we 
wondered if SpsB required some other factor to process AgrD-II. When SpsB was first 
characterized in the literature, it was noted that an inactive type I signal peptidase (termed 
SpsA) is transcribed on the same mRNA and is separated from the SpsB gene by 15 
basepairs.[73] SpsA is proposed to be structurally homologous to SpsB, but it has not been 
extensively characterized. Kavanaugh et al. purified SpsA but found it to be inactive in 
their peptidase assays.[58] Cregg et al. speculated that SpsA might act like some eukaryotic 
proteases that have mutated and become inactive but are still used as a binding partner for 
other proteases.[73] We decided to test whether SpsA assists SpsB cleave AgrD-II, so we 
purified it under the same conditions as fl-SpsB and characterized it using size-exclusion 
chromatography and ESI-MS (data not shown).  As expected, SpsA did not cleave the 
control peptide in the in vitro HPLC assay described in Section 2.4.1 (data not shown), 
which is also the same behavior observed by Kavanaugh et al.[58]   
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With fl-SpsB, SpsA and AgrD(1-32)-II-thiolactone in hand, we incorporated these 
three components into proteoliposomes and then analyzed these vesicles with the β-
lactamase reporter gene assay (Figure 36). In the presence of only SpsA or SpsB, we 
observed no cleavage of the AgrD(1-32)-II-thiolactone, and when both proteins were 
incorporated into vesicles with the group II thiolactone, no cleavage of the AgrD(1-32)-
II-thiolactone was observed. Since AIP-II could be detected when incorporated into 
vesicles, it was unlikely that the reporter gene assay cells were not detecting AIP-II 
produced in vesicles containing fl-SpsB and AgrD(1-32)-II-thiolactone. Instead, we 
suspected that SpsA might prevent SpsB cleavage of AgrD. Therefore, we prepared 
vesicles with the same fl-SpsB and SpsA stocks, but we included the AgrD(1-32)-I-
thiolactone.  We then analyzed these group I reaction vesicles with the β-lactamase 
reporter gene assay (Figure 37). From the analysis of the AgrD(1-32)-I-thiolactone 
vesicles, it was evident that SpsB was active in the presence of SpsA. Furthermore, SpsA 
did not cleave the AIP-I precursor. At the very least, these observations suggest that fl-
SpsB was active in the AgrD(1-32)-II-thiolactone vesicles, and SpsA does not interact 
with fl-SpsB to facilitate the correct processing of AgrD-II. 
 
In a final attempt to determine whether SpsB could cleave AgrD-II, we prepared 
vesicles that also incorporated AgrB-II along with SpsA, fl-SpsB and the group II 
thiolactone. We then analyzed these group II reaction vesicles with the β-lactamase 
reporter gene assay (Figure 38).  Once again, there was no cleavage of the AgrD-II-
thiolactone as indicated by a lack of detectable AIP-II activity. 




Figure 36. SpsA Does Not Promote SpsB Cleavage of the AgrD(1-32)-II-thiolactone  
β-lactamase activity assay of the fl-SpsB, SpsA and AgrD(1-32)-II-thiolactone vesicles is 
plotted. The indicated vesicles were incubated with an exponential phase culture of group 
II S. aureus reporter strain (RN9367). Samples were removed after 60 minutes and 
assayed for β-lactamase activity by the nitrocefin method. Normalized ΔOD490 was 
calculated the same as in Figure 20A. The plot is relative to empty vesicles normalized to 
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Figure 37. SpsB Cleaves the AgrD(1-32)-I-thiolactone in the Presence of SpsA 
β-lactamase activity assay of the fl-SpsB, SpsA and AgrD(1-32)-I-thiolactone vesicles is 
plotted. The indicated vesicles were incubated with an exponential phase culture of group 
I S. aureus reporter strain (RN9222). Samples were removed after 60 minutes and 
assayed for β-lactamase activity by the nitrocefin method. Normalized ΔOD490 was 
calculated the same as in Figure 20A. The plot is relative to empty vesicles normalized to 
zero. Errors; SD, n = 3. The important p-values are designated with a bracket and the 
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Figure 38. AgrB-II Does Not Interact with fl-SpsB to Correctly Cleave the AgrD(1-
32)-II-thiolactone 
β-lactamase activity assay of the fl-SpsB, SpsA, AgrB-II and AgrD(1-32)-II-thiolactone 
vesicles is plotted. The indicated vesicles were incubated with an exponential phase 
culture of group II S. aureus reporter strain (RN9367). Samples were removed after 60 
minutes and assayed for β-lactamase activity by the nitrocefin method. Normalized 
ΔOD490 was calculated the same as in Figure 20A. The plot is relative to empty vesicles 
normalized to zero. Errors; SD, n = 3. 
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3.5.2 A S. aureus Membrane Protein Can Cleave The AgrD(1-32)-II-thiolactone 
With no clear alternative to SpsB, we wanted to confirm that S. aureus whole cells could 
process the AgrD(1-32)-II-thiolactone. Therefore, we incubated the group II thiolactone 
with agr-II null cells (RN9120), where a tetracycline resistance gene replaced the agr-II 
locus. Therefore, these cells provided a membrane that would contain any accessory 
proteins necessary for AIP-II production except for AgrB-II and AgrD-II. As part of the 
experiment, we also prepared a cell culture supernatant where a pre-grown RN9120 
culture was filtered and the AgrD(1-32)-II-thiolactone was added to the filtered 
supernatant. The analysis of this cell culture supernatant could indicate whether a 
secreted protein might process the AIP-II precursor. After a 4-hr incubation period in the 
cell culture, the cells were removed via centrifugation, if necessary, and the culture 
supernatants were filtered. These supernatants were then analyzed with the β-lactamase 
reporter gene assay (Figure 39). In this case, we observed correct cleavage of the 
AgrD(1-32)-II-thiolactone as indicated by the emergence of AIP-II activity. Moreover, 
the cleavage apparently occurs at the membrane, since there was no AIP-II activity 
detected in the filtered, cell-free RN9120 culture supernatant. Thus, the cleavage is likely 
not the result of a secreted factor, although it remains unclear what protein cleaves the 
MAD of AgrD-II to produce AIP-II. 
 
  
	   112 
 
 
Figure 39. A Membrane Protein Can Cleave the AgrD(1-32)-II-thiolactone 
β-lactamase activity assay of cell culture supernatants from agr-II null cells incubated 
with the AgrD(1-32)-II-thiolactone is plotted. Filtered cell culture supernatants were 
incubated with an exponential phase culture of group II S. aureus reporter strain 
(RN9367). Samples were removed after 60 minutes and assayed for β-lactamase activity 
by the nitrocefin method. Normalized ΔOD490 was calculated the same as in Figure 20A. 
The plot is relative to the CY-GP media normalized to zero. Errors; SD, n = 3. Important 
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3.6 Conclusions 
In this chapter, we investigated the role of SpsB in AIP biosynthesis. Our findings extend 
the current understanding of how SpsB is likely only one of several proteases capable of 
processing AgrD(1-32)-thiolactone. To investigate the final cleavage step in AIP 
biosynthesis, we employed several in vitro SpsB biochemical assays to elucidate some of 
the requirements for SpsB cleavage of AgrD. We found that small, non-fluorescein 
labeled peptides are poor substrates for SpsB and that correct cleavage of AgrD-I requires 
a membrane. Once SpsB is incorporated into a lipid bilayer environment, it can correctly 
process AgrD-I and the AgrD(1-32)-I-thiolactone. To our knowledge, this is the first 
study with direct evidence that SpsB is involved in AIP-I biosynthesis. We detected AIP-
I from SpsB-containing vesicles using a biological cell-based assay and directly by RP-
HPLC-MS. Our study is also the first to investigate the possible SpsB cleavage of AgrD-
II. We found that SpsB does not correctly cleave AgrD-II or AgrD(1-32)-II-thiolactone. 
Importantly, we found that S. aureus cells are able to correctly process the AgrD(1-32)-II 
thiolactone to give robust AIP-II activity implying an unknown protease. These studies 
also suggest that this unknown protease is associated with the cell membrane or 
peptidoglycan. Interestingly, our data suggests that multiple proteases are used in the 
final step of AIP biosynthesis and that these proteases may be group-specific. Consistent 
with previous models, we propose that the final proteolysis of AgrD occurs at the outer 
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Chapter 4. Increasing AIP Macrocycle Size Reveals Key Features of agr Activation 
4.1  Introduction 
In the last two decades, a number of SAR studies have explored the importance of amino 
acid sequence in the four AIP groups using alanine-substitution, D-amino acid 
substitution and other native and non-native amino acid mutations.[45, 59, 62, 63, 79, 80, 83-86, 146] 
These studies have identified key amino acid residues, side-chain orientations and 
backbone interactions within AIPs required for activation and inhibition.[45, 59, 61-63, 79, 80, 83-86] 
Moreover, this work has led to the discovery, and in a few cases rational design, of agr 
inhibitors active against all four groups.[45, 62, 80, 83, 84] Examples of these global inhibitors 
include a truncated version of AIP-II lacking the tail region[63, 83] and, of relevance for this 
study, an analog of AIP-I in which the second endocyclic residue (Asp-5 in the primary 
sequence of AIP-I) is replaced by alanine.[63, 80] Note,  this same residue in AIP-I can also 
be replaced with Asn or Phe to produce two agonists with activity comparable to that of 
the native peptide (Table 1).[63] While some specificity determinants important for 
recognition of the AIP with its receptor are understood, particularly for the AIP-I/AgrC-I 
pair (Figure 12C),[82] the molecular recognition principles underlying receptor agonism 
versus antagonism by a given AIP are incomplete. In order to better understand the 
relationship between AIP structure and function, we wanted to investigate the defining 
structural feature of the AIP:  its thiolactone macrocycle (Figure 40). The effect of 
changing the thiolactone linkage to a lactone or lactam on AIP activity has been 
previously explored,[45] and alanine scanning of AIP-I indicated which residues within the 
macrocycle are essential for agr activation.[80] However, the importance of ring size on 
activity remains unclear. Exploiting AIP-I as a scaffold to investigate this question, we 
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used L-β-homo-amino acid (hβ-AA) substitution, proline substitution and amino acid 
deletion mutants as a means to systematically vary the size and backbone conformation 
of the AIP macrocycle (Figure 40, Table 10). We also substituted homocysteine (Hcy) for 
cysteine in AIP-I, -II and -III to see whether extending the thioester linkage effects agr 
activity. Notably, the activity of these analogs was studied using both cell based and 
biochemical assay systems, the first time such a comparative analysis has been possible 
on AIP analogs.   
  






Figure 40.  AIP-I Structure and Some Examples of Enlarged AIP-I Analogs 
A) The AIP-I chemical structure is shown. The native AIP-I amino acid residues are 
numbered, with the macrocycle residues underlined and their ring position italicized. 
Inserting a methylene group into the macrocycle of most AIP-I analogs was 
accomplished using L-β-homo-amino acids as in B) hβ-Asp AIP-I and C) D5A hβ-Ala 
AIP-I (the inserted methylene group and shifted sidechain in the hβ-AA analog is 
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4.2  Design, Synthesis and Functional Analysis of AIP Analogs Featuring Enlarged, 
Reduced or Constrained Macrocycles 
4.2.1 Design and Synthesis of AIP Analogs 
Several SAR studies[45, 63, 80] and AgrC mutant studies[82, 87] have focused on the group I 
system in their investigation of agr activation and inhibition.  This information and data 
provides helpful insight for additional structural studies and makes AIP-I a model 
scaffold to study the effect of macrocycle size on function (Figure 40). This decision was 
also guided by the recently reported biochemical characterization of its cognate receptor, 
AgrC-I, providing new biochemical tools to enhance this SAR study. To enlarge the AIP 
macrocycle, we elected to substitute the canonical L-amino acids in the endocyclic region 
of the molecule with the corresponding L-β-homo-amino acids (hβ-AAs), thereby 
inserting a main-chain atom whilst maintaining the size and stereochemistry of the side-
chains. We also expanded the ring by substituting L-cysteine with L-homocysteine. Note, 
for comparative reasons, this change was also made in AIP-II and AIP-III. To reduce the 
ring size, we decided to prepare two deletion analogs of AIP-I in which either Phe-6 or 
Ile-7 was removed. The design of these peptides was guided by previous alanine-
scanning studies that showed neither of these amino acid sidechains is absolutely 
essential for activity.[80] In contrast, Asp-5, corresponding to the second endocyclic 
position, was found to be important for AIP activity and hence was not deleted. Finally, 
to explore the effect of perturbing the backbone conformation, we generated AIP-I 
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All AIP analogs were generated according to the general strategy of Lyon et al.[63] 
Briefly, linear peptide α-thioesters were generated by solid phase peptide synthesis 
(SPPS) employing a Boc-Nα protection logic and using a 3-mercaptopropionamide-based 
linker system (Figure 41). Following cleavage from the support with anhydrous HF, the 
crude unprotected peptides were cyclized in water at neutral pH via an intramolecular 
trans-thioesterification reaction. AIP analogs were then purified by RP-HPLC and 
characterized by ESI-MS and 1H NMR (See Table 10 and Materials and Methods for 
characterization data). 
 
4.2.2  Functional Analysis of AIP Analogs Featuring Enlarged, Reduced or 
Constrained Macrocycles (work on this section was accomplished in collaboration 
with Boyuan Wang) 
We first assessed the activity of our AIP analogs using a β-lactamase reporter assay (See 
Appendix), which can be used to test the ability of each AIP analog to activate or inhibit 
the agr response in S. aureus cells (Table 11, Figure 42). This assay reports on signal 
transduction through the entire agr TCS and has, over many years, been the workhorse 
tool for assessing AIP activity.[45, 62, 63, 80, 83, 87] All of the peptides were tested against their 












Figure 41.  Synthetic Route for Boc-SPPS of AIP-I 
The 3-mercaptopropionamide-based linker is synthesized on resin whereupon coupling 
the C-terminal amino acid results in formation of a linear thioester. Chain elongation is 
achieved with standard Boc-based solid phase peptide synthesis (SPPS) conditions. The 
peptide is cleaved from the resin with anhydrous HF and cyclized via intramolecular 
trans-thioesterification upon addition of aqueous buffer at neutral pH. The synthesis of 
AIP-I is shown as an example.  For some of the enlarged AIP-I analogs, the aqueous 
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^Observed thiolactone mass is equal to (M + H+) 
*HPLC Retention time of the final, cyclized AIP analog. 
Endocyclic residues of the AIP macrocycle are underlined in the “Sequence” column of the table.  
1Hcy, homocysteine replaces native cysteine residue within the indicated AIP analog 
2hβ, L-β-homo-amino acid replaces indicated residue within the native AIP-I or D5A AIP-I sequence  
3β, β-Alanine replaces indicated residue within the D5A AIP-I sequence 
 
  
Table	  10.	  	  Analytical	  Characterization	  of	  Altered	  Macrocycle	  AIP	  Analogs	   	  















Hcy	  AIP-­‐I	   YSTC1DFIM	   1079.4	   1079.44	   974.4	   975.4	   19.21	  
Hcy	  AIP-­‐II	   GVNAC1SSLF	   997.4	   997.44	   892.4	   893.4	   17.28	  
Hcy	  AIP-­‐III	   INC1DFLL	   937.4	   937.45	   832.4	   833.4	   20.34	  
hβ-­‐Met	  AIP-­‐I	   YSTCDFIM2	   1079.4	   1079.42	   974.4	   975.4	   18.78	  
hβ-­‐Ile	  AIP-­‐I	   YSTCDFI2M	   1079.4	   1079.42	   974.4	   975.4	   18.11	  
hβ-­‐Phe	  AIP-­‐I	   YSTCDF2IM	   1079.4	   1079.41	   974.4	   975.4	   18.35	  
hβ-­‐Asp	  AIP-­‐I	   YSTCD2FIM	   1079.4	   1079.41	   974.4	   975.4	   18.51	  
F6P	  AIP-­‐I	   YSTCDPIM	   1015.4	   1015.4	   910.4	   911.4	   16.76	  
I7P	  AIP-­‐I	   YSTCDFPM	   1049.4	   1049.4	   944.3	   945.3	   16.35	  
ΔF6	  AIP-­‐I	   YSTCDIM	   918.3	   918.33	   813.3	   814.3	   16.27	  
ΔI7	  AIP-­‐I	   YSTCDFM	   952.3	   952.33	   847.3	   848.3	   16.92	  
D5A	  β-­‐Ala	  AIP-­‐I	   YSTCA3FIM	   1021.4	   1021.41	   916.4	   917.4	   18.08	  
D5A	  hβ-­‐Ala	  AIP-­‐I	   YSTCA2FIM	   1035.4	   1035.43	   930.4	   931.2	   18.98	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One mutation at endocyclic position 2 preserves self-activation:  Asp-5 could be 
replaced with hβ-Asp (Table 11, Figures 40A and 42A).  The hβ-Asp AIP-I analog has 
an EC50 value ~30-fold weaker than the native AIP-I (Table 11, Figure 42A), which 
makes it a moderate, nanomolar AIP-I activator similar to Y1A and T3A AIP-I 
analogs.[80] It also has a weaker inhibitory effect on AgrC-II with an IC50 value above 2 
μM (Figure 42A).  For the most part, however, replacing native amino acid residues with 
hβ-AAs in the AIP-I macrocycle produced inactive AIP-I analogs, and the constrained 
and smaller macrocycle AIP-I analogs showed no activity in the cell-based assays (Table 
11). Evidently, the AIP-I macrocycle must have a particular size and some 
conformational flexibility in order for AgrC-I to bind AIP-I. 
 
We were also keen to see the effect of increased AIP macrocycle size on 
antagonism of the AgrC receptor, which has previously been more resilient to changes in 
the AIP macrocycle.[45, 62, 63, 79, 80, 83] This indeed appears to be the case (Table 11). Thus, 
while some trends observed for activation of the response were also seen for inhibition 
(e.g. among the L-β-homo-amino acid substitutions only the hβ-Asp analog retained 
measureable, albeit weakened, activity); a few of the analogs that were inactive as 
agonists were active as antagonists. Specifically, the Hcy containing AIP analogs all had 
the expected cross- group inhibitory activity (Table 11, Figure 42B). The Hcy AIP-III 
analog was a relatively potent inhibitor of AgrC-II (only ~40-fold less than wild-type 
AIP-III), but a weak inhibitor of AgrC-I.  Likewise, Hcy AIP-I was a potent inhibitor of 
AgrC-II (only ~5-fold less than wild-type AIP-I), while inactive against AgrC-I. 
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Table 11. Activity of AIP Analogs  
                                          Cell-based β-lactamase reporter gene assays  in vitro assays using AgrC-I incorporated into nanodiscs 
AIP Analog Self-activation EC50 (95% CI) 
Group I 
Inhibition 
IC50 (95% CI) 
Group II  
Inhibition 






















(5-6.5) +++ 1.51 ± 0.09 
Hcy AIP-I1 — — 123.3 nM (90-163) + 1.04 ± 0.07 
Hcy AIP-II1 — >2 µM — + 0.95 ± 0.06 
Hcy AIP-III1 — >2 µM 234.0 nM (185-296) ++ 1.00 ± 0.06 
hβ-Met AIP-I2 — — — — nt4 
hβ-Ile AIP-I2 — — — — nt4 
hβ-Phe AIP-I2 — — — — nt4 
hβ-Asp AIP-I2 809.1 nM (741-883) — >2 µM +++ 2.8 ± 0.3 
F6P AIP-I — — — — nt4 
I7P AIP-I — — — — nt4 
ΔF6 AIP-I — — — — nt4 
ΔI7 AIP-I — — — — nt4 




(4-17) +++ 3.3 ± 0.3 
D5A hβ-Ala AIP-I2 344.5 nM (316-375) — 
970.5 nM 
(590-1595) +++ 4.1 ± 0.7 
D5A β-Ala AIP-I3 — — — + 1.63 ± 0.09 
 
The dash (—) indicates no activity observed with AIP analogs at concentrations up to 10 
μM. 1Hcy, homocysteine, replaces native cysteine residue within the indicated AIP. 2L-β-
homo-amino acid replaces indicated residue within the native AIP-I or D5A AIP-I 
sequence. 3β-Alanine replaces D5 in the AIP-I sequence. 4nt, not tested. 5These values are 
previously reported,[63] and our data (not shown) confirms them. *AgrC-I Binding assay:  
+++ strong binding, ++ moderate binding, + weak binding and — no binding (Figure 46) 
^AgrC-I Autokinase assay:  reported as a fold-increase (± SD) to the basal level of AgrC-
I autophosphorylation  (Figure 43) 
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Figure 42.  Cellular activity of AIP Analogs.   
A) Activation dose-response curves for indicated AIP-I analogs. AIPs were added in 
increasing concentrations to an exponential phase culture of a group I S. aureus reporter 
strain (RN9222). Samples were removed after 60 minutes and assayed for β-lactamase 
activity by the nitrocefin method. Data is plotted bas % maximal activation, normalized 
for cell density, versus peptide concentration. Errors; SEM, n = 3. B) Inhibition dose 
response curves for AIP analogs. Group II reporter cells (RN9367) were treated with a 
fixed concentration of AIP-II (125 nM) and varying concentrations of the indicated 
analogs. β-lactamase activity was measured and the normalized data presented as in panel 
A. The dose-response for the D5A β-Ala AIP-I analog does not fit an inhibition curve. 
Errors; SEM, n = 3. 
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Previously, the mutation of Asp-5 in AIP-I to an Ala converted the peptide from 
an agonist of its cognate receptor, AgrC-I, into an antagonist,[80] a result that we 
reproduced using the cell-based assay (Table 11, Figure 42B). Thus, we were curious to 
see the effect of replacing Ala with hβ-Ala at this position. Remarkably, this substitution 
converted the peptide back into an activator of the group I agr response, while leaving it 
as a cross-group inhibitor (Table 11, Figure 42A). Indeed, the analog is a more potent 
activator and inhibitor of group I and II cells, respectively, than the corresponding hβ-
Asp AIP-I analog. To our knowledge, this is the first time that an AIP analog with global 
inhibitory activity has been converted back to intra-group activator through the 
incorporation of second, compensatory modification, in this case the addition of a 
methylene group in the backbone. To explore this unexpected reversion phenomenon 
further, we prepared an additional AIP-I analog in which β-Ala was incorporated at 
position 5, i.e. removal of the methyl side-chain whilst keeping the extra methylene in the 
mainchain. Surprisingly, the β-Ala analog had no detectable agonism or antagonism 
activity in our cell-based assay (Table 11, Figure 42). 
 
 While the cell-based β-lactamase reporter assay can provide a way to understand 
some structure-activity relationships between AIP and AgrC, such assays provide no 
information on the strength of the interaction between the AIP and its receptor, AgrC, nor 
does it provide a direct readout of the extent to which this interaction activates the kinase 
activity of the receptor. This information is critical for a full understanding of the 
functional consequences of altering AIP structure, particularly since AIP binding and 
AgrC autophosphorylation may be uncoupled events.[88] With this in mind, we tested the 
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enlarged AIP analogs for cell-based activity in a recently developed in vitro AgrC 
autophosphorylation assay (Figure 43) that uses AgrC-I dimers reconstituted into 
nanometer-scale lipid bilayer discs (AgrC-I nanodiscs).[88] Briefly, Wang et al.[88] 
designed and characterized a protocol to incorporate AgrC-I into a lipid bilayer that is 
enclosed by two copies of a scaffold protein used to determine the size of the nanodisc 
and maintain its shape. AIP-induced activity of AgrC can be determined using 
autoradiography and/or scintillation counting. Working with Boyuan Wang, we were able 
to prepare AgrC-I nanodiscs and test the AIP analogs.  This SAR study is the first to use 
such a biochemical tool to directly interrogate the AIP-AgrC interaction, and it provides a 
direct readout of the extent to which our enlarged AIP analogs activate AgrC-I (Figure 
43). 
 
Consistent with the cellular activity, the hβ-Asp and D5A hβ-Ala AIP-I analogs 
stimulate AgrC-I autophosphorylation in vitro (Table 11, Figure 43).  However, the 
extent of that activation was not as robust as AIP-I, which also corresponds with the 
higher EC50 values determined for these enlarged AIP-I analogs.  The behavior of the 
AgrC-I nanodiscs was further confirmed by testing the activity of AIP-II and AIP-III, 
which are known to act as an inverse agonist and a neutral antagonist, respectively.[87, 88] 
AIP-II induced less AgrC-I autophosphorylation than the basal level seen when no AIP 
was incubated with AgrC-I nanodiscs, which demonstrates AIP-II clearly acts as an 
inverse agonist of AgrC-I. Likewise, the D5A β-Ala AIP-I analog only weakly activates 
the AgrC-I receptor at high concentrations (10 μM) above basal level 
autophosphorylation, displaying similar activity to the cross-group inhibitor AIP-III 
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(Figure 43).  The Hcy containing AIP analogs induced no significant autophosphorylation 
activity in AgrC-I. 
 
 In the course of our investigations we encountered one highly unexpected result. 
The D5A AIP-I analog, which as already noted is a global inhibitor of the agr response in 
cells,[63, 80] was found to activate AgrC-I autophosphorylation in vitro (Figure 43). None 
of the other analogs investigated in this study exhibited such discordant behavior in the in 
vitro and in vivo assays. In an effort to explain this contradictory result, we first turned 
our attention to the phospho-relay step in the agr TCS, i.e. phosphoryl-group transfer 
from AgrC to AgrA. Conceivably, the D5A AIP-I analog might inhibit the phospho-relay 
process, rather than AgrC autophosphorylation, thereby explaining the data. In the assay, 
AgrA was incubated with AgrC-I discs labeled with [γ-32P]ATP and mixed with an AIP 
or AIP analog.  Over a time-course, aliquots were removed and analyzed by SDS-PAGE 
followed by autoradiography. However, we saw no direct or indirect inhibition of 
phospho-transfer from AgrC-I to AgrA by the D5A AIP-I analog—especially when 
compared to AIP-II (Figure 44).  
  




Figure 43.  Stimulation of AgrC-I autokinase activity in vitro by AIP analogs  
AgrC-I nanodiscs were treated with the indicated AIP analog (10 μM) in the presence of 
[γ-32P]-ATP. Phosphorylation levels were analyzed by autoradiography (top) or 
quantified by scintillation counting (bottom). Reactions were also analyzed by SDS-
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Figure 44.  AgrC-I to AgrA Phospho-relay Assay 
Phospho-relay assays show the phosphoryl-group transfer from AgrC-I to AgrA.  AgrA 
was incubated with AgrC-I discs labeled with [γ-32P]-ATP and the indicated AIP analogs.  
Aliquots were then removed at various time points and analyzed by SDS-PAGE followed 
by autoradiography.  D5A AIP-I does not directly or indirectly inhibit phosphoryl-group 
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Next, we turned our attention back to the AgrC-I autokinase activation step. Our 
initial in vitro AgrC-I autophosphorylation assay employed a single concentration of AIP 
(10 μM). Such a high AIP concentration may not be achievable locally at the AgrC 
receptor in the context of a cell due to the presence of the peptidoglycan. Hence, we 
decided to check whether there was a concentration-dependence of D5A AIP-I activation 
of AgrC-I in the autokinase activity assay. Accordingly, two separate AgrC-I activation 
assays, using AgrC-I nanodiscs at a concentration of either 2.8 μM or 500 nM, were 
tested in a dose-response manner by increasing the D5A AIP-I analog concentration. The 
assays were quantified using scintillation counting, and normalized AgrC-I autokinase 
activity is reported relative to basal activity (no AIP added). We observed a striking 
difference in the behavior of AIP-I and the D5A analog in the dose-response assays 
(Figure 45A); the former activates the receptor even at sub-stoichiometric concentrations 
relative to AgrC-I nanodiscs, whereas the latter only has a stimulatory effect once the 
ligand/receptor ratio exceeds 2:1. In the high AgrC-I concentration assay (2.8 μM), the 
AgrC-I dimer concentration is substantially higher than the IC50 value for the D5A AIP-I 
analog on group I cells (6 nM, Table 1), suggesting that the absence of response at low 
D5A AIP-I peptide concentrations is not due to a lack of receptor binding (Figure 45A). 
Still, there was no observed inhibitory effect by D5A AIP-I at a high concentration of 
AgrC-I dimers. 
 
In the low AgrC-I concentration assay (500 nM), D5A AIP-I again had a 
stimulatory effect once the ligand/receptor ratio exceeded 2:1 (Figure 45B). However, in 
this case we observed some inhibitory effect by D5A AIP-I at a sub-stoichiometric 
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concentration relative to AgrC-I nanodiscs before a strong stimulatory effect began at the 
ligand/receptor ratio of 2:1.  Furthermore, the D5A AIP-I analog did not stimulate AgrC-I 
to similar levels as AIP-I in either assay (Table 11, Figure 45).  Using these two 
additional AgrC-I autophosphorylation assays combined with the known cell-based assay 
data indicated that the D5A AIP-I analog might access multiple binding sites within the 
AgrC-I nanodiscs (discussed further later). 
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Figure 45.  Further Characterization of D5A AIP-I Activation of AgrC-I 
A) Dose response curves for AgrC-I autokinase activity assays at varying concentrations 
of AIP-I and D5A AIP-I.  AgrC-I is at a concentration of 2.8 μM in each assay. The 
normalized activity for both AIP-I and D5A AIP-I are relative to the baseline level of 
phosphorylation in the absence of any ligand.  32P-labeled AgrC-I in each reaction was 
quantified through scintillation counting.  Error bars = SD (n = 3). B) Dose-response 
curve for AgrC-I autokinase activity assays at varying concentrations of D5A AIP-I.  
Assays were performed and analyzed as described in A, except that AgrC-I is at a 
concentration of 500 nM in each assay. C) AgrC-I autokinase activity assays at 
concentrations of 10 μM and 1 μM of AIP-I and AIP-II. These assays were analyzed as 
described in A, and the concentration of AgrC-I was 500 nM. They are provided for 
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4.3  Receptor Binding and NMR Characterization of AIP Analogs (work on this 
section was accomplished in collaboration with Boyuan Wang and Dr. Galia 
Debelouchina) 
4.3.1 AgrC-I Binding Assay for AIP Analogs  
Since many of the AIP-I analogs showed little or no activity in the cell-based and AgrC-I 
autokinase activity assays, we developed an AIP-AgrC binding assay to gauge the 
relative affinities of the AIP analogs for the receptor. This assay is based on changes in 
steady-state anisotropy (SSA) that occur upon competitive displacement of fluorescein-
labeled AIP-I (FAM-AIP-I) from AgrC-I nanodiscs (Figure 46A).  In the binding assay, a 
high concentration of AIP analog (10 μM) was added to displace FAM-AIP-I (21 nM). 
Using this AgrC-I binding assay in conjunction with the other assays described in Section 
3.2, we imagined that it should be possible to tease apart AIP analogs that bind AgrC and 
solicit a functional output (agonism) versus those that bind but do not effect signal 
transduction. As detailed below, these binding studies were entirely consistent with the 
results from both the cell-based and AgrC biochemical activity assays. 
  








Figure 46.  Binding of AIP analogs to AgrC-I   
A) Schematic of the AgrC-I binding assay.  A cross-section of the AgrC-I nanodisc 
assembly is shown, where AgrC-I is initially bound to FAM-labeled AIP-I.  Upon adding 
unlabeled AIP-I or any other AIP in excess, the FAM-labeled AIP-I will be displaced 
resulting in low anisotropy, which indicates binding of the unlabeled AIP.  B) The AIP 
analogs were tested using an in vitro assay that measures the change in steady-state 
anisotropy (SSA) that occurs upon competitive displace of a fluorescein-linked AIP-I 
(FAM-AIP-I) from AgrC-I nanodiscs. Open and solid bars correspond to the SSA before 
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In general, replacement of the endocyclic residues in AIP-I with the 
corresponding L-β-homo-amino acids led to a total loss of AgrC-I binding (Table 11, 
Figure 46B). As expected, AIP-I, -II and -III all bind tightly to AgrC-I, which validates 
the use of AgrC-I nanodiscs for measuring AIP binding affinity. Predictably, the hβ-Asp 
analog of AIP-I was able to bind tightly to the receptor, reflecting its stimulatory activity 
(Table 11, Figure 46B). Binding was abolished for those AIP analogs containing amino 
acid deletions as well as those containing proline. The homocysteine containing AIP 
analogs appear to have reduced affinity for the AgrC-I receptor as indicated by a partial 
displacement of FAM-AIP-I at the high concentration of AIP analogs employed.  
Consequently, the Hcy AIP-I is not an AgrC-I agonist and the cross group Hcy AIP 
analogs (II and III) do not inhibit AgrC-I. However, with respect to group II antagonism, 
the cross group Hcy AIP analogs (I and III) do have a strong inhibitory effect on AgrC-II 
as discussed in Section 3.2.2. Not surprisingly, the antagonist-turned-agonist D5A hβ-Ala 
AIP-I analog also binds tightly to the AgrC-I receptor; while the D5A β-Ala AIP-I analog 
only weakly interacts with the AgrC-I receptor (Table 11, Figure 46B). Clearly, insertion 
of a single methylene group at most positions in the AIP macrocycle backbone has 















Figure 47.  Solution NMR analysis of selected AIP-I analogs   
Change in backbone amide 1H chemical shift differences (CSDs) within the macrocycle 
of indicated analogs relative to native AIP-I normalized to zero (performed in DMSO-d6 
at 298 K).  Position 2 (Asp) includes CSDs for the D5A AIP-I analogs, where Ala or hβ-
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4.3.2  NMR Analysis of AIP-I Analogs 
From the cell-based and AgrC-I binding assay data, it was apparent that hβ-AAs 
replacement within the AIP macrocycle for the most part disrupts the interaction between 
the AIP and the AgrC receptor.  We wanted to investigate whether these non-binding, 
enlarged AIP-I analogs induced major structural changes within the AIP macrocycle, 
which might impede the interaction with the AgrC-I receptor.  To interrogate the lack of 
binding among some of the hβ-AA AIP-I analogs, two-dimensional NMR studies of hβ-
Asp, hβ-Phe, hβ-Met, Hcy, D5A hβ-Ala and D5A AIP-I analogs were performed (See 
Appendix for each analogs 2D NMR assignments).  Figure 47 shows a comparison of the 
chemical shift differences (CSDs) of the macrocycle backbone amide protons within 
these six AIP-I analogs (determined in DMSO-d6 at 298 K) relative to the AIP-I amide 
protons at the same position. 
 
In every instance, the hβ-AA substitution strongly affects the amide proton at that 
native position, which indicates a perturbation within the AIP-I macrocyle and is 
consistent with our 2σ analysis of the CSD data (Figure 48). In the two analogs where the 
hydrophobic “knob” was perturbed (Phe-6 and Met-8),[59, 86] the perturbation was not only 
observed at the site of hβ-AA substitution but also propagated along the backbone to 
neighboring residues (Figure 48, Ile-7 and Met-8 in the hβ-Phe AIP-I analog, Ile-7 and 
Cys-4 in the hβ-Met AIP-I analog). Replacing Cys-4 with Hcy in AIP-I also caused a 
major perturbation at the Phe residue of Hcy AIP-I (Figure 48), which might disrupt 
AgrC-I binding as seen in the binding assay (Figure 48). In contrast, this residue specific 
2σ analysis indicates that none of the substitutions at macrocycle position 2 in the 
enlarged AIP-I analogs propagate significant CSDs throughout the AIP macrocycle.  
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Figure 48.  2σ Analysis of Amide 1H Residue-specific CSDs for Selected Enlarged 
AIP Analogs Indicates Which CSDs Significantly Affect AIP Binding of AgrC   
Amide 1H CSDs for the AIP-I analogs investigated with 2-D NMR (performed in DMSO-
d6 at 298 K) are plotted according to each endocyclic position in the AIP macrocycle 
relative to a corresponding average CSD from the four AIP-I analogs (hβ-Asp AIP-I, 
D5A hβ-Ala AIP-I, D5A AIP-I and the native AIP-I) that bind AgrC-I (Figure 43B), 
which was normalized to zero.  Using this average, a CSD standard deviation (σ) was 
calculated and plotted as dotted lines equal to ± 2σ.  If a residue-specific CSD lies outside 
the ± 2σ zone, it is considered a significant CSD within that AIP-I analog.  A) Met, B) 











AIP-I D5A D5A hβ-
Ala





















AIP-I D5A D5A hβ-
Ala























AIP-I D5A D5A hβ-
Ala





















AIP-I D5A D5A hβ-
Ala



















AIP-I D5A D5A hβ-
Ala










Tyr amide 1H Avg = 7.983 ppm 
	   138 
4.4  Conclusion  
In this chapter, we investigated the effect of altering AIP macrocycle size and 
conformation on agr activation and inhibition. Our data support and extend the current 
understanding of the key features in the AIP required for receptor engagement. In 
general, we found that changing the chemical structure of the AIP-I macrocycle has a 
catastrophic effect on the ability of the peptide to bind and activate the AgrC-I receptor. 
The sole exception to this broad sensitivity is the second endocyclic position (Asp-5 in 
primary sequence) where ring expansion is permitted. Solution NMR studies suggest that 
this position is more tolerant of backbone changes relative to other positions in the 
macrocycle. This study underlines the key importance of the second endocyclic position 
in AIP-I for canonical receptor activation. Surprisingly, we found that incorporation of 
hβ-Ala at this position yields an activator of AgC-I even though the corresponding L-Ala 
analog is an inhibitor (at least at physiologically relevant concentrations), which suggests 
that the hβ-Ala analog can penetrate sufficiently into the relevant receptor pocket so as to 
trigger activation. Interestingly, we also found that, in terms of inhibition, methylene 
insertion is acceptable on one side of the thiolactone linkage (Hcy) but not on the other 
(hβ-Met). This indicates that receptor engagement is highly sensitive to the separation 
between the thioester and the Met sidechain. Collectively, our data suggests that there are 
three discrete regions in the AIP macrocycle that must cooperatively engage the receptor 
for activation to occur: the hydrophobic patch defined by C-terminus of the peptide,[59, 86] 
the thiolactone linkage (which must be appropriately juxtaposed to that patch), and the 
second endocyclic position, which must have a certain amount of steric bulk. 
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Chapter 5. Discussion and Future Directions 
5.1 Discussion and Implications of This Work 
5.1.1 AIP Secretion Does Not Require AgrB 
In Chapter 2, we investigated the possible role of AgrB in AIP secretion. At the start of 
this study, it was necessary to develop an assay that could be used to investigate AIP 
secretion in the absence of AgrB.  Thoendel et al. were able to demonstrate that AIP 
production was disrupted by non-catalytic point mutantions in AgrB, but they were 
unable to determine whether the lack of secretion or hydrolysis of the acyl-enzyme 
thioester intermediate stopped AIP production.[72] One strategy to resolve this issue would 
involve removing AgrB from the system. However, this experimental strategy would 
require replacing its enzymatic activity in vivo to form the AgrD(1-32)-thiolactone. The 
solution presented in this study uses intein chemistry to form the AgrD(1-32)-thiolactone. 
The newly engineered S. aureus cells reported in this study express AgrD(1-32)-inteinNpu 
and AgrD(1-32)-inteinSsp proteins (Figure 18) and secrete AIP-I into the extracellular 
environment (Figure 19). To our knowledge, these S. aureus cells are the first to produce 
AIP in an AgrB-independent manner. More importantly, these AgrD(1-32)-intein-
expressing cells produce functional AIP, which stimulates AgrC-I to induce β-lactamase 
activity (Figure 20). We also demonstrated that controlling the observed activity in the 
assay can be regulated by expressing a D29A AgrD(1-32)-intein construct, which 
produces the known D5A AIP-I inhibitor of AgrC-I (Figure 21).[63, 80] Collectively, these 
data indicate that we developed a biological assay to investigate AIP secretion. 
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 For this assay to correctly function, presumably, the AgrD(1-32)-I-thiolactone 
embeds itself into the membrane, crosses the membrane in either an active or passive 
manner and is then processed to release AIP-I outside of the cell. Understandably, one 
concern for this assay then is cellular lysis, which would bypass the correct secretion 
pathway but still result in AIP-I in the extracellular milieu—especially if AIP-I were to 
build up in the cytoplasm of our new assay cells. Using a controlled cell lysis experiment, 
the AgrD(1-32)-inteinSsp cells approach cellular lysis of ~40% (Table 4) but AIP-induced 
β-lactamase activity remains statistically the same (Figure 22). These data indicate that 
AIP does not accumulate in the cytoplasm of the cell, since cell lysis does not directly 
increase AgrC activation and β-lactamase activity. Furthermore, the Western blot 
analysis of controlled cell lysis indicates that AgrD(1-32)-intein protein is present in both 
of the cell-free lysates tested (Figure 22), but it again does not cause increased AIP-
induced β-lactamase activity, which would suggest that the AgrD(1-32)-intein protein is 
unlikely to be further processed into AIP-I even if the intein-mediated formation of the 
AgrD(1-32)-I-thiolactone occurs in the cell culture supernatant. Taken together, the 
controlled cell lysis data suggests that the AIP-I produced by the AgrD-fused split intein 
expressing cells is likely secreted across the membrane. 
 
 Having developed and characterized this new AIP secretion assay, we could 
investigate what role AgrB-I might have in AIP secretion. To accomplish this, we 
engineered a new set of cells that express the AgrD-fused split intein construct along with 
AgrB-I as well as mutants thereof, namely C84A (catalytically dead), C84A and K129E, 
or C84A and K131E (Figure 23). Based on the observations of Thoendel et al., who 
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supposed that mutations in the lysine (K129-131) patch might inhibit AIP secretion,[72] we 
anticipated that C84A AgrB might increase AIP-induced β-lactamase activity, while the 
C84A and K129E or K131E AgrB-I mutants would not. Unexpectedly, the C84A AgrB-I 
mutants did not cause an increase in AIP-induced β-lactamase activity when compared to 
non-AgrB expressing cells (Figures 24 and 25). We had confirmed AgrB expression in 
the cells via Western blot analysis (Figure 23), so we were confident that AgrB-I mutants 
were expressed. Conceivably the C84A mutation might affect the putative secretion 
function of AgrB-I, hence we also expressed WT AgrB-I in the presence of the AgrD-
intein. However, it also did not increase AIP-induced β-lactamase activity above the non-
AgrB expressing cells (Figures 24 and 25). The data suggest that AgrB does not facilitate 
AIP secretion, since its effect on AIP-induced β-lactamase activity was inconsequential. 
Furthermore, the results with cells containing AgrB-I suggest that secretion of AgrD(1-
32)-I-thiolactone is not coupled to the enzymatic processing of AgrD. In our cells, the 
WT AgrB-I could have formed the acyl-enzyme thioester intermediate and then re-
catalyzed formation of AgrD(1-32)-I-thiolactone, which should induce the necessary 
structural changes to facilitate secretion, if AIP secretion were coupled to AgrB cleavage 
of AgrD. While the absence of any structural characterization of the AgrB-AgrD thioester 
intermediate limits our ability to explain how AgrB may interact with AgrD in the 
membrane, our data nonetheless suggests that AgrB does not facilitate secretion of the 
AgrD(1-32)-I-thiolactone. 
 
With no apparent AgrB-mediated increase of AIP activity, we wanted to develop 
a working hypothesis to guide future experiments. In order to help formulate this 
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hypothesis, we investigated some of the physicochemical properties of AgrD. As 
expected, AgrD(1-32)-I-thiolactone is slightly lipophilic (Table 5), which likely promotes 
membrane association similar to that seen with the N-terminus of full-length AgrD.[64] 
Using the AgrD(1-32)-intein platform, we designed another construct to confirm the 
chemical characteristics of the SID sequence. If this sequence does inhibit secretion in the 
full-length AgrD, it should also inhibit AIP secretion if inserted into the AgrD(1-32) 
domain of the AgrD(1-32)-inteinNpu and AgrD(1-32)-inteinNpu constructs. As expected, 
inserting the 15-residue SID sequence of AgrD-II into the AgrD(1-32) domain to make 
the chimera AgrD-inteinSsp led to inhibition of AIP secretion as measured by β-lactamase 
assay activity (Figure 26). This insertion into the MAD sequence of AgrD suggests that 
the SID sequence does not contain the necessary physicochemical properties to maintain 
and promote membrane association, since AIP activity was not detected in the cell culture 
supernatants. This finding corroborates the only known role of AgrB: SID removal to 
form the AIP macrocycle, which can facilitate secretion.[57] 
 
 Based on our findings, our current working model of AIP secretion begins with 
AgrB-mediated removal of the SID to form AgrD(1-32)-thiolactone (Figure 39). This 
lipophilic molecule remains associated with the membrane, awaiting secretion. Recent 
research has reported the presence of the MAD sequence of AgrD incorporated into 
amyloid fibrils of S. aureus biofilms,[66] strongly suggesting that both the AIP and the 
MAD can be secreted. Our finding that AgrB does not facilitate AIP secretion suggests 
either 1) another unknown, non-agr protein is involved in transporting AgrD(1-32)-
thiolactone across the membrane or 2) AgrD(1-32)-thiolactone has intrinsic properties 
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that facilitate “self-secretion” of diffusion across the membrane. The former secretion 
pathway would make AIP biosynthesis dependent on two non-agr proteins. The latter 
“self-secretion” mechanism requires only one non-agr protein to produce AIP, and in the 
absence of a clear AgrD transporter, it is possible for AgrD(1-32)-thiolactone to partition 
the membrane and access the outer leaflet, where SpsB, for example, can cleave it. 
Membrane partitioning of AgrD(1-32)-thiolactone would be consistent with recent 
research, describing the cytolytic properties of the AgrD MAD sequence, which suggests 
the MAD can form pores in a membrane.[66, 67] It is also curious that AIP biosynthesis can 
be replicated in E. coli by only expressing AgrB and AgrD,[57, 72] so if a transporter were 
involved, E. coli cells would also have to express a transpoter analogous to the S. aureus 
one. While this seems unlikely, given that Gram-negative and Gram-positive bacteria 
employ very different quorum sensing systems, the data so far cannot completely rule this 
out. Whatever the mechanism, the AgrD(1-32)-thiolactone must access the outer leaflet 
of the membrane for further processing (Figure 49). 
  




Figure 49. Proposed AIP Secretion Model 
Using AIP-I biosynthesis as an example, we propose a secretion model for the AgrD(1-
32)-thiolactone. Once AgrB-I has removed the SID of AgrD-I, the resulting lipophilic 
AgrD(1-32)-I-thiolactone remains associated with the membrane. The AIP-I precursor 
then partitions the membrane to access the outer leaflet, where SpsB can recognize and 
cleave the MAD of AgrD-I, releasing AIP-I to the extracellular environment. Although 
not depicted, an unknown protein could facilitate AgrD(1-32)-thiolactone secretion, and 
based on the results of AgrD-II cleavage study, there are likely other proteases besides 
SpsB that cleave the MAD of AgrD. 
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5.1.2 SpsB Can Only Cleave AgrD(1-32)-I-thiolactone 
In chapter 3, we investigated the role of SpsB in AIP biosynthesis. SpsB is a non-agr 
regulated type I signal protease that has previously been shown to cleave an AgrD-I 
derived peptide.[58] Attempting to elaborate on this initial finding, we tried to characterize 
the SpsB catalysis of several AgrD derived peptides. While we were successful in 
purifying and characterizing SpsB, it would only cleave a fluorescein labeled AgrD 
derived peptide in vitro (Table 7, Figure 29), which was the only peptide Kavanaugh et 
al. had tested. [58] Even inclusion of the conserved IG sequence motif of AgrD (Figure 
5A), which could help determine where a type I signal peptidase cleaves,[65] did not 
promote SpsB cleavage (Table 7, Figure 30B). Using a cell-based assay, however, did 
produce correct cleavage of the IG-AIP-I peptide, although other non-specific cleavage 
products were detected in IG-AIP-I and IG-AIP-III (Table 8). If SpsB catalyzed the 
correct cleavage of the IG-AIP-I peptide, it seemed to do so only in the context of a cell 
membrane (Table 8, Figure 30B). 
 
 To investigate the role of the membrane, we reconstituted SpsB and several 
variants of AgrD into proteoliposomes (vesicles), and in some instances, we also included 
AgrB. SDS-PAGE analysis of the vesicles indicated that SpsB can cleave AgrD-I and 
AgrD-II (Figure 33, lanes 2 and 6). However, it provided little molecular characterization 
of those cleavage products, and when group-specific AgrB was included in the vesicles, 
reconstituting the whole AIP biosynthetic pathway, SDS-PAGE provided even less 
resolution among the possible products. For further characterization of the vesicle 
cleavage products, we employed RP-HPLC and ESI-MS analysis. We confirmed the 
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correct SpsB and AgrB cleavages of AgrD-I (Table 8, rxns 1-4), which is the first direct 
evidence that two proteases are indeed needed for AIP biosynthesis. The AgrD(1-32)-I-
thiolactone was also detected (Table 8, rxn 2), which was significant since AIP-I was 
undetected. Taken together, these data suggest a role for SpsB in AIP-I biosynthesis. 
 
 While initial attempts to detect AIP production by the AIP biosynthesis vesicles 
were inconclusive, we detected AIP activity using the β-lactamase reporter assay when 
SpsB and the AgrD(1-32)-I-thiolactone were reconstituted into vesicles (Figure 34). 
Subsequent RP-HPLC-MS analysis of these same vesicles confirmed AIP production 
(Figure 35). To our knowledge, this data provides the first direct evidence of in vitro AIP 
production, but more importantly, it argues strongly for the role of SpsB in AIP-I 
biosynthesis.  
 
 Having studied the role of SpsB in AIP-I biosynthesis, we turned our attention to 
AIP-II biosynthesis. While the SDS-PAGE analysis indicated SpsB cleaves AgrD-II 
(Figure 33, lane 6), the RP-HPLC and ESI-MS analysis detected only non-specific 
cleavage products (Table 8, rxns 5 and 6), and importantly this non-specific cleavage 
would actually produce a known antagonist of AgrC-II.[62, 83] The correct AgrB-II 
cleavage of AgrD-II was detected (Table 8, rxn 6), although it was the hydrolyzed 
product, not the thiolactone. To further explore the role, if any, of SpsB in AIP-II 
biosynthesis, we reconstituted the full-length protease and AgrD(1-32)-II-thiolactone into 
vesicles. These vesicles should represent the final two components necessary for AIP-II 
production, and in the case of AIP-I biosynthesis, these two protein components were 
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sufficient (Figures 33 and 34). However, using the β-lactamase reporter assay, we were 
unable to detect AIP-II activity from these vesicles or from vesicles also incorporating 
SpsA as a potential binding partner for SpsB or AgrD(1-32)-II-thiolactone (Figure 36). 
We thought SpsA might help guide SpsB to the correct cleavage site, but it played no 
such role in our reconstituted system. To test the idea that a larger protein complex 
consisting of AgrB-II, SpsB and SpsA or some combination thereof might be required for 
the final cleavage step in AIP-II production, all four components were reconstituted into 
vesicles. However, we again failed to detect any AIP-II activity in the coupled cellular 
assay (Figure 38). Thus, collectiviely our biochemical data argue against a role for SpsB 
in the biosynthesis of AIP-II. 
 
 While it is unclear what protein cleaves the AgrD(1-32)-II-thiolactone, cleavage 
does occur at the membrane (Figure 39). Specifically, AIP-II was detected in a cell 
culture supernatant from agr-II null cells (RN9120) incubated with the AgrD(1-32)-II-
thiolactone. However, AIP-II was not detected in a pre-grown RN9120 culture filtered 
and then incubated with the group II thiolactone. Taken together, these data suggest that 
AIP-II production occurs at or near the membrane, because no secreted S. aureus factor 
cleaved the AgrD(1-32)-II-thiolactone to produce AIP-II. Furthermore, our data suggest 
that the processing step likely occurs at the outer leaflet of the membrane, because 
cleavage at the inner leaflet would lead to AIP-II accumulation in the cytoplasm, trapping 
the hydrophilic AIP-II molecule inside the cell unless a peptide pump or transporter were 
involved (Table 5, AIP-II LogD5.9 value). While a transporter may be involved in AIP-II 
biosynthesis, our data discussed in Section 5.1.1 suggests a model where that transporter, 
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if necessary, would likely transport the AgrD(1-32)-II-thiolactone to the outer leaflet for 
further processing (Figure 49).    
 
5.1.3 AIP-I Activation of AgrC-I Requires Three Distinct Interactions Within the 
AIP Macrocycle 
In Chapter 4, we investigated the effect of altering AIP macrocycle size and 
conformation on agr activation and inhibition. As can be seen from the SAR data 
summarized in Table 11, activation of the agr response is extremely sensitive to 
perturbations in the AIP macrocycle. Indeed, we found only one position that tolerated 
any change, namely Asp-5 of AIP-I corresponding to the second endocyclic position. In 
contrast, replacement of the other endocyclic residues in AIP-I with the corresponding L-
β-homo-amino acids led to a total loss of cellular and biochemical activity (Table 11, 
Figures 42A and 46B). This was also true for those AIP analogs containing amino acid 
deletions, as well as those containing the proline and Hcy substitutions (Table 11, Figures 
42, 43 and 46B). Collectively these data indicate that even relatively subtle changes in the 
macrocycle, for instance the insertion of a single methylene group at most positions in the 
ring, can have catastrophic effects on agonism of the ArgC receptor. Comparing the 
backbone amide 1H chemical shifts of the inactive ring-expanded analogs indicated that 
methylene insertion affects the overall structure of the AIP-I macrocycle, presumably 
leading to a lack of receptor binding (Figures 46 and 47). By contrast, the active hβ-Asp 
analog had a more modest difference on backbone amide 1H chemical shifts compared to 
native AIP-I, particularly at two hydrophobic sites (Phe, Met) which are known to be 
critical for receptor binding.[59, 86] The overall sensitivity to change in the macrocycle size 
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is broadly consistent with the many previous SAR studies on the agr system, which have 
converged on the idea that agonism is largely intolerant to changes in AIP structure.[45, 59, 
63, 80, 83-86]   
 
 Previous work suggests that AIP has a hydrophobic patch or “knob” essential for 
AgrC binding.[59, 86] In addition, McDowell et al. reported that D-Met and D-Phe could be 
substituted into the hydrophobic knob of AIP-I and still stimulate AgrC-I.[80] There was 
some surprise then that the enlarged AIP analogs within this region were not only 
inactive (Table 11) but also incapable of binding AgrC (Figure 46B). We hypothesized 
that the AIP binding pocket in AgrC might be able to accommodate a small perturbation 
such as methylene insertion as opposed to removing large hydrophobic sidechains using 
alanine substitution.  Our results clearly indicate that AgrC-I cannot tolerate even small 
perturbations to the AIP hydrophobic patch.  Our solution NMR work provides some 
clarification as to why AgrC-I cannot bind these enlarged AIP-I analogs. The large CSD 
values produced by replacing Met with hβ-Met or Phe with hβ-Phe were indicative of 
major structural changes within the local environment of these AIP-I analogs (Figure 47). 
Since AIP-I is such a small peptide that doesn’t exhibit traditional secondary structure, 
the resulting amide CSD at endocyclic position 5 of hβ-Met AIP-I, for example, does not 
describe a change in secondary structure, but rather suggests that the macrocycle 
backbone has repositioned, which likely explains the lack of binding in this AIP-I analog.  
Furthermore, the 2σ analysis of the CSD data suggests that inserting a methylene group at 
Phe-6 or Met-8 does not only directly affect the AIP macrocycle at that position but the 
perturbation is propagated through the macrocycle, affecting neighboring residues within 
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the AIP macrocycle (Figure 45). By drastically perturbing the hydrophobic knob of the 
AIP macrocycle with hβ-AAs, AIP binding of AgrC was abolished, explaining why most 
of the enlarged AIP analogs were inactive.  Conversely, while inserting a methylene 
group at endocyclic position 2 of AIP-I did produce some large CSD values at that 
position, the structural effect was not further propagated throughout the AIP macrocycle 
(Figure 48).  Consequently, the hβ-Asp and D5A hβ-Ala AIP-I analogs were able to bind 
AgrC-I, enabling activation.   
 
In our attempts to characterize the biologically active AIP analogs featuring 
enlarged macrocycles with biochemical assays, the in vitro activation of AgrC-I by D5A 
AIP-I was surprising. There is no doubt that D5A AIP-I is an inhibitor of AgrC-I in a 
cellular context; this has been reported previously and was confirmed in the current study 
(Table 11).[63, 80] We performed several biochemical studies to try and understand the 
basis of the observed in vitro activation. We showed that the D5A AIP-I analog does not 
inhibit the phospho-relay between AgrC and AgrA, ruling this out as a possible 
explanation for the in vivo versus in vitro observations (Figure 44). In the AgrC-I 
autokinase activity assays, every control indicated that the AgrC-I nanodiscs behaved 
according to previously reported in vivo findings for AIP-I, -II and -III (Figure 43). [45, 59, 
63, 80, 83-86] Finally, dose-response AgrC-I autokinase activity assays indicated that D5A 
AIP-I activation appeared to be delayed until two ligands had bound the AgrC-I 
nanodiscs (Figure 45). Since D5A AIP-I competes with FAM-AIP-I to bind the 
orthosteric site of AgrC-I (Figure 46B) and AIP-I binds AgrC-I in a 2:2 stoichiometry,[88] 
our dose-response curves would indicate that D5A AIP-I stimulation of AgrC-I occurs 
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after the canonical binding site of AgrC-I is occupied. Collectively, the in vitro and in 
vivo data point to their being multiple AgrC-I binding sites for the D5A AIP-I analog. At 
low concentrations the analog binds to the ‘high-affinity’ binding site on the receptor 
where it inhibits activation through competitive antagonism, whereas at elevated 
concentrations it binds to a putative second ‘low-affinity’ site where it can somehow 
activate the receptor. The location of this possible ‘low-affinity’ site is unclear, and we 
cannot rule out that this site might reside somewhere on the ‘intracellular side’ of the 
AgrC-I nanodiscs (i.e. in the cytoplasmic domain which would of course be accessible in 
the reconstituted system). Therefore, we surmise that only the ‘high affinity’ site is 
physiologically relevant, thereby accounting for the behavior of the D5A AIP-I analog on 
cells. 
 
 In contrast to activation of the agr response, antagonism of the AgrC receptor is 
more resilient to changes in the AIP macrocycle.[45, 62, 63, 79, 80, 83] While some trends 
observed for activation of the response were also seen for inhibition (e.g. among the L-β-
homo-amino acid substitutions only the hβ-Asp analog retained measureable, albeit 
weakened, activity), a few of the analogs that were inactive as agonists were active as 
antagonists (Table 11). Specifically, the homocysteine containing AIP analogs all had the 
expected cross-group inhibitory activity (Table 11, Figure 42B). Thus, antagonism of the 
agr response does seem to be a little more tolerant to changes in the macrocycle; for 
example a methylene group insertion is acceptable in two positions within AIP-I. With 
regard to AgrC-I antagonism, it appears that replacing Cys with Hcy in AIP-II disrupted 
its mode of inhibition.  Hcy AIP-II is no longer an inverse agonist like AIP-II, but it may 
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act as a very weak neutral antagonist, since it does not activate AgrC-I above basal levels 
(Figure 43) and it weakly binds AgrC-I (Figure 46B). Interestingly, group II cells seem to 
be more susceptible to inhibition by the relevant Hcy analogs than group I cells; the Hcy 
analog of AIP-III was a relatively potent inhibitor of AgrC-II (only ~40-fold less than 
wild-type AIP-III), but a weak inhibitor of AgC-I. While the absence of structural 
information on any AgrC sensor domain limits our ability to explain such differential 
effects in molecular terms, the data nonetheless highlight the fact that the molecular 
recognition mechanisms employed by the different AgrC receptors are far from identical. 
 
While AIP-I endocyclic position 2 (Asp-5) was previously known to be essential 
to AgrC-I activation,[63, 80] the pivotal finding of this SAR study was the conversion of the 
known global inhibitor D5A AIP-I into an agonist of AgrC-I by replacing Ala with hβ-
Ala. Furthermore, the loss of activity observed in the D5A β-Ala AIP-I analog provided 
another key insight. Collectively, these data highlight the importance of the second 
endocyclic position in AIP-I for receptor agonism. Thus, reduction in the size of the 
sidechain (Asp to Ala) converts the peptide into an antagonist, addition of a backbone 
methylene (Ala to hβ-Ala) flips it back to being an agonist, while removal of the 
sidechain in the expanded ring context (hβ-Ala to β-Ala) essentially removes all activity. 
In trying to interpret these observations, we were cognizant of previous SAR studies that 
indicate Asp-5 of AIP-I can be replaced with Asn, Phe or Tyr without losing the ability to 
activate AgrC-I.[63] Together, our SAR data is consistent with a model in which the AgrC 
receptor is switched on when it senses sufficient steric bulk (rather than a specific 
functional group, per se) at the second endocyclic position in AIP-I. This requirement is 
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not fulfilled by an Ala (at least not at physiologically meaningful concentrations, vide 
supra), but apparently is by hβ-Ala. We postulate that the added methylene group in the 
hβ-Ala AIP-I analog allows the sidechain methyl to extend further into the critical 
binding pocket in the receptor, triggering activation. Presumably, the β-Ala AIP-I analog, 
by lacking the sidechain, cannot extend far enough into this receptor pocket to fulfill this 
steric requirement. 
 
Collectively, the available SAR data on the group I agr system points to three 
discrete regions in the AIP macrocycle that must cooperatively engage the receptor for 
activation to occur (Figure 50). These features are the hydrophobic patch defined by the 
C-terminus of the peptide,[59, 86] the thiolactone linkage (which must be appropriately 
juxtaposed to that patch), and the second endocyclic position, which must have a certain 
amount of steric bulk. Altering any one of these three features is sufficient to eliminate 
receptor agonism. However, it appears that maintaining the native structure of the 
hydrophobic patch is the only feature that absolutely must be retained for cross-group 
inhibition.[45, 59, 62, 63, 79, 80, 83, 84, 86] It is likely that this binding model will be a useful guide 
for the design of additional AIP analogs for probing the receptor interaction using 
biochemical methods that exploit the reconstituted AgrC nanodisc system. 
  






Figure 50.  Proposed Role of AIP Macrocycle in agr Activation   
Schematic illustrating the three key regions of the AIP-I macrocycle required for AgrC 
receptor activation. In our model, all three of these interactions must be satisfied before 
receptor activation ensues. 
  
3-Points-of-contact AIP Macrocycle Activation Model 
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5.2 Future Directions 
5.2.1. Future Directions for AIP Secretion and Biosynthesis 
Develop an AgrD(1-32)-thiolactone Membrane Crossing Assay 
To test our hypothesis that AgrD(1-32)-thiolactone can partition and cross the membrane, 
we have recently endeavored to develop an AgrD(1-32)-thiolactone vesicle crossing 
assay. Our initial attempts at developing a vesicle-based assay have been unsuccessful. 
Briefly, lipid vesicles were formed using a reverse-phase evaporation method.[145] Lipid is 
dissolved in diethyl ether and then aqueous buffer is added. This solution is then 
sonicated to form an emulsion, and the ether is removed in vacuo, forming vesicles of 
~150 nM. The vesicle suspension is then diluted with more aqueous buffer. As part of the 
aqueous buffer, we tried incorporating a Cys-FLAG peptide (sequence: H-
CGGDYKDDDDKK-OH), L-cysteine or cysteamine into the lumen of the lipid vesicles. 
These small molecules could react with the thiolactone, leading to C-terminal ligation 
and increasing the molecular weight of the AgrD(1-32)-thiolactone peptide, which we 
monitored via RP-HPLC and ESI-MS analysis. In all of the assays, the vesicles were 
washed with buffer to remove any thiol-containing small molecule from the outside of 
the vesicles. The AgrD(1-32)-II-thiolactone was then added to the outside of the vesicles. 
Presumably, if a reaction is detected via RP-HPLC and ESI-MS analysis, then AgrD(1-
32)-II-thiolactone must have crossed the membrane to react with the thiol-containing 
molecules in the vesicle lumen. However, we have not detected the elongated AgrD 
peptide in washed vesicles.  In controls, where the washed vesicles are lysed with 
detergent after 2-3 hours of incubation with the AgrD(1-32)-II-thiolactone and the 
reaction continues for 2-3 hours post-lysis, the reaction is also not detected. If any of the 
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thiol-containing molecules are added to the outer solution around the vesicles, however, 
the reaction can be detected. More effort is need to optimize this assay. 
  
While a version of this vesicle-crossing assay may potentially work after 
optimization, it might be necessary to consider an alternative route. Recently, Schwartz et 
al.[66] developed two assays to determine the cytolytic properties of the AgrD-I MAD 
sequence (Figure 5A). One assay measured the hemolysis of human red blood cells, and 
the other assay measured lysis of human neutrophils. Employing these assays with AgrD-
I(1-32)-thiolactone and AgrD(1-32)-II-thiolactone could provide similar insights into the 
ability of the AIP precursor to partition and cross the membrane as the vesicle-crossing 
assay. Additionally, Schwartz et al. provide an independent dataset to compare the 
AgrD(1-32)-thiolactone activity in these assays with the MAD of AgrD. 
 
Develop a Crosslinking Strategy to Find Proteins That Interact With the AgrD(1-
32)-thiolactone 
In the event that the AgrD(1-32)-thiolactone cannot cross a membrane on its own, it will 
be necessary to identify the protein that facilitates AIP secretion. One way in which to 
accomplish this would be with a crosslinking strategy. Using S. aureus protoplasts, or 
whole membrane fractions, membrane proteins would be accessible to react with 
exogenously added peptides.  Incorporating a combination of amino acids such as p-
benzoyl-L-phenylalanine (Bpa), L-photo-methionine (photo-Met), and/or L-photo-
leucine (photo-Leu) into AgrD(1-32)-I-thiolactone peptide (e.g. 2 Met, 5 Phe and 3 Leu 
residues in group I) would cover the whole length of the peptide sequence and increase 
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possible crosslinking with potential AgrD(1-32)-thiolactone binding partners. N-terminal 
biotinylation of the AgrD thiolactone would provide an excellent handle to recover any 
crosslinked protein complexes involving the AgrD(1-32)-thiolactone for further analysis 
via SDS-PAGE and/or mass spectrometry. 
  
Synthesize the AgrD(1-32)-III-thiolactone for Biochemical Assays 
There is currently no study investigating the cleavage of AgrD(1-32)-III-thiolactone. 
Since the peptide is only 32 residues, it is synthetically accessible.  The synthetic strategy 
would employ the same general approach to synthesize AgrD(1-32)-I-thiolactone and 
AgrD(1-32)-II-thiolactone, where the linear peptide α-thioester is generated by SPPS 
employing a Boc-Nα protection logic and using a 3-mercaptopropionamide-based linker 
system. Upon forming the C-terminal thiolactone macrocycle via an intramolecular trans-
thioesterification reaction, the peptide can be purified using RP-HPLC. 
 
With the peptide in hand, it would then be possible to investigate whether it can 
be cleaved by fl-SpsB. In this study, we found that fl-SpsB cannot correctly cleave AgrD-
II. Instead, it cleaved AgrD-II at a position that would actually produce an inhibitor of 
AgrC-II.[62, 83] Likewise, for AIP-III biosynthesis, it is critical that the protease responsible 
for cleaving AgrD(1-32)-III-thiolactone be very specific in its cleavage. Therefore, the 
initial investigation of the AgrD(1-32)-III-thiolactone should try to determine whether fl-
SpsB is responsible for its cleavage. Further characterization may suggest that fl-SpsB 
does not process the AgrD(1-32)-III-thiolactone into AIP-III.  At which point, it would be 
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necessary to identify the protein necessary to cleave and remove the MAD of AgrD-III 
for successful production of AIP-III. 
 
Generate the AgrD(1-32)-II-thiolactone and/or AgrD(1-32)-III-thiolactone Using the 
Fused Split Intein System 
One goal of this study was a proof of principle that an AgrD(1-32)-thiolactone could be 
produced in vivo in the absence of AgrB. Having accomplished that, it would be 
worthwhile to replicate our findings with another agr specificity groups, confirming the 
observation that AIP is secreted through a non-AgrB pathway. All of the necessary 
analytical tools are available for studying secretion of AgrD(1-32)-II-thiolactone. In order 
to study the secretion of the AgrD(1-32)-III-thiolactone, it would be necessary to 
engineer a better β-lactamase reporter gene assay strain (RN9537), because in our hands, 
the current strain is not as sensitive to AIP-III agonism and does not produce as reliable 
data as the group I or group II β-lactamase reporter gene assay strains. If necessary, it 
might be possible to obtain or engineer the group III GFP reporter gene assay strain used 
by Tal-Gan et al.[84] 
 
Identify the Protease Responsible for Cleaving and Removing the MAD of AgrD-II 
In Section 3.5.2, we present data suggesting a membrane-bound or peptidoglycan-
associated protease cleaves AgrD(1-32)-II-thiolactone. In order to identify the protein 
responsible for this cleavage, the first step could be membrane fractionation of group II 
cell membranes—a classical, biochemical technique. Since synthesis and purification of 
the AgrD(1-32)-II-thiolactone has fairly low-yields because of its hydrophobicity, there 
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are several preliminary experiments to try. First, synthesize a peptide similar to the IG-
AIP-I substrate peptide that is derived from the AgrD-II sequence and then digest this 
new group II derived peptide with the RN9120 cells (agr-II null). If the peptide were 
correctly cleaved, it would be a better substrate peptide, with which to test each of the 
membrane fractions. Once activity is detected within a fraction, characterization of the 
proteins within that fraction will provide possible candidates as the protease responsible 
for AgrD-II cleavage. These candidate membrane proteins could be expressed, purified, 
and incorporated into proteoliposomes for further biochemical analysis. Similar work 
could be done to find the protease that cleaves AgrD-III.  
 
This membrane fractionation approach could also be validated using group I 
derived peptides, especially if amino acid residues such as Bpa, Photo-Met, and/or Photo-
Leu were incorporated into them. These chemical handles could be used to crosslink with 
any proteins that interact with AgrD-I. Presumably, these group I, crosslinking peptides 
would at least identify SpsB as one of the proteins that bind and cleave AgrD-I within the 
membrane fractions. 
 
5.2.2  Future Directions to Further Study AIP Macrocycle Size 
Enlarging the Macrocycle of AIP-III  
This work provides further support that the sidechain of the residue at endocyclic position 
2 of AIP-I helps to stimulate AgrC-I. Interestingly, AIP-III has a native Asp residue at 
this position, making it identical to AIP-I; and recently, a potent, global inhibitor analog 
of AIP-III was reported at this same position.[84] A similar SAR study to enlarge the AIP-
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III macrocycle would not only provide interesting insight into the binding pocket of 
AgrC-III but also reveal a possible trend within AgrC-I, -III and -IV activation. Namely, 
AgrC-III may require a similar stimulatory effect to AIP-III, which could be satisfied 
with a D4A hβ-Ala AIP-III analog.  
 
Activity of a D5G AIP-I analog 
With regards to the results presented in Section 3.2.2, replacing Asp-5 with Gly would 
produce another AIP-I analog to test.  Since D5A AIP-I inhibits AgrC-I activation in a 
cellular context, it would be interesting to see if a D5G AIP-I analog activates or inhibits 
AgrC-I or if it has no activity.  Our current model suggests it would likely be an inhibitor, 
since it has no sidechain and should still bind AgrC-I. This same experiment could be 
repeated with AIP-III, replacing Asp-4 with Gly, and included in an SAR study of the 
enlarged macrocycle of AIP-III. 
 
Enlarging the Macrocycle of AIP-II 
Enlarging the macrocycle of AIP-II is another SAR study worth pursuing. Recently, 
AgrC-II nanodiscs were prepared in our lab, and this biochemical tool may be very 
useful, since the AIP-II alanine scan indicated that alanine substitution at endocyclic 
position 2 only reduces activation of AgrC-II.[45] Furthermore, replacing Ser-7 with Ala 
made the resulting AIP-II analog more active than the native AIP-II. Thus, there are two 
potential endocyclic positions within AIP-II that may tolerate methylene insertion. This 
previous result also suggests AIP-II not only has a smaller hydrophobic patch than AIP-I 
and AIP-III but also indicates activation of AgrC-II likely entails a different molecular 
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interaction with the AIP-II macrocycle. An SAR study enlarging the AIP-II macrocycle 
may provide greater insight into the stimulating interaction of group II. 
 
Structural Characterization of AgrC-I  
Using AgrC-I nanodiscs, some recent work has attempted to locate the binding pocket by 
crosslinking a photoactive AIP-I analog to AgrC-I.[147] As this investigation continues, a 
photoactive analog, like p-benzoyl-L-phenylalanine (Bpa), at endocyclic position 2 might 
identify some of the residues responsible for AgrC activation.  Making the Bpa-5 AIP-I 
analog might be possible, since the D5F AIP-I analog activates AgrC-I.[63] Of course, the 
best insight into the AgrC binding pocket would come from a crystal structure of the 
receptor, which would be a challenging endeavor to undertake.    
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5.3 Conclusion 
The work presented here elucidated several mechanistic features of the AIP biosynthetic 
pathway and AgrC-I activation. This study provides insight into the defined roles of both 
AgrB and SpsB in AIP-I biosynthesis. The finding that AgrB does not facilitate secretion 
is the first such evidence that AIP secretion may not be mediated by a protein or requires 
an unidentified, as of yet, protein transporter. The investigation of SpsB cleavage found 
that it correctly cleaves AgrD-I and did not correctly cleave AgrD-II. This finding 
indicates that all the essential proteins for group-specific AIP biosynthesis may not yet be 
identified. In the final portion of this study, the conversion of a known, global inhibitory 
peptide (D5A AIP-I) into a self-activator using L-β-homoalanine provided a key insight 
into AgrC activation. Namely, that the sidechain at the second endocyclic position in 
AIP-I plays an important role in AgrC-I activation. Indeed, this study builds on the 
current understanding of agr activation by proposing three distinct interactions between 
the AIP macrocycle and AgrC. The development of several new technologies to 
investigate AIP biosynthesis can aid future studies into AIP-II and AIP-III biosynthesis. 
The cell-based secretion assay is the first instance of AIP-I production in the absence of 
AgrB-I and can be replicated for the other S. aureus specificity groups. The vesicle 
assays employed to investigate SpsB cleavage of AgrD lay a foundation for further 
characterization of the final cleavage step in AIP biosynthetic pathway. Intriguing future 
directions for investigation of agr include developing an assay to determine whether the 
AgrD(1-32)-thiolactone can intrinsically cross a membrane, identifying the proteases 
responsible for cleaving the AIP-II and AIP-III precursor peptides, and using crosslinking 
studies to find potential binding partners for the AgrD(1-32)-thiolactone. 
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Whether agr proves to be therapeutically relevant, a deeper understanding of the 
mechanisms that contribute to virulence will increase knowledge of S. aureus infections 
and provide the foundation for new discoveries and eventual advances in treatment. The 
insights described in this work will hopefully be applicable to other autoinducer peptide 
biosynthetic pathways and serve to build connections between the molecular mechanisms 
involved in AgrD-thiolactone formation, secretion, and cleavage among the 
staphylococci and other Gram-positive bacteria.  
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Chapter 6.  Materials and Methods 
Materials. All buffering reagents, salts, glucose and 2,2,2-Trifluoroethanol (TFE) were 
purchased from Fisher Scientific (Pittsburgh, PA).  Bacto™ Casamino acids and Yeast 
Extract along with Tryptic Soy Agar were purchased from BD Biosciences (San Jose, 
CA).  β-Glycerophosphate, Disodium Salt, Pentahydrate was purchased from EMD-
Millipore (Darmstadt, Germany).  Tryptic Soy Broth, Acetonitrile, S-trityl 
mercaptopropionic acid, N,N-diisopropylethylamine (DIPEA), Coomassie brilliant blue, 
N,N-dimethylformamide, (DMF), triisopropylsilane (TIPS), N,N’-
diisopropylcarbodiimide (DIC) and 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) were 
purchased from Sigma-Aldrich (St. Louis, MO). Tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP) was purchased from Thermo Scientific (Rockford, IL).  Standard 
Nα-Fmoc protected amino acids and Nα-Boc protected amino acids were purchased from 
Novabiochem (Läufelfingen, Switzerland).  The Nα-BOC protected L-β-homo-amino 
acid derivatives, Nα-BOC protected β-alanine and 2-(1H-Benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) were purchased from AnaSpec 
(Fremont, Ca).  Trifluoroacetic acid (TFA) was purchased from Halocarbon (North 
Augusta, SC).  Nitrocefin was purchased from TOKU-E USA (Bellingham, WA).  
DMSO-d6 was purchased from Cambridge Isotope Laboratories (Andover, MA).  All 
denaturing SDS-PAGE gels were purchased from Bio-Rad (Hercules, CA).  [γ-32P]-
Adenosine triphosphate and Ultima Gold Cocktail was from PerkinElmer (Waltham, 
MA).  All lipids were purchased from Avanti Polar lipids (Alabaster, AL).  All detergents 
were purchased from Anatrace (Maumee, OH).  
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Reversed-Phase HPLC and Mass Spectrometry. Analytical and semi-preparative RP-
HPLC were performed on Hewlett-Packard 1100 and 1200 series instruments equipped 
with a C18 Vydac column (5 μm, 4.6 x 150 mm) at a flow rate of 1 mL/min or a C18 
Vydac 218TP152010 column (15-20 μm; 10 x 250 mm) at a flow rate of 4 mL/min.  All 
runs were carried out employing gradients of solvent A (0.1% TFA in water) and solvent 
B (90% acetonitrile in water with 0.1% TFA).  For semi-preparative HPLC runs, an 
initial five-minute isocratic period in initial conditions was followed by a 40-minute 
linear gradient with increasing solvent B concentration.  For analytical HPLC runs of the 
AIP analogs, there was a two-minute isocratic period in initial conditions followed by a 
20-minute 0-73% linear gradient with increasing solvent B concentration.  Once the AIP 
analogs were purified and in a DMSO stock, analytical HPLC runs included an initial 
five-minute isocratic period in 100% solvent A followed by a 20-minute 0-73% linear 
gradient with increasing solvent B concentration.  For analytical HPLC runs of the in 
vitro tr-SpsB assays, there was a two-minute isocratic period in initial conditions 
followed by a 30-minute 0-73% linear gradient with increasing solvent B concentration. 
For analytical HPLC runs of any AgrD-containing reactions, there was a five-minute 
isocratic period in initial conditions followed by a 20-minute 0-90% linear gradient with 
increasing solvent B concentration. The solvent gradients are specified in each HPLC 
experiment when necessary.  Electrospray ionization mass spectrometric analysis (ESI-
MS) was performed on all peptides and proteins by direct infusion on a Bruker Daltonics 
MicrOTOF-Q II mass spectrometer. For large peptides and proteins, the mass observed is 
reported as a deconvoluted mass obtained from Bruker software using the following 
parameters: Maximum Entropy, a molecular weight range at least twice the size of the 
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expected mass, and 20000 resolving power.  MS/MS analysis was performed using 
Bruker Daltonics BioTools 3.2 software (Bruker Daltonics Inc., Billerica, MA).   
General Methods. Coomassie stained gels were imaged on a LI-COR Odyssey Infrared 
Imager.  The β-lactamase activation and inhibition assays were recorded on a Molecular 
Devices Spectramax M3 micro plate reader with absorbance measurements at 490 and 
650 nm. Electroporation was accomplished using a Biorad MicroPulser™ Electroporator. 
S. aureus Growth Conditions. When used for any assay in this study, the S. aureus cells 
were grown in CY-GP broth (Casamino acids, 10 g/L; yeast extract, 10 g/L; glucose, 5 
g/L; NaCl, 5.9 g/L; and 1.5 M β-Glycerophosphate 40 mL/L added after autoclaving) 
with shaking at 37°C.[148] Cell growth was monitored at OD540 over time.  Overnight S. 
aureus cultures in tryptic soy medium were routinely used as inocula, and the cultures 
were prepared from bacteria grown on tryptic soy agar plates containing erythromycin 
(10 μg/mL) and/or chloramphenicol (10 μg/mL).  
Protein Sequence Information. Amino acid sequences of full-length AgrB-I (1-189), 
AgrD-I (1-46), AgrB-II (1-187), AgrD-II (1-47), SpsB (1-191) and SpsA (1-174) were 
obtained from the NCBI protein database (Refseq accession: YP_001332977.1, 
YP_001332978.1, NP_372560.1, NP_372561.1, WP_000711486, and WP_000758209, 
respectively). E. coli-codon[149] optimized cDNA synthesis was purchased from Genewiz 




















split intein sequence  












split intein sequence  






*Important residues are in boldface. The His6-tag is underlined. cDNA synthesis was 
purchased from Genewiz and was codon optimized for S. aureus expression.[150]  
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Table 13. Cell Strains and Plasmids Used in This Study 
Strain or Plasmid Genotype or Description Reference 
S. aureus strains 
RN4220 Restriction-deficient mutant of strain 8325-4 [151] 
RN6734 Group I strain, φ-13 lysogen of 6390b [62] 
RN9120 agr::tetM derivative of RN9130 [62, 151] 
RN9222 RN6911 (agr::tetM  replacement RN6734) containing 
pRN7062 (P2-agrCA-I; P3-blaZ ), Group I β-lactamase 
reporter strain 
[62] 
RN9367 RN7206 (agr::tetM  replacement in agr-I strain) containing 
pRN7105 (P2-agrCA-II and P3::blaZ) 
[62] 
RN9532 RN6911 (agr::tetM  replacement in agr-I strain) containing 
pRN7131 (P2-agrCA-III and P3::blaZ) 
[63] 
RN10306 RN6911 Δspa::cadC unpublished 
AgrD(1-32)-inteinNpu RN10306 with pJJSA130 This study 
D29A AgrD(1-32)-inteinNpu RN10306 with pJJSA130D29A This study 
C33A  AgrD(1-32)-
inteinNpu 
RN10306 with pJJSA130C33A This study 
AgrD(1-32)-inteinSsp RN10306 with pJJSA131 This study 
D29A AgrD(1-32)-inteinSsp RN10306 with pJJSA131D29A This study 
C33A AgrD(1-32)-inteinSsp RN10306 with pJJSA131C33A This study 
InteinNpu RN10306 with pJJSA132 This study 
InteinSsp RN10306 with pJJSA133 This study 
chimera AgrD(1-32)-
inteinNpu 
RN10306 with pJJSA134 This study 
chimera AgrD(1-32)-
inteinSsp 
RN10306 with pJJSA135 This study 
AgrB+ AgrD(1-32)-
inteinNpu 
RN10306 with pJJSA130 and pJJSA140WT This study 
C84A AgrB+AgrD(1-32)-
inteinNpu 
RN10306 with pJJSA130 and pJJSA140C84A This study 
K129E AgrB+AgrD(1-32)-
inteinNpu 
RN10306 with pJJSA130 and pJJSA140C84A,K129E This study 
K131E AgrB+AgrD(1-32)-
inteinNpu 
RN10306 with pJJSA130 and pJJSA140C84A,K131E This study 
AgrB+AgrD(1-32)-inteinSsp RN10306 with pJJSA131 and pJJSA140WT This study 
C84A AgrB+ AgrD(1-32)-
inteinSsp 
RN10306 with pJJSA131 and pJJSA140C84A This study 
K129E AgrB+ AgrD(1-
32)-inteinSsp 
RN10306 with pJJSA131 and pJJSA140C84A,K129E This study 
K131E AgrB+ AgrD(1-
32)-inteinSsp 
RN10306 with pJJSA131 and pJJSA140C84A,K131E This study 
E. coli strains 
DH5α Chemically competent cells, Standard recipient for plasmid 
cloning 
Promega 
XL10-Gold Supercompetent cells Stratagene 
BL-21(DE3) Standard E. coli protein expression strain, E. coli B strain 
with DE3, a λ prophage carrying the T7 RNA polymerase 
gene and lacIq 
 
OverExpress™ C43(DE3) OverExpress E. coli strain for toxic proteins, F– ompT gal 
dcm hsdSB(rB- mB-)(DE3) 
Lucigen 
tr-SpsB BL-21(DE3) strain containing pJJ59 This study 
fl-SpsB BL-21(DE3) strain containing pJJ60 This study 
SpsA BL-21(DE3) strain containing pJJ70 This study 
AgrB-I C43(DE3) cells containing pBW-B1-2 [152] 






AgrB-II C43(DE3) cells containing pBW-B2-2 [152] 
AgrD-I BL-21(DE3) strain containing pBW-D1-1 [152] 
FLAG-AgrD-I BL-21(DE3) strain containing pBW-D1-7 [152] 
FLAG-AgrD-II BL-21(DE3) strain containing pBW-D2-7 [152] 
Plasmids 
pCN51 Shuttle vector with pT181cop-wt repC replicon, Pcad-cadC 
promoter, ermC (erythromycin selection), and amp ColE1ori 
(E. coli replication and selection) and Transcription 
terminator sequence 
[140] 
pJC1361 Shuttle vector with the pE194 replicon, Pcad-cadC promoter, 
cat194 (chloramphenicol selection), amp ColE1ori (E. coli 
replication and selection) and Transcription terminator 
sequence 
unpublished 
pET-15b TEV Plasmid derived from pET-15b (Novagen) with the thrombin 
cleavage sequence has been mutated to the TEV cleavage 
sequence 
This study 
pET-24b GSTC-term Plasmid derived from pET-24b (Novagen) with the GST-tag 
cloned to be C-terminal of the protein to be expressed.  
[152] 
pJJSA130 pCN51 with agrD-I Δ33-46-npuCN-His6 This study 
pJJSA130D29A pCN51 with agrD-I Δ33-46 (D29A)-npuCN-His6 This study 
pJJSA130C33A pCN51 with agrD-I Δ33-46-npuCN-(C33A)-His6 This study 
pJJSA131 pCN51 with agrD-I Δ33-46-sspCN-His6 This study 
pJJSA131D29A pCN51 with agrD-I Δ33-46 (D29A)-sspCN-His6 This study 
pJJSA131C33A pCN51 with agrD-I Δ33-46-sspCN-(C33A)-His6 This study 
pJJSA132 pCN51 with npuCN-His6 This study 
pJJSA133 pCN51 with sspCN-His6 This study 
pJJSA134 pCN51 with agrD-I (Δ3-17::agrD-II 33-47)-npuCN-His6 This study 
pJJSA135 pCN51 with agrD-I (Δ3-17::agrD-II 33-47)-sspCN-His6 This study 
pJJSA140WT pJC1361 with agrB-I-FLAG This study 
pJJSA140C84A pJC1361 with agrB-I (C84A)-FLAG This study 
pJJSA140C84A,K129E pJC1361 with agrB-I (C84A, K129E)-FLAG This study 
pJJSA140C84A,K131E pJC1361 with agrB-I (C84A, K131E)-FLAG This study 
pJJ59 pET-15b TEV with spsB Δ1-22 This study 
pJJ60 pET-15b TEV with spsB This study 
pJJ70 pET-15b TEV with spsA This study 
pBW-B1-2 pET-24b GSTc-term with agrB-I-His6 [152] 
pBW-B2-2 pET-24b GSTc-term with agrB-II-His6 [152] 
pBW-D1-1 pET-24b with agrD-I-gyrA-His7 [152] 
pBW-D1-7 pET-24b GSTc-term with FLAG-His6-agrD-I [152] 
pBW-D2-7 pET-24b GSTc-term with FLAG-His6-agrD-II [152] 
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Plasmid Construction. To generate plasmids (Table 13), target genes were amplified 
using primers (Table 14) and inserted into vectors via the overlap extension PCR 
method.[153] Plasmids pCN51 or pJC1361 were obtained from the Novick lab and were 
used as the backbone vectors for the fused split intein constructs or AgrB point mutants, 
respectively. The agrD(1-32)-npuNC, agrD(1-32)-sspNC were inserted into pCN51 and 
the agrB gene was inserted into pJC1361. The genes for the chimera agrD(1-32)-npuNC 
and agrD(1-32)-sspNC were synthesized by Genewiz and then inserted into the backbone 
vector pCN51. Various point mutations in AgrD, the AgrD(1-32)-intein constructs or 
AgrB were introduced via the QuikChange method (Stratagene). The pET-15b TEV 
plasmid was used as the backbone vector for spsB and spsA. The full-length spsB was 
constructed using multiple primers annealed together and cloned using PCR to make a 
large primer for insertion into pJJ59 using overlap extension PCR. Clones for all of these 
constructs were sequenced by Genewiz.  All BW-B/D#-# cell strains and plasmids were 
designed and generously provided by Boyuan Wang, a graduate student in the lab. 
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Table 14. Oligonucleotide Primers Used in This Study 
Primer Sequence (5’-3’) 
QC 15b TEV for CATCATCACAGCAGCGGCGAGAACCTGTATTTTCAGGGCCATATGCTCGAGGAT
CCG 






SpsA overhang for GGCGAGAACCTGTATTTTCAGGGCATGAAAAAAGTTGTTAAATACCTGATCTC
TC 
SpsA overhang rev GTTTAGAGGCCCCAAGGGGTTATGCTAGTTAAGATTTGAACTGGATGGTCCAT
TTAGAG 
SpsB piece1 for AGCAGCGGCGAGAACCTGTATTTTCAGGGCATGAAAAAAGAAATCCTGGAA 
SpsB piece2 rev GAACGCAACCGCGATAGAGATGATCCATTCCAGGATTTCTTTTTTCATGCC 
SpsB piece3 for GATCATCTCTATCGCGGTTGCGTTCGTTATCCTGTTCATCGTTGGTAAATTC 
SpsB piece4 rev TTTGATGGTGTACGGGGTAACGATGAATTTACCAACGATGAACAGGATAAC 
AgrD-intein overhang for GAAAGAAGTGAAGGTCAATGTCTGAACCTGCAGATTAAGGAGGACTTAAAAT
GAATACAT 
AgrD-intein overhang rev TCAGTATTTATTATGCATTAGAATAGGCGCGCCTTAATGATGATGATGATGAT
GATTGAA 
Npu 132 for GAACCTGCAGATTAAGGAGGACTTAAAATGTGTTTATCATATGAAACAGAAA
TTTTAACA 
Npu 132 rev TGTTAAAATTTCTGTTTCATATGATAAACACATTTTAAGTCCTCCTTAATCTGC
AGGTTC 
Ssp 133 for GAACCTGCAGATTAAGGAGGACTTAAAATGTGTTTATCATTCGGTACAGAAAT
TTTAACA 
Ssp 133 rev TGTTAAAATTTCTGTACCGAATGATAAACACATTTTAAGTCCTCCTTAATCTGC
AGGTTC 
QC 130 D29A for GGTAACATCGCAGCTTATAGTACTTGTGCTTTCATAATGTGTTTATCATATGAA
ACA 
QC 130 D29A rev TGTTTCATATGATAAACACATTATGAAAGCACAAGTACTATAAGCTGCGATGT
TACC 
QC 131 D29A for GGTAACATCGCAGCTTATAGTACTTGTGCTTTCATAATGTGTTTATCATTCGGT
ACA 
QC 131 D29A rev TGTACCGAATGATAAACACATTATGAAAGCACAAGTACTATAAGCTGCGATGT
TACC 
QC 130 C33A for AGTACTTGTGACTTCATAATGGCATTATCATATGAAACAGAA 
QC 130 C33A rev TTCTGTTTCATATGATAATGCCATTATGAAGTCACAAGTACT 
QC 131 C33A for AGTACTTGTGACTTCATAATGGCATTATCATTCGGTACAGAA 
QC 131 C33A rev TTCTGTACCGAATGATAATGCCATTATGAAGTCACAAGTACT 
134/135 overhang for GAAAGAAGTGAAGGTCAATGTCTGAACCTGCAGATTAAGGAGGACTTAAAAT
GAATACAT 
pCAD overhang for CTTTGAGTGAGCTGGCGGCCGCTGCATGCGCACTTATTCAAGTGTATTTTTTAA
TAAAT 
AgrB overhang for GCCAAGCTCGGCGCGCCATTGGGATGGAACGCATGCGCACTTATTCAAGTGTA
TTTT 
AgrB overhang rev TTTTACACCACTCTCCTCACTGTTCATGTCGACCTGCAGGTTCAGACATTGACC 
QC AgrB C84A for CATGCACCTTCTTCTTTTTGGGCATATGTAGAAAGTATTATACTA 
QC AgrB C84A rev TAGTATAATACTTTCTACATATGCCCAAAAAGAAGAAGGTGCATG 
QC AgrB C129E for GTATATGCTCCTGCAGCAACTGAGAAGAAGCCCATTCCTGTGCGA 
QC AgrB C129E rev TCGCACAGGAATGGGCTTCTTCTCAGTTGCTGCAGGAGCATATAC 
QC AgrB C131E for GCTCCTGCAGCAACTAAAAAGGAGCCCATTCCTGTGCGACTTATT 
QC AgrB C131E rev AATAAGTCGCACAGGAATGGGCTCCTTTTTAGTTGCTGCAGGAGC 
for = forward primer sequence, rev = reverse primer sequence 
PstI sequences are underlined. While endonucleases were not used to insert genes, PstI was included in the 
overhang primer design for pCN51 inserts in case restriction digest was necessary to remove the Pcad-cadC 
promoter cassette or the gene to be expressed.  
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Western blot analysis of cell cultures. Uninduced and induced cell cultures were grown 
for a total of 8 hrs. Cells were harvested via centrifugation and frozen. Upon thawing the 
cells on ice, lysostaphin digestion of the peptidoglycan was carried out in the lysostaphin 
digest buffer (20 mM Tris-HCl (pH 8), 100 mM NaCl, 20 mM MgCl2, and 27% (w/v) 
sucrose) with lysostaphin at 50 or 100 μg/mL. Cells from either a 2- or 5-mL cell growth 
were resuspended in 0.3 or 0.5 mL, respectively, digest buffer and incubated at 37°C for 
~30 minutes. Lysostaphin digest of the peptidoglycan was monitored by adding a small 
amount of the digest to 20% SDS in PBS to see if the solution would clarify indicating 
solubilization of the formed protoplasts. After the digest, the protoplasts were incubated 
in PBS with protease inhibitors (Roche) on ice for 15 minutes and then sonicated. Cell 
debris was pelleted via centrifugation. The whole cell lysates were analyzed via SDS-
PAGE and Western blot. For cell culture supernatants, the supernatant was directly 
analyzed using SDS-PAGE. For Western blot analysis of the AgrD(1-32)-intein 
constructs the nitrocellulose membrane was probed with a α-His6 antibody (Waters).  
AgrB constructs were probed using a α-FLAG antibody. Images were taken with a LI-
COR Odyssey Infrared Imager (GE Healthsystems). 
HPLC-MS Analysis of Cell Culture Supernatants. Initial purification of the AgrD(1-
32)-inteinNpu, AgrD(1-32)-inteinSsp or group I WT cell culture supernatants was performed 
using a 5-g C18 SPE cartridge. Prior to use, each cartridge was activated by flowing 
through HPLC buffer B, followed by 25 mL of HPLC buffer A. Cell culture supernatants 
were acidified to 1% (v/v) neat TFA prior to loading onto the column. Columns were 
washed twice under gravity flow with HPLC buffer A; peptides were then eluted from the 
column by elutions of 20% buffer B, 50% buffer B, and 70% buffer B (2x 500 μL). The 
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elutions were lyophilized and then resuspended in methanol (HPLC grade) for 
submission for analysis at the Mass Spectrometry Facility in the Princeton University 
Molecular Biology Department.  Analysis of these samples was performed on an LTQ-
XL platform (Thermo Fisher Scientific) using RP-HPLC-MS. RP-HPLC Analysis was 
run on an Agilent 1100 series HPLC using a 1 mM Jupiter 5μ C4 300A column. HPLC 
runs employed a 5-75% B linear gradient over 80 minutes (Buffer A, 0.02% TFA, 0.5% 
formic acid, 0.1% acetic acid, 3% acetonitrile and 97% H2O; Buffer B, 0.02% TFA, 0.5% 
formic acid, 0.1% acetic acid, and 99.5% acetonitrile). SPE samples were compared to 
growth media from RN6734 prepared under the same protocol to provide a positive 
control for AIP-I detection. 
Expression and Purification of tr-SpsB. The JJ59 expression strain was grown at 37°C 
in 1-L cultures of LB broth containing ampicillin at a concentration of 0.1 mg/mL. When 
the OD600 reached 0.6, expression was induced by the addition of 1 mM IPTG. Cells were 
harvested 3 hours post-induction and centrifuged at 6000 g for 15 minutes and the cell 
pellets were resuspended in 20 mL of urea lysis buffer (50 mM pH 7.6 phosphate, 6 M 
urea, 300 mM NaCl, 10 mM imidazole). The cells were then lysed by 3-4 repeated 
passages through a French press homogenizer. The cell-wall debris was removed by 
centrifugation at 40000 g for 30 minutes at 4°C. Supernatant was then purified by affinity 
purification using Ni-NTA resin (Qiagen). Ni-NTA columns were equilibrated with 5 
column volumes (CV) of urea lysis buffer. The protein was then loaded onto the column 
and incubated on a nutating mixer at 4°C for 1 hour. The column was first washed with 3 
CV of urea lysis buffer and 5 CV of wash buffer (lysis buffer and 25 mM imidazole). The 
protein was then eluted with elution buffer (lysis buffer with 300 mM imidazole) in three 
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fractions of 3 mL each. Urea removal via dialysis was carried out in a step-wise manner 
from 6 M urea to 4 M to 2 M and no urea. The dialyzed supernatant was concentrated and 
purified via S75 size-exclusion chromatography (CV = 25 mL), and the protein was 
eluted in degassed FPLC buffer (50 mM phosphate (pH 7.5), 150 mM NaCl) over a 
volume of 40 mL. Fractions collected near the peak of interest were analyzed by SDS-
PAGE using a 15% Bis-Tris gel. The final product ~95% pure by SDS-PAGE analysis 
was concentrated to ~40 μM and frozen in liquid nitrogen for storage at -80°C. Protein 
concentration was determined using UV-Vis spectroscopy. tr-SpsB was also analyzed via 
RP-HPLC and ESI-MS. 
Expression and Purification of SpsB and SpsA. fl-SpsB or SpsA expression strains 
were grown at 37°C in 1-L cultures of LB broth containing ampicillin at a concentration 
of 0.1 mg/mL. When the OD600 reached 0.6, expression was induced by addition of 1 mM 
IPTG. Cells were harvested 3 hours post-induction via centrifugation at 6000 g for 15 
minutes and the cell pellets were resuspended in 20 mL of lysis buffer (50 mM pH 7.6 
phosphate, 300 mM NaCl, 10 mM imidazole). Protease Inhibitor Cocktail (Roche, 
Penzberg, Germany) was then added to the cell suspension, and the cells were then lysed 
by 3-4 repeated passages through a French press homogenizer. The cell-wall debris was 
removed by centrifugation at 40000 g for 30 minutes at 4°C, and the membrane vesicles 
were pelleted by ultracentrifugation at 90000 g for 1 hour at 4°C. The membrane fraction 
was extracted using 20 mL of lysis buffer with 0.05% (w/v) DDM overnight at 4 °C. 
After another ultracentrifugation step at 50000 g for 30 mins, supernatant from the 
extraction was then purified by affinity purification using TALON Co-NTA resin 
(Clontech Technologies, Mountain View CA). Co-NTA columns were equilibrated with 
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incubated on a nutating mixer at room temperature for 2 hours. The columns were first 
washed with 3 CV of wash buffer 1 (lysis buffer and 0.05% DDM) and 2 CV of wash 
buffer 2 (lysis buffer and 0.05% DDM with 30 mM imidazole). The protein was then 
eluted with elution buffer (lysis buffer with addition of 300 mM imidazole and 0.05% 
DDM) in three fractions of 3 mL each. The elution fractions were concentrated to about 
1.5 mL in 10 kDa MWCO concentrators. The concentrate was then purified via S200 
size-exclusion chromatography (CV = 25 mL), and the protein was eluted in degassed 
FPLC buffer (50 mM phosphate (pH 7.5), 150 mM NaCl, 0.05% DDM) over a volume of 
40 mL. Fractions collected near the peak of interest were analyzed by SDS-PAGE using a 
15% Bis-Tris gel. The most concentrated fractions were then combined and concentrated 
to ~40 μM, and aliquots of the purified protein were frozen in liquid nitrogen and stored 
at -80 °C. Protein concentration was determined using UV-Vis spectroscopy. 
Expression and Purification of AgrB-I and AgrB-II. E. coli C43(DE3) cells 
transformed with the appropriate AgrB expression plasmids were grown at 37 °C in one 
liter of LB medium containing 50 µg/mL kanamycin. When the OD600 reached 0.8, the 
medium was cooled down to 22°C and overnight expression was induced by addition of 
0.4 mM IPTG. Cells were harvested at 6000 g for 20 minutes and the cell pellets were 
resuspended in 18 mL of lysis buffer (20 mM sodium phosphate, 100 mM NaCl and 
1mM PMSF, pH 7.5). Cells were lysed by four passages through a French-press 
homogenizer. Cell-wall debris was spun down at 15000 g for 10  minutes and removed. 
Cell-membrane vesicles were then pelleted by ultracentrifugation at 200,000 g for 1  hour. 
The membrane fraction was extracted using 5 mL of buffer containing 20  mM Phosphate 
pH 7.5, 100  mM NaCl, 2% (w/v) DDM for 3  hours at 4  °C. After another 
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ultracentrifugation step at 100,000 g for 20  min, supernatant from each liter of expression 
culture was loaded to 2.5 mL of Talon cobalt resin. After incubation at 4 °C for 60 
minutes, the resin was repacked in a 25-mL Bio-Rad disposable plastic column. The 
flow-through was discarded and the column was washed with 20CV of wash buffer (20 
mM sodium phosphate, 100 mM NaCl, 5mM β-mercaptoethanol, 0.1% (w/v) fos-choline-
12 (FC-12) and 25 mM imidazole, pH 7.5). Bound protein was eluted with 3CV of 
elution buffer (wash buffer with 500 mM imidazole). The elution was concentrated to 1 
mL and further purified on Superdex 200 size-exclusion chromatography with running 
buffer (20 mM phosphate, 100 mM NaCl, 0.14% (w/v) FC-12, 1mM TECP, pH 7.0), 
from which the desired peak fractions were collected.  
Expression and Purification of Full-length AgrD-I. Full-length, non-tagged AgrD-I 
was expressed as an N-terminal fusion to a GyrA-His7 intein protein in E. coli 
BL21(DE3) strain. Expression strain harboring the appropriate expression vector was 
grown at 37oC to OD600 = 0.6 and then induced by addition of IPTG to 1.0 mM. The 
culture was shaken at 37oC for 4 additional hours post-induction and cells were collected 
through centrifugation. Cells were resuspended in PBS (20 mM Phosphate (pH 7.5), 100 
mM NaCl). PMSF (100 mM stock in ethanol) was added to the cell suspension 
immediately prior to lysis at a final concentration of 1mM. Cells were disrupted by four 
French-Press passages. The lysate was spun at 30000 g for 1 hour. Supernatant was 
decanted and discarded. The pellet was resuspended in a buffer containing 7.5M GuHCl, 
50mM Phosphate buffer pH = 7.5 and 2mM TCEP. The suspension was homogenized, 
gently shaken at 4oC for 1hr and then spun at 30000 g for 1 hour. Supernatant from the 
cleared GuHCl extract was loaded to a column packed with Ni-NTA resin (Qiagen), and 
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the resin was washed with buffer containing 25mM imidazole and 6M GuHCl and eluted 
using a buffer containing 300mM imidazole, 7.2M urea and 0.05% (w/v) DDM. The 
eluted protein was immediately chilled and refolded through dialysis against a series of 
phosphate buffer with decreasing urea concentrations at 4oC.   
Upon dialysis, the full-length AgrD-intein-His7 construct was cleaved by 50 mM 
DTT and 5 mM TCEP with the presence of 0.1% (w/v) DDM under argon atmosphere at 
RT for 12 hours. Free intein released from DTT treatment as well as uncleaved fusion 
protein was removed in a reverse-Ni-NTA affinity process. The combined flow-through 
and wash fractions containing predominantly full-length AgrD-DTT esters were then 
supplemented by 0.1% FC-12. Residual amount of urea in this solution was removed 
through two concentration-dilution cycles. In each cycle, the solution was concentrated to 
10% of its original volume and then diluted back using a buffer containing 50 mM 
phosphate (pH 7.5), 50 mM DTT and 0.07% FC-12. The solution after the second 
dilution was concentrated to <5 mL, to which equal weight of GuHCl was added to make 
a concentration of 6 M. EDTA was added at 10 mM and NaOH was used to basify the 
solution to pH 9.5. The solution was incubated under argon atmosphere at 37oC for 4 
hours for complete saponification of full-length AgrD-DTT esters, acidified to pH < 2 
using neat TFA, filtered, and submitted to C4 semi-prep HPLC for final purification.  
Expression and Purification of the Full-length FlagHis6-AgrD-I and FlagHis6-AgrD-
II. Both constructs were expressed as C-terminal GST fusion proteins in E. coli 
BL21(DE3) host cells. The expression culture was grown at 37oC to OD600 = 0.6 and then 
was cooled down to 16°C prior to induction by addition of 0.4 mM IPTG. After overnight 
incubation, cells were isolated from the culture medium, resuspended in lysis buffer (20 
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mM sodium phosphate, 100 mM NaCl, pH 7.5), and lysed by four passages through a 
French-press homogenizer. After centrifugation at 30000g for 30min, the cleared lysate 
was supplemented with 0.1% (v/v) DDM and then incubated with GS4FF resin in a 
plastic column at 4 °C for 60 minutes. The lysate was then drained, and the resin was 
washed by 20 CV of lysis buffer, resupsended in 2 CV of lysis buffer, and treated with 10 
units thrombin or 0.2 mg/mL PreScission protease at room temperature with gentle 
shaking for 3 hours. The released full-length FlagHis6-AgrD product was collected and 
allowed to flow through a 4-mL bed packed with Ni-NTA resin. The Ni-NTA bed was 
washed with 10 CV of lysis buffer with 15 mM imidazole, 10 CV of 6 M GuHCl 
buffered by Na-phosphate (pH 7.5) and eluted with 3 CV of elution buffer (6 M 
Guanidinium chloride, 0.2M acetic acid). Elution was treated with TCEP (5mM, final 
concentration) and then purified over a semiprep-scale C18 HPLC column. 
in vitro tr-SpsB assays. Assays for all AgrD derived substrate peptides were carried out 
in two different buffer conditions. Glycerol conditions[58] (similar to those used by 
Kavanaugh et al.) were 25 mM Tris-HCl (pH 8), 50 mM NaCl, and 20% Glycerol. Triton 
conditions[143] (similar to those used by Rao et al.) were 50 mM Tris-HCl (pH 8), 150 mM 
NaCl, and 0.5% Triton X-100.  All assays contained 10 μM tr-SpsB and 150 or 200 μM 
substrate peptide. AH or IG-AIP1 inhibition assays were under Triton assay conditions 
and contained 150 μM substrate peptide with 150 μM control peptide. Experiments to 
determine whether there is a concentration-dependence for SpsB cleavage of AH or IG-
AIP1 were under Trition conditions and varied AH and IG-AIP1 peptide concentration up 
to 400 μM or 1 mM, respectively. Assays were incubated at room temperature for 12 
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hours unless otherwise indicated. At the end of the incubation time, samples were 
acidified with HPLC buffer A and then analyzed via RP-HPLC and ESI-MS. 
β-lactamase Cell Culture Supernatant Assays. Cell cultures containing a cell strain of 
interest were grown in CY-GP growth medium for ~2 hours (strains expressing various 
AgrD(1-32)-intein proteins and RN6734) until OD540 ~0.2-0.3. When necessary, protein 
expression was induced with 10 μM Cd2+ followed by a 6-hour induced growth period 
unless specified. RN9120 cell cultures were grown for 3-4 hours after adding AgrD(1-
32)-II-thiolactone. Cell density (OD540) measurements were taken at the end of the 
growth period to normalize all of the cultures. Cells were removed via centrifugation 
4500 g for 10 minutes after which cell culture supernatants were sterilized using syringe-
filtration (0.2 μm filter). Sterilized cell culture supernatants were then aliquoted and 
frozen at -80°C. 
 Thawed cell culture supernatants were normalized to cell density readings of 
original cell cultures by diluting with CY-GP broth, when necessary. Each supernatant 
was then buffered with 1 M MES buffer (pH 5.9) for analysis with the β-lactamase 
reporter gene assay. Cell culture supernatants were incubated with reporter gene strains 
for 1 hour with shaking at 37°C in a Spectramax M3 micro plate reader (Molecular 
Devices). Cell density was monitored by OD650 readings taken every 2 minutes. 
Immediately following Nitrocefin addition, an initial OD490 and OD650 reading was taken 
and then β-lactam hydrolysis was monitored by OD490 readings taken every 45 s over 15 
minutes. Once saturation of OD490 for one of the cell culture supernatants in the assay was 
detected, the assay was stopped and a final OD490 and OD650 measurement was taken. The 
initial and final OD490 readings were normalized to cell density (OD650) and the ΔOD490 
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readings were calculated by subtracting the normalized initial OD490 from the normalized 
final OD490 reading. Each cell culture supernatant was assayed in triplicate at least two 
times. Error bars represent the standard deviation from the mean. 
Proteoliposome Cleavage Assays. A lipid mixture of 75% POPC and 25% POPG (w/w) 
was prepared in an aqueous stock solution containing 1% (w/v) total lipid and solubilized 
in 4% n-dodecylphosphocholine (FC-12). Reconstitution experiments were prepared as a 
100-μL volume containing 1 μM of each protein, 10 μM of D-TL (or AIP), 2.5 mg of 
lipid, and 30 mM Tris-HCl (pH 8.0). After mixing the samples, polystyrene beads (Bio-
Beads, Bio-Rad) were added to achieve a Bio-Beads to detergent (w/w) ratio of 30:1, 
respectively. The reaction was mixed for 2 hours on a nutator. The polystyrene beads 
were removed via centrifugation at 5100g for 20 seconds. The reconstituted liposome 
mixture was then incubated at room temperature (25 °C) for 12 hours. After the 12-hour 
incubation period, the liposome mixture was acidified slightly by the addition of 1 M 
MES (pH 5.9) buffer. This proteoliposome mixture was then directly used in the β-
lactamase reporter assay or SPE extraction.  
SPE extraction was performed using 200-mg C2 SPE cartridges. The cartridge 
was activated with HPLC buffer B and equilibrated with HPLC buffer A. The buffered 
vesicle solution was then added to the column and washed with buffer A. Elutions with 
20%, 50% and 70% buffer B were collected and lyophilized.  Analysis of lyophilized 
elutions was performed on an Orbitrap XL platform (Thermo Fisher Scientific) using 
reversed-phase nano-UPLC-MS at the Mass Spectrometry Facility in the Princeton 
University Molecular Biology Department. SPE samples were compared to an AIP-I 
standard to identify the presence of AIP. 
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β-lactamase Activation and Inhibition Activity Assays. The activation and inhibitory 
activities of the AIP analogs were analyzed using an established a β-lactamase reporter 
assay.[10,23-25,27,31] Briefly, cell cultures of agr-null cell lines RN9222 (CA1-I), RN9367 
(CA2-II) and RN9537 (CA3-III) with plasmids containing agrCA and agr-P3::blaZ were 
grown in CYGP growth media to exponential phase growth (OD650 ≈ 0.30-0.6).  For 
activation assays, 90 μL aliquots of cells were treated with varying concentrations of AIP 
analogs or buffer for 60 mins (RN9222) or 80 mins (RN9367 and RN9537) with shaking 
at 37°C in a Spectramax M3 micro plate reader (Molecular Devices).  For inhibition 
assays, 80 μL aliquots of cells were treated with 125 nM agonist AIP and varying 
concentrations of AIP analogs or buffer for 60 mins (RN9222) or 80 mins (RN9367) with 
shaking at 37°C in a micro plate reader.  Cell density was monitored by OD650 readings 
taken every 2 mins. Immediately following Nitrocefin addition, β-lactam hydrolysis was 
monitored by OD490 readings taken every 45 s over 20 min. Assay data were collected as 
initial β-lactamase hydrolysis velocity. The values obtained for initial velocity were then 
normalized to cell density and percent maximal activation, plotted as percent maximal 
activation versus log peptide concentration, and fit to a sigmoidal dose response curve 
using the PRISM 5.0 package (GraphPad Software, San Diego, CA), which fits 
individual dose-response curves via nonlinear regression to the following four-parameter 
logistic equation: 
 
in which E denotes effect, [A] denotes the agonist concentration, ηH denotes the midpoint 
slope, EC50 denotes the midpoint location parameter, and Emax and basal denote the upper 
and lower asymptotes, respectively. For inhibition curves, the midpoint location 
	   182 
parameter from the above equation reflects the IC50. Each AIP analog was assayed in 
triplicate at least two times. Error bars represent the standard deviation from the mean. 
Fluorescent anisotropy measurements. Fluorescence measurements were performed on 
a Fluorolog-3 instrument (HORIBA Jobin Yvon) equipped with automated dual 
polarizers and using a Semi-Micro Fluorometer Cell (Starna Cells) with a 10-mm path 
length. The measurement chamber was held at a constant temperature of 30.0°C by an 
Advanced Series AC200 thermostat (Thermo Scientific) connected to an Arctic series 
refrigerated circulating water bath (Thermo Scientific). The excitation wavelength was 
490 nm and emission wavelength was recorded at 520 nM, both with a bandwidth of 5 
nm. Ten measurements were taken per titration point with an integration time of 0.5 sec 
for V/V, V/H, H/H and H/V polarizer settings (excitation/emission, V: vertical 
polarization, H: horizontal polarization). The final anisotropy, r, was calculated from r = 
(IVV – G × IVH)/(IVV + 2 × G × IVH), with G = IHV/IHH. 
In a typical experiment, 700 µL of measurement buffer (20 mM HEPES, pH 7.0, 
100 mM NaCl, 1 mM TCEP, 2 µM BSA and 100 nM of empty nanodiscs) containing 21 
nM FAM-AIP-I was transferred to the cuvette and the fluorescent anisotropy was 
measured as a reference. AgrC-I nanodiscs (4.2 µM, 26.8 µL) were then added for a final 
concentration of 150 nM, and the mixture allowed to equilibrate for 3 minutes before 
taking the pre-competition anisotropy measurement.  Finally, the competitor AIP or AIP 
analog (500µM, 15µL in 50% DMSO) was mixed in for a final concentration of 10 µM 
and the post-competition anisotropy was measured following 3-minute incubation. Three 
individual competitions were performed for each compound. The averaged, reference-
subtracted anisotropy measured both pre- and post-competition were plotted for each 
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compound as shown in Figure 5.  SSA (y-axis) is calculated by subtracting the SSA value 
at the starting stage (free FAM-AIP-I, before the addition of AgrC-I discs) from the SSA 
values measured before or after competition. 
AgrC Autophosphorylation Assay. All autokinase reactions were performed in reaction 
buffer containing 50 mM Tris-HCl, 15 mM HEPES-Na pH 7.8, 100 mM NaCl, 10 mM 
MgCl2 and 1 mM TCEP.  AIPs were included as indicated (from DMSO stocks), and 
DMSO was added to make the overall DMSO concentration up to 2.7% (v/v).  Typically, 
an autokinase reaction contained 20 μM [γ-32P]-ATP (1Ci/mmol) and 1.4 μM AgrC-I 
discs. After incubation at 37 °C for 40 minutes, the reaction was either spotted on 
nitrocellulose membrane (5µL/spot in triplicate) or mixed with 4x SDS sample buffer (1x 
concentration: 50 mM Tris-HCl pH 8.0, 2 % (w/v) SDS, 10 (v/v) % glycerol, 10 mM 
dithiothreitol and 0.01 (w/v) % bromophenol blue). Samples spotted on nitrocellulose 
membrane were analyzed with scintillation counting. Samples from a mock reaction (in 
the absence of AgrC-I) under the same conditions were also included as the background.  
All samples were air-dried and then washed 3x5min with TBST buffer (50mM Tris pH 
8.5, 150 mM NaCl and 0.1% (v/v) Tween-20) and air-dried again.  Each piece of 
membrane was subsequently transferred to a 4mL counting vial containing 3.5mL of 
Ultima Gold™ Cocktails (Perkin Elmer) and luminescence from the vial was quantified 
in a scintillation counter.  Background-corrected count numbers (in count per minute, 
CPM) of each reaction was normalized to the AIP-free reaction and plotted.  Dose-
response plots were prepared from several AgrC autophosphorylation assays with varying 
concentrations of AIP-I or D5A AIP-I. Samples mixed with SDS-PAGE loading buffer 
were immediately resolved on a 15% Tris-HCl SDS-polyacrylamide gel.  The gel was 
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then dried, and incubated with Eastman Kodak BIOMAX MR film for 5 hrs at RT.  After 
development, the autoradiogram (film) was scanned using ImageQuant LAS 4000 (GE). 
Phospho-relay from AgrC-I to AgrA Assay. AgrC-I discs (4.0 µM) were 
phosphorylated in the absence of AIP with 50 µM [γ-32P]-ATP at 37oC for 120 min, and 
subsequently exchanged into an ATP-free reaction buffer (50 mM Tris-HCl, 15 mM 
HEPES-Na pH 7.8, 10mM MgCl2, 100 mM NaCl and 1 mM TCEP) using Bio-Rad Micro 
Bio-Spin™ P-6 Gel Columns.  The stock was equally divided into four portions, to which 
was added 10 µM (final concentration) D5A AIP-I, AIP-I, AIP-II or vehicle (DMSO).  
These pre-phosphorylated AgrC-I stocks (50 µL) were mixed with 10 µL AgrA protein 
(50 µM stock in 50 mM Tris-HCl pH 8.0, 100 mM NaCl , 5 mM TCEP in 20% (v/v) 
glycerol) to initiate the phospho-relay.  The AgrA buffer was used to mix with AgrC-I 
samples in mock reactions.  All reactions were incubated at 30oC from which 10-µL 
samples were withdrawn at indicated time points, mixed with 4x SDS sample buffer and 
chilled on ice. All samples were resolved on a 15% Tris-HCl SDS-polyacrylamide gel 
and detected through autoradiography as described in the Autophosphorylation Assay 
secton of this chapter. 
Fmoc-SPPS of SpsB Substrate Peptides. AgrD derived substrate peptides were 
synthesized manually or with a Liberty microwave-assisted automated peptide 
synthesizer (CEM). All peptides were synthesized on a rink amide resin (Novabiochem). 
Chain assembly was carried out with HBTU (4.9 eqv. to resin) and HOBt (4.9 eqv. to 
resin) activation using a 5-fold excess of standard Nα-Fmoc protected amino acid over the 
resin in DMF (dimethylformamide) with DIEA (N,N-diisopropylethylamine, 8 eqv. to 
resin). The Fmoc protecting group was removed with 20% piperidine in DMF. Peptides 
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were acetylated at the N-terminus with a solution (20:40  eqv. to resin) of acetic 
anhydride/DIPEA in DMF for 10 minutes. Peptides were cleaved from the resin using the 
standard TFA cleavage cocktail (95% (v/v) TFA, 2.5% (v/v) triisopropylsilane (TIS) and 
2.5% (v/v) H2O). Crude peptide products were precipitated and washed with cold Et2O, 
dissolved in solvent A with a minimal amount of solvent B and then purified by RP-
HPLC and characterized by ESI-MS. 
Boc-SPPS of the AIP Analogs Featuring Enlarged, Reduced or Constrained 
Macrocycles and the AgrD-I-thiolactone and AgrD-II-thiolactone peptides. AIP 
analogs used in this study are listed in Table 10. All AIP analogs and the AgrD-I-
thiolactone and AgrD-II-thiolactone peptides were chemically synthesized using standard 
solid-phase approaches with 4-methylbenzhydrylamine-copoly(styrene-1% DVB) 
(MBHA resin) as a support.[63, 141] S-trityl mercaptopropionic acid was coupled to the 
MBHA resin to form a thioester linker before peptide elongation using standard Boc-
SPPS with in situ neutralization/HBTU activation. The 3-thiopropionic acid linker on 
MBHA resin is labile to HF cleavage conditions, thereby releasing linear α-thioester 
peptides upon global deprotection with anhydrous HF. Following removal of HF, the 
crude peptide product was precipitated using cold ethyl ether, washed thoroughly with 
ethyl ether, and then dissolved in 50% HPLC solvent B for the AIPs and AIP analogs or 
50% TFE for the AgrD(1-32)-thiolactone peptides. 
After lyophilization, AIP linear α-thioester peptides were dissolved in 50% HPLC 
solvent B and cyclized in solution by the addition of 1 equivalent volume of 0.2 M 
phosphate buffer at pH 7 (proline substitution and deletion AIP analogs) or 7.2 (enlarged 
AIP analogs). For the constrained and deletion AIP analogs, the cyclization reaction 
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required ~4 hours and was monitored by analytical RP-HPLC. For the enlarged AIP 
analogs, the cyclization reaction was allowed to proceed overnight (~16 hours) and was 
monitored by analytical RP-HPLC. During the overnight cyclization reactions, the 
solution was brought up to 10 mM TCEP incrementally. After the AIP cyclization, the 
AIP and AIP analog peptides were purified by semi-preparative RP-HPLC and 
characterized by analytical RP-HPLC, mass spectrometry and NMR spectroscopy. The 
concentrations of stock solutions for AIPs and AIP analogs were calculated on the basis 
of amino acid analysis (New England Peptide, Gardner, MA), with the peptides dissolved 
in 50% DMSO. Frozen peptide stocks were kept in 50% DMSO after amino acid analysis 
and serially diluted into an assay buffer of 20% propylene glycol and 100 mM phosphate, 
pH 5.9, which was also used for assays with cells. 
For cyclization of the D(1-32)-thiolactone peptides, the lyophilized crude α-
thioester was dissolved in a solution of 60% acetonitrile and 40% water, with 50 mM 
HEPES (pH 7) and 2.5 mM TCEP. During the overnight cyclization reactions, the 
solution was brought up to 10 mM TCEP incrementally. The reaction mixture was 
injected directly into the HPLC and purified on a protein C4 semi-preparative column 
(Vydac, Deerfield, IL) using a gradient of 50-90% solvent B over 30 minutes. Peaks were 
collected in fractions; fractions were analyzed by C4 analytical RP-HPLC and MS to 
assess purity. All pure fractions were combined and lyophilized. The AgrD(1-32)-II-
thiolactone and AgrD(1-32)-I-thiolactone frozen stocks were kept in 100% DMSO. 
Data for Control Peptide. ESI-MS m/z calculated for C42H73N15O15 1027.54, found 
1028.5 ([M + H]+). 
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Data for Fl-AH Peptide. ESI-MS m/z calculated for C53H61N9O17 1095.42, found 1096.4 
([M + H]+). 
Data for AH Peptide. ESI-MS m/z calculated for C34H53N9O12 779.38, found 780.4 ([M 
+ H]+). 
Data for IG-AIP1. ESI-MS m/z calculated for C52H85N15O17 1191.62, found 1192.6 ([M 
+ H]+). 
Data for IG-AIP3. ESI-MS m/z calculated for C57H87N17O17 1281.65, found 1282.6 ([M 
+ H]+). 
Data for Hcy AIP-I. 1H NMR (500 MHz, DMSO-d6) δ 8.74 (d, 1H J = 7.63 Hz), δ 8.52 
(d, 1H, J = 7.86), δ 8.20 (d, 1H J = 8.26 Hz), δ 8.13 (d, 1H, J = 8.04 Hz), δ 8.01 (m, 3H), 
δ 7.92 (d, 1H, J = 7.91), δ 7.29 (t, 2H, J = 7.39 Hz), δ 7.22 (m, 3H), δ 7.06 (d, 2H, J = 
8.11 Hz), δ 6.69 (d, 2H, J = 7.88 Hz), δ 5.21 (m 1H), δ 4.87 (d, 1H J = 4.22), δ 4.56 (m, 
2H), δ 4.34 (m, 2H), δ 4.23 (dd, 1H), δ 4.09 (m, 1H), δ 4.02 (m, 1H), δ 3.75 (t, 1H, J = 
8.025 Hz), δ 3.67 (m, 2H), δ 3.60 (m 2H), δ 3.48 (m, 1H), δ 3.07 (m, 2H), δ 3.02 (m, 
2H), δ 2.95 (m, 1H), δ 2.79 (m, 2H), δ 2.67 (m, 2H), δ 2.06 (s, 3H), δ 1.99 (m, 3H), δ 
1.77 (m, 1H), δ 1.64 (m, 1H), δ 1.56 (m, 1H), δ 1.24 (d, 3H), δ 1.06 (d, 2H, J = 6.15 Hz), 
δ 0.88 (m, 2H), δ 0.80 (d, 2H, J = 6.69 Hz), δ 0.77 (t, 3H, J = 7.225 Hz); ESI-MS m/z 
calculated for C44H62N8O13S2 974.39, found 975.4 ([M + H+]). 
Data for Hcy AIP-II. 1H NMR (500 MHz, DMSO-d6) δ 8.39 (d, 1H, J = 9.06 Hz), δ 
8.32 (d, 1H, J = 7.36 Hz)), δ 8.19 (d, 1H, J = 8.92 Hz), δ 8.09 (d, 1H, J = 9.07 Hz), δ 
8.01 (d, 1H, J = 8.21 Hz), δ 7.98 (d, 1H, J = 6.23 Hz), δ 7.86 (m, 3H), δ 7.80 (d, 1H, J 
=7.08 Hz), δ 7.31 (s, 1H), δ 7.26 (d, 1H, J = 7.93 Hz), δ 7.20 (m, 2H), δ 7.13 (m, 3H), δ 
6.85 (s, 1H), δ 5.26 (m, 1H), δ 4.95 (m, 1H), δ 4.54 (m, 1H), δ 4.48 (m, 1H), δ 4.34 (m, 
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1H), δ 4.26 (m, 2H), δ 4.18 (m, 2H), δ 3.87 (m, 2H), δ 3.63 (m, 1H), δ 3.55 (m, 2H), δ 
3.25 (m, 1H), δ 2.90 (m, 1H), δ 2.81 (m, 1H), δ 2.57 (m, 1H), δ 2.51 (d, 1H), δ 2.48, (d, 
1H), δ 2.30 (m, 1H), δ 1.90 (m, 2H), δ 1.75 (m, 1H), δ 1.40 (m, 1H), δ 1.35 (m, 1H), δ 
1.24 (m, 1H), δ 1.12 (d, 3H, J = 6.80 Hz), δ 0.80 (d, 3H, J = 6.79 Hz), δ 0.75 (t, 6H, J = 
6.375 Hz), δ 0.68 (d, 3H, J = 6.52 Hz); ESI-MS m/z calculated for C39H60N10O12S 892.41, 
found 893.4 ([M + H+]). 
Data for Hcy AIP-III. 1H NMR (500 MHz, DMSO-d6) δ 8.55 (d, 1H, J = 7.22 Hz), δ 
8.18 (t, 2H, J = 7.76 Hz), δ 8.11 (d, 1H, J = 7.44 Hz), δ 8.05 (m, 2H), δ 7.99 (s, 2H), δ 
7.34 (s, 1H), δ 7.21 (t, 2H, J = 7.33 Hz), δ 7.13 (m, 3H), δ 6.91 (s, 1H), δ 5.12 (t, 1H, J = 
4.95 Hz), δ 4.52 (m, 2H), δ 4.26 (m, 1H), δ 4.19 (m, 1H), δ 4.15 (m, 1H), δ 3.86 (m, 
1H), δ 3.56 (s, 1H), δ 3.41 (d, 2H, J = 4.85 Hz), δ 3.07 (m, 1H), δ 2.93 (m, 1H), δ 2.80 
(m, 1H), δ 2.58 (m, 2H), δ 2.50 (d, 1H), δ 2.39 (d, 1H, J = 5.17 Hz),  δ 2.35 (m, 1H), δ 
2.32 (m, 1H), δ 1.98 (m, 1H), δ 1.65 (m, 3H), δ 1.48 (m, 2H), δ 1.40 (m, 2H), δ 1.32 (m, 
1H), δ 1.05 (m, 1H), δ 0.84 (m, 6H), δ 0.78 (m, 6H), δ 0.73 (d, 3H, J = 6.47 Hz); ESI-
MS m/z calculated for C39H60N8O10S 832.42, found 833.4 ([M + H+]). 
Data for hβ-Met AIP-I.  1H NMR (500 MHz, DMSO-d6) δ 8.75 (d, 1H, J = 7.9 Hz), δ 
8.57 (d, 1H, J = 7.05 Hz), δ 8.08 (d, 1H, J = 6.83 Hz), δ 7.99 (m, 4H), δ 7.88 (m, 2H), δ 
7.30 (m, 2H), δ 7.24 (m, 3H), δ 7.07 (d, 2H, J = 8.21 Hz), δ 6.69 (d, 2H, J = 8.34), δ 5.17 
(t, 1H, J = 5.18 Hz), δ 4.97 (d, 1H, J = 4.76 Hz), δ 4.55 (m, 1H), δ 4.45 (m, 1H), δ 4.37 
(m, 1H), δ 4.30 (dd, 1H, J = 3.21 Hz), δ 4.24 (m, 1H), δ 4.09 (m, 2H), δ 4.02 (m, 1H), δ 
3.68 (m, 3H), δ 3.61 (m, 2H), δ 3.18 (m, 1H), δ 3.10 (m 1H), δ 3.08 (m, 1H), δ 3.04 (m, 
1H), δ 2.79 (m, 1H), δ 2.69 (m, 1H), δ 2.65 (m, 1H), δ 2.61 (m, 1H), δ 2.57 (m, 1H), δ 
2.43 (m, 2H), δ 2.03 (s, 3H), δ 1.90 (m, 1H), δ 1.75 (m, 2H), δ 1.32 (m, 1H), δ 1.24 (s, 
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1H), δ 1.05 (d, 2H, J = 6.19 Hz), δ 0.96 (m, 1H), δ 0.85 (d, 3H, J = 6.79 Hz), δ 0.78 (t, 
3H, J = 7.21 Hz); ESI-MS m/z calculated for C44H62N8O13S2 974.39, found 975.4 ([M + 
H+]). 
Data for hβ-Ile AIP-I.  1H NMR (500 MHz, DMSO-d6) δ 9.27 (s, 1H), δ 8.68 (d, 1H, J 
= 7.71 Hz), δ 8.42 (d, 1H, J = 7.41 Hz), δ 8.37 (d, 1H, J = 7.42 Hz), δ 7.93 (m, 2H), δ 
7.85 (d, 1H, J = 8.31 Hz), δ 7.62 (d, 1H, J = 7.12 Hz), δ 7.42 (d, 1H, J = 8.16 Hz), δ 7.20 
(m, 2H), δ 7.12 (m, 3H), δ 7.00 (d, 2H, J = 8.3 Hz), δ 6.62 (d, 2H, J = 8.31 Hz), δ 5.07 
(m, 1H), δ 4.76 (m, 1H), δ 4.47 (m, 2H), δ 4.34 (m, 2H), δ 4.26 (m, 1H), δ 4.17 (dd, 1H, 
J = 3.57), δ 3.97 (m, 2H), δ 3.61 (m, 1H), δ 3.55 (m, 1H), δ 3.45 (m, 3H), δ 3.12 (m, 
2H), δ 3.00 (m, 2H), δ 2.87 (m, 2H), δ 2.80 (m, 2H), δ 2.72 (m, 2H), δ 2.37 (m, 2H) δ 
2.22 (m, 1H), δ 1.96 (s, 3H), δ 1.89 (m, 1H), δ 1.75 (m, 1H), δ 1.69 (m, 1H), δ 1.18 (m, 
1H), δ 0.98 (d, 2H, J = 6.38 Hz), δ 0.86 (m, 1H), δ 0.70 (m, 6H); ESI-MS m/z calculated 
for C44H62N8O13S2 974.39, found 975.4 ([M + H+]). 
Data for hβ-Phe AIP-I.  1H NMR (500 MHz, DMSO-d6) δ 9.27 (s, 1H), δ 8.68 (d, 1H, J 
= 7.98 Hz), δ 8.18 (m, 1H), δ 8.03 (m, 2H), δ 7.92 (m, 3H), δ 7.69 (d, 1H, J = 9.9 Hz), δ 
7.43 (d, 1H, J = 7.33 Hz), δ 7.25 (t, 2H, J = 7.43 Hz), δ 7.16 (d, 3H, J = 7.33 Hz), δ 7.00 
(d, 2H, J = 8.19 Hz), δ 6.62 (d, 2H J = 8.19 Hz), δ 5.13 (m, 1H), δ 4.85 (m, 1H), δ 4.46 
(m, 2H), δ 4.37 (m, 1H), δ 4.28 (m, 1H), δ 4.15 (m, 2H), δ 4.04 (m, 1H), δ 3.96 (m, 2H), 
δ 3.60 (m, 1H), δ 3.53 (m, 1H), δ 2.97 (m, 4H), δ 2.84 (m, 1H), δ 2.73 (m, 1H), δ 2.57 
(m, 4H), δ 2.33 (m, 2H), δ 2.20 (m, 1H), δ 2.07 (m, 1H), δ 1.96 (s, 3H), δ 1.83 (m, 1H), 
δ 1.66 (m, 1H), δ 1.27 (m, 1H), δ 1.17 (s, 1H), δ 0.97 (d, 3H, J = 6.25 Hz), δ 0.73 (m, 
6H); ESI-MS m/z calculated for C44H62N8O13S2 974.39, found 975.4 ([M + H+]). 
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Data for hβ-Asp AIP-I.  1H NMR (500 MHz, DMSO-d6) δ 9.26 (s, 1H), δ 8.67(d, 1H, J 
= 7.57 Hz), δ 8.58 (m, 1H), δ 7.91 (m, 5H), δ 7.66 (d, 1H, J = 9.14 Hz), δ 7.21 (m, 2H), 
δ 7.15 (d, 3H, J = 7.32 Hz), δ 7.00 (d, 2H, J = 8.36 Hz), δ 6.62 (d, 2H, J = 8.36 Hz), δ 
5.18 (m, 1H), δ 4.81 (m, 1H), δ 4.48 (m, 2H), δ 4.38 (m, 1H), δ 4.24 (m, 1H), δ 4.18 (dd, 
1H, J = 3.28 Hz), δ 4.12 (m, 1H), δ 4.02 (m, 1H), δ 3.95 (m, 1H), δ 3.89 (m, 1H), δ 3.81 
(m, 1H), δ 3.62 (m, 2H), δ 3.53 (m, 2H), δ 3.00 (m, 1H), δ 2.95 (m, 2H) δ 2.74 (m, 2H), 
δ 2.57 (m, 2H), δ 2.39 (m, 1H), δ 2.30 (m, 1H), δ 2.23 (m, 2H), δ 2.16 (m, 1H), δ 2.01 
(s, 1H), δ 1.99 (s, 3H), δ 1.90 (m, 2H), δ 1.30 (m, 1H), δ 1.17 (s, 1H), δ 0.97 (d, 3H, J = 
6.24 Hz), δ 0.75 (m, 6H); ESI-MS m/z calculated for C44H62N8O13S2 974.39, found 975.4 
([M + H+]). 
Data for D5A β-Ala AIP-I.  1H NMR (500 MHz, DMSO-d6) δ 9.29 (s, 1H), δ 8.84 (d, 
1H, J = 7.62 Hz), δ 8.33 (d, 1H, J = 6.88 Hz), δ 8.27 (d, 1H, J = 8.18 Hz), δ 8.18 (d, 1H, 
J = 8.18 Hz), δ 7.97 (m, 2H), δ 7.83 (m, 2H), δ 7.22 (m, 2H), δ 7.17 (m, 3H), δ 6.96 (d, 
2H, J = 8.74), δ 6.62 (d, 2H, J = 8.18 Hz), δ 4.94 (s, 1H), δ 4.76 (m, 1H), δ 4.39 (m, 1H), 
δ 4.31 (m, 1H), δ 4.24 (m, 2H), δ 4.12 (m, 2H), δ 4.04 (m, 1H), δ 3.97 (m, 1H), δ 3.09 
(m, 1H), δ 2.97 (m, 1H), δ 2.91 (m, 1H), δ 2.80 (m, 1H), δ 2.71 (m, 4H), δ 2.39 (t, 2H, J 
= 7.91 Hz), δ 2.23 (m, 2H), δ 2.10 (m, 2H), δ 1.96 (s, 3H), δ 1.85 (m, 2H), δ 1.72 (m, 
2H), δ 1.39 (m, 1H), δ 1.02 (d, 3H, J = 6.51 Hz), δ 0.79 (m, 7H); ESI-MS m/z calculated 
for C42H60N8O11S2 916.38, found 917.4 ([M + H+]). 
Data for D5A hβ-Ala AIP-I.  1H NMR (500 MHz, DMSO-d6) δ 9.27(s, 1H), δ 8.68 (d, 
1H, J = 7.85 Hz), δ 8.58 (d, 1H, J = 8.11), δ 7.99 (m, 1H), δ 7.92 (m, 4H), δ 7.62 (d, 1H, 
J = 9.36 Hz), δ 7.21 (m, 2H), δ 7.15 (d, 3H, J = 7.41 Hz), δ 6.99 (d, 2H, J = 8.54 Hz), δ 
6.61 (d, 2H J = 8.39), δ 5.18 (s, 1H), δ 4.83 (s, 1H), δ 4.48 (m, 2H), δ 4.26 (m, 1H), δ 
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4.18 (dd, 2H, J = 3.08 Hz), δ 4.02 (m, 1H), δ 3.95 (m, 1H), δ 3.89 (m, 1H), δ 3.82 (m, 
1H), δ 3.61 (m, 1H), δ 3.54 (m, 1H), δ 3.02 (m, 1H), δ 2.95 (m, 2H), δ 2.74, (m, 2H), δ 
2.57 (m, 1H), δ 2.39 (m, 1H), δ 2.32 (m, 1H), δ 2.30 (m, 1H), δ 2.03 (m, 1H), δ 1.99 (s, 
3H), δ 1.92 (m, 3H), δ 1.31 (m, 1H), δ 1.17 (s, 2H), δ 0.97 (d, 3H, J = 6.54 Hz), δ 0.91 
(d, 3H, J = 6.66 Hz), δ 0.79 (d, 1H), δ 0.75 (m, 6H); ESI-MS m/z calculated for 
C43H62N8O11S2 930.4, found 931.2 ([M + H+]). 
Data for F6P AIP-I.  1H NMR (500 MHz, DMSO-d6) δ 9.50 (s, 1H), δ 9.33 (d, 1H, J = 
6.58 Hz), δ 8.72 (d, 1H, J = 7.95 Hz), δ 8.34 (d, 1H, J = 7.72 Hz), δ 8.02 (m, 2H), δ 7.93 
(d, 1H, J = 8.62 Hz), δ 7.49 (d, 1H, J = 6.35 Hz), δ 7.05 (d, 2H, J = 7.53 Hz), δ 6.68 (d, 
2H, J = 8.67 Hz), δ 4.74 (m, 1H), δ 4.54 (m, 2H), δ 4.33 (m, 1H), δ 4.24 (m, 1H), δ 4.14 
(m, 1H), δ 3.04 (m, 2H), δ 2.87 (m, 1H), δ 2.82 (m, 1H), δ 2.39 (m, 3H), δ 2.13 (m, 1H), 
δ 2.04 (m, 2H), δ 1.98 (s, 3H), δ 1.92 (m, 2H), δ 1.71 (m, 1H), δ 1.30 (m, 1H), δ 1.22 
(m, 1H), δ 1.05 (d, 3H, J = 6.36 Hz), δ 0.95 (m, 1H), δ 0.80 (m, 7H); ESI-MS m/z 
calculated for C39H58N8O13S2 910.36, found 911.4 ([M + H+]). 
Data for I7P AIP-I.  1H NMR (500 MHz, DMSO-d6) δ 9.28 (s, 1H), δ 8.70 (m, 3H), δ 
8.43 (d, 1H, J = 7.72 Hz), δ 7.91 (m, 4H), δ 7.28 (t, 2H, J = 7.21 Hz), δ 7.23 (t, 1H, J = 
7.31 Hz), δ 7.14 (d, 2H, J = 7.1 Hz), δ 7.00 (d, 2H, J = 7.93 Hz), δ 6.62 (d, 2H, J = 8.36 
Hz), δ 5.15 (m, 1H), δ 4.93 (d, 1H, J = 4.81), δ 4.59 (m, 1H), δ 4.47 (m, 2H), δ 4.36 (m, 
1H), δ 4.20 (dd, 1H, J = 2.79 Hz), δ 4.10 (m, 1H), δ 4.03 (m, 1H), δ 3.95 (m, 1H), δ 3.58 
(m, 2H), δ 3.16 (m, 1H), δ 3.11 (m, 1H), δ 2.98 (m, 2H), δ 2.76 (m, 3H), δ 2.37 (m, 1H), 
δ 2.23 (m, 1H), δ 2.00 (m, 2H), δ 1.94 (s, 3H), δ 1.78 (m, 1H), δ 1.54 (m, 1H), δ 1.25 
(m, 1H), δ 1.17 (s, 1H), δ 0.97 (d, 3H, J = 6.52 Hz), δ 0.84 (m, 1H); ESI-MS m/z 
calculated for C42H56N8O13S2 944.34, found 945.3 ([M + H+]). 
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Data for ΔF6 AIP-I.  1H NMR (500 MHz, DMSO-d6) δ 9.37 (s, 1H), δ 8.73 (d, 1H, J = 
7.14 Hz), δ 8.38 (d, 1H, J = 9.22 Hz), δ 8.31 (d, 1H, J = 9.22 Hz), δ 8.19 (d, 1H, J = 8.53 
Hz), δ 7.95 (d, 1H, J = 8.76 Hz), δ 7.55 (d, 1H, J = 8.53 Hz), δ 7.06 (d, 2H, J = 8.53 Hz), 
δ 6.69 (d, 2H, J = 8.53 Hz), δ 4.56 (m, 2H), δ 4.45 (m, 1H), δ 4.36 (m, 1H), δ 4.22 (m, 
2H), δ 4.10 (m, 1H), δ 3.94 (m, 2H), δ 3.21 (m, 1H), δ 3.02 (m, 2H), δ 2.75 (m, 4H), δ 
2.59 (m, 2H), δ 2.41 (m, 3H), δ 2.07 (m, 1H), δ 2.03 (s, 3H), δ 1.88 (m, 1H), δ 1.73 (m, 
1H), δ 1.45 (m, 1H), δ 1.24 (s, 1H), δ 1.08 (m, 1H), δ 1.04 (d, 3H, J = 6.46 Hz), δ 0.83 
(m, 7H); ESI-MS m/z calculated for C34H51N7O12S2 813.3, found 814.3 ([M + H+]). 
Data for ΔI7 AIP-I.  1H NMR (500 MHz, DMSO-d6) δ 9.27 (s, 1H), δ 8.68 (d, 1H, J = 
7.82 Hz), δ 8.41 (d, 1H, J = 8.49 Hz), δ 8.34 (d, 1H, J = 9.84 Hz), δ 8.12 (d, 1H, J = 8.27 
Hz), δ 7.92 (s, 1H), δ 7.88 (d, 1H), δ 7.59 (d, 1H, J = 8.26 Hz), δ 7.21 (m, 2H), δ 7.14 
(m, 4H), δ 6.99 (d, 2H, J = 8.49 Hz), δ 6.62 (d, 2H, J = 8.50 Hz), δ 5.21 (m, 1H), δ 4.87 
(d, 1H, J = 4.92 Hz), δ 4.50 (m, 2H), δ 4.31 (m, 4H), δ 4.16 (dd, 1H, J = 3.25 Hz), δ 4.03 
(m, 1H), δ 3.94 (m, 1H), δ 3.62 (m, 1H), δ 3.52 (m, 1H), δ 3.13 (m, 1H), δ 2.95 (m, 1H), 
δ 2.88 (d, 2H, J = 7.61 Hz), δ 2.73 (m, 3H), δ 2.59 (m, 2H), δ 2.26 (m, 1H), δ 2.19 (m, 
1H), δ 1.98 (m, 1H), δ 1.94 (s, 3H), δ 1.80 (m, 1H), δ 0.96 (d, 3H, J = 6.09 Hz); ESI-MS 
m/z calculated for C37H49N7O12S2 847.29, found 848.3 ([M + H+]). 
Data for AIP-I. ESI-MS m/z calculated for C43H60N8O13S2 960.4, found 961.4 ([M + 
H+]). (See Appendix for 2-D NMR data as well.) 
Data for Ac-AIP-I. ESI-MS m/z calculated for C45H62N8O14S2 1002.4, found 1003.4 ([M 
+ H+]). 
Data for AIP-II. ESI-MS m/z calculated for C38H58N10O12S 878.4, found 879.4 ([M + 
H+]). 
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Data for Ac-AIP-II. ESI-MS m/z calculated for C40H60N10O13S 920.4, found 921.4 ([M + 
H+]). 
Data for AgrD(1-32)-I-thiolactone.  ESI-MS m/z calculated for C170H253N37O45S3 
3631.24, found 3630.8 ([M + H+]). 
Data for AgrD(1-32)-II-thiolactone.  ESI-MS m/z calculated for C159H251N37O40S3 
3417.14, found 3417.09 ([M + H+]). 
NMR Spectroscopy. Lyophilized AIP analogs were dissolved in 100% DMSO-d6 
(Cambridge Isotope Laboratories).  1H NMR spectra were recorded on a Bruker 500 
Avance-III equipped with a Cryo-QNP probe (Bruker BioSpin, Billerica, MA).  1H NMR 
chemical shifts are reported in parts per million (ppm) and referenced relative to the 
residual solvent proton signal for DMSO-d6 at 2.50 ppm.  One hundred and twenty-eight 
scans were recorded for each AIP analog 1H NMR experiment.  1H NMR analysis yielded 
complete assignments for all synthetic peptides.  Two-dimensional TOCSY (70 ms 
mixing time) and NOESY experiments (500 ms mixing time) for certain AIP-I analogs 
were performed on an Avance III spectrometer operating at a 1H Larmor frequency of 
800 MHz and equipped with a TCI cryoprobe (Bruker BioSpin, Billerca, MA). Spectra 
were acquired at 25°C, with acquisition times of 393 ms (8192 points) and 32 ms (512 
points) in the direct and indirect dimensions, respectively.  16 scans per point (TOCSY) 
and 16 to 64 scans per point (NOESY) were acquired for different samples.  Data were 
processed with the NMRPipe software[154] and visualized in Sparky.[155] Two-dimensional 
NMR experiments characterized several enlarged AIP-I analogs.  See the Appendix for 2-
D NMR data tables. 
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Appendix.  
Schematic of Various Samples Added to β-lactamase Reporter Gene Assay Cells  
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2D-NMR Chemical Shift Assignments for AIP-I, D5A AIP-I and the Enlarged AIP-I 
Analogs 
AIP-I HN Hα Hβ Hγ Other 
Met 8.988 4.275 2.184 2.442 1.942, Hε 
Ile 8.320 3.732 1.933 1.134, 1.107, 0.7594 0.7192, Hδ 
Phe 7.848 4.477 2.978 -- 7.194, HAr 
Asp 8.217 4.415 2.483, 2.373 -- -- 
Cys 8.227 4.361 3.182, 2.915 -- -- 
Thr 7.953 4.244 4.061 1.038 -- 
Ser 8.739 4.555 3.689, 3.593 -- 5.22, HO 
Tyr 7.986 4.027 3.037, 2.796 -- 7.075, HAr 
 
 
D5A AIP-I HN Hα Hβ Hγ Other 
Met 9.074 4.243 2.188 -- 1.95, Hε 
Ile 8.257 3.771 -- 1.163, 0.7755 -- 
Phe 7.806 4.493 2.963 -- 7.271, 7.195, HAr 
Ala 7.996 4.283 1.034 -- -- 
Cys 8.238 4.278 3.183, 2.889 -- -- 
Thr 7.966 4.258 4.089 1.046 -- 
Ser 8.726 4.556 3.683, 3.57 -- -- 




AIP-I HN Hα Hβ Hγ Other 
Met 8.645 4.31 2.124 2.575 1.969, Hε 
Ile -- 3.883 -- 1.379, 1.015, 0.8119 -- 
Phe 7.963 4.562 3.021, 2.832 -- 7.225, HAr 
hβ-Asp 7.716 2.479 4.455* 2.306, 2.231 -- 
Cys 7.999 3.971 3.084, 2.656 -- -- 
Thr 7.951 4.251 4.096 1.045 -- 
Ser 8.73 4.551 3.692, 3.612 -- 5.238, HO 




AIP-I HN Hα Hβ Hγ Other 
Met 8.648 4.328 2.116 2.584 1.986, Hε 
Ile 8.071 3.891 -- 1.387, 0.8115 -- 
Phe 7.991 4.559 -- -- 7.219, HAr 
hβ-Ala 7.679 2.396, 2.086 4.24* 0.9817 -- 
Cys 7.973 3.978 3.089, 2.643 -- -- 
Thr 7.948 4.253 4.098 1.044 -- 
Ser 8.733 4.548 3.687, 3.611 -- 5.234, HO 
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hβ-Phe 
AIP-I HN Hα Hβ Hγ Other 
Met 8.241 4.354 2.146 2.41 1.901, Hε 
Ile 7.743 4.215 1.734 1.342, 1.068, 0.7927 -- 
hβ-Phe 7.482 2.272 4.116* 2.915, 2.631 7.31, 7.233, HAr 
Asp 8.103 4.528 2.543, 2.507 -- -- 
Cys 8.086 4.451 3.087, 3.029 -- -- 
Ser 8.731 4.544 3.679, 3.598 -- 5.183, HO 
Thr 7.934 4.232 4.043 1.042 -- 
Tyr 7.977 4.023 3.034, 2.793 -- 7.07, 6.693, HAr 
 
hβ-Met  
AIP-I HN Hα Hβ Hγ Other 
hβ-Met 7.313 -- 4.077* 2.438 2.688, Hδ 1.743, Hε 
Ile 7.867 3.683 1.899 1.316, 0.956, 0.8415 0.7772, Hδ 
Phe 8.064 4.443 3.308, 3.147 -- 7.294, 7.238, HAr 
Asp 7.878 4.25 3.19, 3.083 -- -- 
Cys 8.557 4.367 2.582, 2.417 -- -- 
Thr 7.96 4.294 4.096 1.046 -- 
Ser 8.729 4.546 3.669, 3.613 -- 5.174, HO 
Tyr 7.991 4.016 3.029, 2.797 -- 7.065, 6.689, HAr 
 
Hcy AIP-I HN Hα Hβ Hγ Other 
Met 8.499 4.324 2.056 2.537, 2.446 1.958, Hε 
Ile 8.105 3.745 1.972 1.212, 0.881 0.7823, Hδ 
Phe 8.17 4.537 2.977 -- 7.278, 7.207, HAr 
Asp 8.002 4.333 2.482 -- -- 
Hcy 7.919 4.317 2.939, 2.673 2.018, 1.764 -- 
Thr 7.967 4.209 4.09 1.047 -- 
Ser 8.701 4.54 3.661 3.608 -- 5.252, HO 
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